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Abstract 
Background: Lewy body dementia (LBD), consisting of Parkinson’s disease dementia 
(PDD) and dementia with Lewy bodies (DLB), is known to make up more than 15% of 
dementia cases at autopsy, however the clinical prevalence rate is reported to be much 
lower at around 5-6%. Difficulties with diagnosis and/or lack of specific treatments may 
contribute to this difference. This study investigated the diagnosis and management 
pathways of LBD and whether inflammation could play a role in the pathophysiology and 
hence provide a route for future diagnostic and treatment pathways. 
Methods: Clinical diagnostic rates of LBD in clinics across several NHS trusts in East 
Anglia were reviewed, followed by an in-depth notes review of patients identified with 
LBD together with age and gender matched controls. A literature review of the current 
evidence for inflammation in LBD, preceded a case control study to investigate further. 
Nineteen DLB patients together with 16 age and gender matched healthy controls 
underwent [11C]PK11195 PET imaging, and the same cohorts, plus an additional 10 
matched control subjects underwent peripheral cytokine analysis. 
Results: The clinical prevalence rate of LBD was low compared to the known pathology 
rates, with delays identified in the diagnosis of DLB compared to other dementia 
subtypes. Delays were also seen between the onset of dementia symptoms and the 
clinical diagnosis of dementia in Parkinson’s disease (PD). The literature review 
identified studies providing evidence of inflammation in PD but few studies had been 
carried out in DLB. PET imaging revealed microglial activation negatively correlated with 
disease severity in DLB, suggesting inflammation occurs early in the disease. DLB 
patients also showed evidence of differences in cytokine levels compared to healthy 
controls.  
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Conclusion: The study showed evidence of inflammatory changes in DLB, providing a 
potential target for treatment and/or biomarkers, that could assist in increasing clinical 
diagnostic rates.  
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1.1 Introduction 
The term Lewy body dementia (LBD) describes two syndromes: dementia with Lewy 
bodies (DLB) and Parkinson’s disease dementia (PDD). This chapter will describe both 
conditions and review studies investigating their frequency and prevalence from both 
clinical and pathological series. 
Both DLB and PDD are characterised by Lewy bodies found in the brain on post-mortem 
in patients who have a clinical dementia syndrome. Lewy bodies were first described by 
Frederick Lewy in 1912 (Lewy, 1912), who found concentric inclusion bodies 
characterised by a densely staining core and a pale surrounding halo within the nucleus 
basalis of Meynert in a patient who had died from Parkinson’s disease. Alpha-synuclein 
has since been discovered as the chief component of Lewy bodies (Spillantini et al., 
1997). 
Both PDD and DLB share several clinical characteristics, the most common being 
dementia and a parkinsonian syndrome. Indeed, conventionally they are somewhat 
arbitrarily distinguished by a one-year rule. Namely that in PDD, the patient must have 
had idiopathic Parkinson’s disease (PD) for at least one year before they are diagnosed 
with dementia. In DLB, the patient must have either developed dementia before, or within 
one year of onset of the parkinsonian symptoms. At autopsy the two conditions are 
difficult, if not impossible, to distinguish and so the distinction has to be made on the 
clinical history. 
Both PDD and DLB have their own internationally agreed consensus clinical diagnostic 
criteria. DLB is diagnosed using the 2005 consensus criteria (McKeith et al., 2005). All 
subjects must first satisfy the criteria for dementia, defined as a progressive cognitive 
decline of sufficient magnitude to interfere with normal social or occupational function.  
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Table 1.1 DLB Diagnostic Criteria (McKeith et al., 2005) 
Core Criteria Suggestive Features 
Recurrent visual hallucinations Rapid eye movement (REM) sleep 
behaviour disorder 
Fluctuating cognition Abnormal dopamine transporter scan 
(DaTscan) 
Spontaneous features of parkinsonism Severe neuroleptic sensitivity 
 
A ‘probable’ DLB diagnosis is made when either two core criteria or one core and one 
suggestive criteria are present (see Table 1.1 for the list of core criteria and suggestive 
features). A lower threshold ‘possible’ DLB diagnosis only requires the presence of one 
of the six core or suggestive features listed. Newer criteria for the diagnosis of DLB were 
published in June 2017 (McKeith et al., 2017), following the completion of the studies in 
this thesis and they are discussed further in Chapter 4. 
The PDD criteria were published by a Movement Disorder Society (MDS) task force in 
2007 (Emre et al., 2007) before a further clarification was released to aid in its diagnosis 
by the same group (Dubois et al., 2007). They list criteria that define dementia on the 
background of PD. Multi-domain cognitive impairments are required which are not 
explained by other plausible causes such as major depression or delirium.   
DLB has recently been incorporated into the International Classification of Diseases 
(ICD) 9 and 10 (WHO, 2016) however ICD-9 does not specifically include PDD as a 
dementia subtype, whereas ICD-10 includes PDD as a subtype of DLB. The Diagnostic 
and Statistical Manual of Mental Disorders (DSM)-5 (American Psychiatric Association, 
2013) has also recently incorporated DLB.   
Autopsy studies suggest that LBD is the second commonest form of dementia after AD, 
responsible for 15-20% of cases (Perry et al., 1989; Oinas et al., 2007). However, clinical 
studies consistently show a low rate of prevalence, at the 5-10% level (Vann Jones and 
O’Brien, 2014; D. B. Hogan et al., 2016; Yue et al., 2016), suggesting difficulty in 
diagnosing these conditions. This chapter looks at this discrepancy in depth.  
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1.2 Early Pathological Studies 
Early autopsy studies of patients with dementia identified a group of subjects that shared 
the amyloid pathology of Alzheimer’s dementia (AD) and the subcortical neuron loss of 
PD but did not exhibit significant tau pathology, nor the severity in neuron loss in the 
substantia nigra seen in these two conditions respectively. This group was classified as 
having a senile dementia of Lewy body type, forming 15-20% of demented subjects that 
went to autopsy (Perry et al., 1989, 1990). It should be noted that these studies did not 
include cases of ‘diffuse’ Lewy body disease in this figure, as this was considered a 
separate entity, with higher amounts of neocortical Lewy bodies. However, diffuse Lewy 
body disease has since been added to the spectrum of disorders considered to be DLB 
(McKeith et al., 1996). Adding the diffuse DLB group in these early studies, would have 
increased the proportion of dementia cases with DLB.  
Another issue in these early papers is the attempt to separate the diagnosis of DLB and 
PDD pathologically based on the severity of substantia nigra pathology. Parkinsonism is 
a core diagnostic criteria of DLB and the involvement of the substantia nigra in DLB is 
not disputed, although the severity of involvement does vary (McKeith et al., 2005). The 
authors admitted that including all the patients with Lewy body disorders and associated 
dementia: PDD and diffuse Lewy body disease, as well as PD with AD (the latter defined 
as AD pathology but with severe neuron loss and Lewy bodies in the substantia nigra 
and other subcortical nuclei only) would lead to a number that is even higher at 25% 
(Perry et al., 1990). In contrast, the inclusion of patients who have co-existing moderate 
to severe amyloid pathology, and in one case severe neurofibrillary tangles, could have 
inflated the numbers considered to have DLB in these studies. However, at the time there 
were no clear pathological (or even clinical) diagnostic criteria for DLB and there would 
have been difficulty in determining which patients with both DLB and AD pathologies had 
which disorder.  
Hence early autopsy studies suggested LBD represented about 25% of dementia cases 
but did not address the relevance of co-existing AD pathology that could have inflated 
this figure. 
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1.3 New Pathological Criteria 
In 1996 the report of the DLB Consortium suggested the first set of both clinical and 
pathological criteria for DLB. Pathologically, the presence of Lewy bodies anywhere in 
the brain of a patient diagnosed clinically with dementia (McKeith et al., 1996) was 
sufficient for a diagnosis of DLB. Whilst these simplistic criteria allow for the inclusion of 
a wide range of cases, they also include patients who clinically have an AD like profile 
with no DLB symptoms. Three different pathological types were introduced: 
1. ‘brainstem’, where Lewy bodies are mainly found in the brainstem with no cortical 
involvement;  
2. ‘limbic’, where there are Lewy bodies mainly in the amygdala and cingulate, with 
no parietal lobe involvement; and  
3. ‘diffuse cortical’, where Lewy bodies are found throughout the cortex as well as 
the limbic and brainstem areas. 
In 2005, the DLB Consortium reassembled and tried to address the question of how co-
existing AD pathology affected the likelihood of a patient with dementia clinically having 
DLB (McKeith et al., 2005). Up to 60% of AD cases were reported to be considered to 
meet the pathological criteria for DLB, however as the vast majority of these patients did 
not have the DLB clinical syndrome, this led to the clinical criteria being deemed 
inadequate in terms of sensitivity (McKeith et al., 2005). Hence the consortium took steps 
to take into account AD pathology when determining the extent to which Lewy body 
pathology explained the clinical DLB syndrome. They introduced new pathological 
criteria that suggested such likelihood was “directly related to the severity of Lewy related 
pathology, and inversely related to the severity of concurrent Alzheimer’s disease type 
pathology”. The three pathological classifications for DLB were kept: brainstem, limbic 
and diffuse cortical but the likelihood of a patient with dementia having DLB was 
attributed to being “low”, “intermediate” or “high” dependent on the severity of Lewy body 
and AD pathology in these different categories. 
A patient with brainstem Lewy bodies was said to have a low likelihood of clinically having 
DLB if they had any element of AD pathology. Whereas, patients with diffuse cortical 
Lewy bodies could have even high levels of AD pathology and still have an intermediate 
probability of having DLB. Patients with the limbic type sat in the middle in terms of the 
likelihood of a DLB syndrome if there was co-existing AD pathology (McKeith et al., 
2005).  
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Alpha-synuclein immunohistochemistry was also recommended instead of  haematoxylin 
and eosin staining or ubiquitin staining for Lewy body quantification in order to increase 
detection of Lewy bodies (McKeith et al., 2005). 
 
1.4 Recent Pathological Studies 
The new pathology criteria do not appear to have diminished the proportion of dementia 
cases with a pathological diagnosis of DLB reported at autopsy. The earliest study to 
assess the utility of the new pathological criteria was carried out by Fujimi and colleagues 
(Fujimi et al., 2008). It reported the autopsy results of 205 consecutive patients with 
dementia. 32 (15.6%) were found to have an intermediate and high likelihood of DLB 
and the authors viewed this group of patients to have a pathological diagnosis of  DLB. 
A further 27 (13.2%) had Lewy body pathology but were thought to have a low likelihood 
of DLB. The authors however found the three pathological classifications (brainstem, 
limbic and diffuse cortical) inadequate as about half of their 59 cases did not fit well into 
the criteria. Lewy body distribution was found to be highly variable and not as easily 
amenable to classification as AD pathology. PDD patients, of which there were 8, were 
excluded from detailed assessment. 
Another difficulty was with patients exhibiting AD pathology but with a co-existing heavy 
burden of Lewy bodies in the amygdala and thus in the limbic category, yet often without 
any core features of DLB clinically. The authors proposed that this group required further 
investigation with respect to the clinical significance of Lewy bodies found in the 
amygdala. A previous study investigating co-existing Lewy body pathology in 
Alzheimer’s disease patients, had found that 62 (or 18%) of 347 consecutive AD cases 
had co-existing Lewy bodies within the amygdala with minimal Lewy body deposits 
elsewhere in the brain. A comparison with AD patients without co-existing Lewy bodies 
found no significant differences in their clinical features (Uchikado et al., 2006).  A further 
category of “amygdala predominant” has since been suggested for addition to the 
pathological subtypes, after another group showed this subtype accounted for 20% of 
dementia cases with Lewy body pathology at autopsy but didn’t fit into any of the 2005 
pathological categories (Leverenz et al., 2008).   
Another interesting aspect of the Fujimi study (Fujimi et al., 2008) was that the group 
with diffuse cortical Lewy bodies and also severe AD pathology had the highest 
frequency of core clinical features of DLB but were categorised as having an intermediate 
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likelihood of DLB pathologically. This would suggest that those with severe dual AD and 
DLB pathologies are likely clinically to be diagnosed with DLB, but that a mixed AD and 
DLB diagnosis may be more appropriate in some of these cases. AD pathology was seen 
to increase with age as expected, as did DLB pathology, but the greater prevalence of 
AD with age meant the likelihood of DLB reduced with age. 
Another interesting aspect of the study was the equal spread of Lewy body prevalence 
across the genders. However, the distribution of the pathology varied - with females 
having more diffuse cortical Lewy bodies compared to males and females also having a 
higher prevalence of AD pathology. Hence any gender differences seen clinically could 
be due to increased AD pathology in females particularly with age, leading to 
predominantly AD symptoms. Again further research needs to be carried out as this 
study involved only 59 DLB subjects (Fujimi et al., 2008). 
Another four autopsy studies have been reported since the release of the 2005 
pathological criteria for DLB, but only one considered the clinical history to determine if 
some of the cases were PDD rather than DLB. This Austrian hospital based autopsy 
series (Jellinger and Attems, 2011) retrospectively assessed 1,100 dementia cases aged 
70 or over who died between 1990 and 2007. The study showed the percentage of DLB 
cases as a proportion of all dementia cases, to be 8.5% (where AD pathology was only 
found at low levels and quantified as Braak stage 4 or less) with another 8.9% having 
concomitant DLB and AD pathology (with Braak stage of 5 or 6). Interestingly for both 
groups the percentage of cases diagnosed clinically as having DLB pathology was lower, 
at 10%. However given many of the cases would have died before the DLB consensus 
criteria were established, this is likely to represent a lack of recognition of the condition 
at the time of diagnosis. Indeed, the majority of both these groups were clinically 
diagnosed with PDD, a condition which was much better recognised at the time. 
However, this study was limited by a lack of clinical information for the autopsied patients. 
Interestingly the percentage of cases with DLB pathology again fell with age.  
The other autopsy studies did not differentiate DLB from PDD using clinical records, so 
any reference to DLB has to be considered to be a reference to LBD as a whole. Oinas 
and colleagues (Oinas et al., 2007) reclassified autopsy cases with the newer 2005 
criteria and newer staining techniques and found a prevalence rate of 20% (11 of 55) of 
pathological DLB in consecutive hospitalised dementia cases, but all of these cases had 
co-existing AD pathology and nine had high levels of AD pathology. One of the strengths 
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of this study was the broad range of ages of the patients’ autopsied, with half younger 
than 65.  
A study comparing consecutive autopsy cases in community and clinic cohorts found 
differences in Lewy body pathology between the two cohorts, though the actual 
pathological prevalence rates of DLB were not stated (Schneider et al., 2009). Those 
seen in the specialty memory clinic were reported to have increased Lewy body 
pathology, suggesting a referral bias – the community and clinic cohorts both had a 
similar autopsy rate and autopsies were all carried out at the same centre, reducing other 
potential sources of bias such as operator bias or selection bias. However, the study did 
not take into account the 2005 pathological criteria for assessing likelihood of DLB nor 
did it mention the diagnosis of PDD. However, it did show that the prevalence of patients 
with neocortical Lewy bodies, which significantly increase the likelihood of a DLB 
diagnosis irrespective of the presence of AD pathology, formed about the same 
proportion of dementia patients in each cohort - at 20%.  
The “90+study” by Corrada and colleagues (Corrada, Berlau and Kawas, 2012) found 
that 13 out of 64 (21%) patients aged 90 and over from a retirement community who 
underwent autopsy had diffuse Lewy body disease. However, only 1.5% of patients with 
dementia were diagnosed with Lewy body disease clinically prior to autopsy. The study 
did not appear to assess for the other categories of DLB (limbic and brainstem) nor state 
what histological methods were used for assessing Lewy bodies.  It was not stated that 
the diagnosis of PDD was considered. Given the age group and lack of detail around the 
methodology, it is difficult to extrapolate the findings to the general dementia population. 
To summarise, the two studies (Fujimi et al., 2008; Jellinger and Attems, 2011) using the 
2005 pathological criteria and clinical history to identify pathological DLB in autopsy 
studies, suggest the prevalence of dementia subjects with intermediate or high likelihood 
of DLB to be about 15-20%. The only other study which used the 2005 criteria reported 
a DLB prevalence of 20%, though it did not verify the clinical history using medical 
records. Two further studies which chose not to use such criteria, still reported the 
presence of diffuse cortical Lewy bodies in their dementia cohorts, which by definition 
meant at least an intermediate likelihood of DLB, to be similarly about 20%.  
This 15-20% prevalence figure for DLB however is tempered by major methodology 
problems, including: a lack of recognition of PDD as a diagnostic entity (in 3 out of the 5 
studies), small sample sizes and differing or unstated histological methods. In addition, 
a large number of autopsy studies of patients with dementia carried out recently but not 
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discussed here do not even take into account the DLB consensus criteria for its 
pathological diagnosis and therefore did not report on its prevalence specifically, for 
example studies by Brunnström and colleagues and Leiros and colleagues (Brunnström 
et al., 2009; Leiros et al., 2016).  
Another difficulty with interpreting autopsy studies where consecutive cases are used to 
measure prevalence rates is the likely selection bias inherent in patients referred for 
autopsy. Complex cases where diagnoses are doubted are much more likely to be 
referred, in addition some centres have a specialist interest in Lewy body disease and 
will have a higher suspicion rate for the diagnosis. DLB is therefore likely to be more 
common in these sample populations.  
Despite these difficulties, the evidence that we do have from pathological studies 
suggests that DLB forms about 15-20% of dementia cases as a whole. As most studies 
have not distinguished DLB from PDD at autopsy, we would need to take this figure to 
represent DLB and PDD combined (LBD) rather than DLB specifically. Albeit the studies 
that do take the distinction into account, still state a DLB prevalence of 15-20%. Hence 
LBD as a whole appears to represent a significant proportion of dementia. However 
clinically the proportion appears to be much lower and this is discussed below. 
  
1.5 DLB Clinical Prevalence 
There have been two reviews of the literature carried out recently to attempt to identify 
the rate of DLB diagnosed clinically (without pathological verification). The two studies 
used different methodologies and therefore represent a robust survey of the current 
prevalence of DLB in the community. 
In the first study (Vann Jones and O’Brien, 2014), a literature search of PubMed carried 
out in 2013, revealed 18 population prevalence studies and 10 clinical prevalence 
studies. Papers were only included if they stated that the DLB consensus criteria from 
either 1996 or 2005 were used in their methods.  The mean proportion of DLB cases 
within secondary care patients with dementia, was found to be higher at 7.5% than the 
mean rate in population studies, which was 4.2%.  This may be because of the higher 
burden of symptoms in DLB that means a higher proportion attend secondary care. 
However, it could also represent the difficulty in differentiating AD and DLB in the 
community, with specialists more likely to pick up the extra-pyramidal signs in DLB and 
also the more difficult to identify clinical symptoms of fluctuation and REM sleep 
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behaviour disorder. There was also an increased prevalence found in those studies using 
the 2005 criteria compared to the 1996 criteria, of 8.2% compared to 3.7%. The addition 
of a DaTscan and REM behaviour disorder to the criteria could have played a part in 
increasing diagnostic rates using the 2005 criteria.  
It was also noted that in three studies where the primary aim was to identify the 
prevalence of DLB, the prevalence rates within dementia patients was much higher: 
19.9%-24.9%. Suggesting that if specific evidence of DLB was sought, this resulted in a 
higher diagnostic rate (Vann Jones and O’Brien, 2014). Overall the results of this 
literature review suggest there is difficulty in diagnosing DLB, particularly outside of 
secondary care, but also where there is a lack of awareness or expertise in the core 
features of the disease. 
In the second review by Hogan and colleagues (Hogan et al. 2016), a literature search 
was carried out on MEDLINE and EMBASE, revealed 17 prevalence studies, of which 
10 were in the earlier study by Vann Jones. As a proportion of all dementia cases, DLB 
made up a wide range of prevalence of 0.3 to 24.4%, with no difference found in this 
review between those studies using the 1996 criteria compared to the 2005 criteria. A 
pooled prevalence figure was not attempted due to the varying methodologies used in 
the underlying papers. It was noted in this review that the majority of the studies did not 
report on whether it was “possible” or “probable” DLB prevalence being reported. Another 
difficulty was the inconsistency in the classification of mixed AD and DLB disease, where 
this was considered at all.  The authors concluded that clinically defined DLB accounted 
for “about 5% of all dementia cases encountered in older populations”.  
 
1.6 Recent DLB Clinical Prevalence Studies 
An updated literature search was carried out to identify if further studies on the 
prevalence of DLB as a proportion of dementia cases has been carried out since the 
review by Hogan and colleagues. The search also included papers on the prevalence of 
PDD. 
A search of PubMed was carried out on 17 February 2017, looking for the following terms 
in the Title or Abstract:   
1. “LEWY” OR “PARKINSON*”, AND  
2. “INCID* OR “PREVAL*”,  AND 
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3. “DEMENTIA”  
Only articles written in English were included. Table 1.2 shows a summary of the articles 
on DLB prevalence that have been published since these two reviews.  
Yue and colleagues (Yue et al., 2016) found the prevalence of DLB in rural China to be 
10.1% using an initial door to door survey to identify dementia, followed by a clinical 
review to confirm the subtype. The authors carried out the survey with the aim of 
identifying the proportion of DLB cases in dementia as a whole. Another population study 
by Ikejima and colleagues (Ikejima et al., 2012) found a DLB prevalence of 4.6% in over 
65s with dementia in rural Japan. Once again an initial screening procedure was followed 
by a clinical assessment, but this study was not focussed on identifying DLB cases.  
Another study by Bonanni and colleagues (Bonanni et al., 2017) did not state the 
prevalence of DLB in percentage terms but found frontotemporal dementia (FTD) to be 
more common than DLB and AD. As FTD is an uncommon disorder mainly affecting 
people below the age of 65, with a prevalence of about 2.5% in the over 65s (Hogan et 
al., 2016), this was a surprising result. The study used email questionnaires and had 
limited success with a low 25% response rate. The questionnaire also focussed on the 
opinions of clinicians about the diagnosis of DLB, AD and FTD specifically, which may 
have biased the results.   
Two further studies did not distinguish between DLB and PDD and found the rate of LBD 
in dementia patients to be 5.4% and 0.8% (Perera et al., 2016; Goodman et al., 2017). 
They are discussed below under PDD prevalence.  
To summarise, the two systematic reviews suggest DLB has a prevalence of 4.2% to 5% 
of all dementia cases, which would mean that of the 800,000 dementia patients in the 
UK (Prince et al., 2014), 33,000-40,000 would have DLB. Three further studies have 
additionally investigated the presence of DLB as a proportion of dementia, but only two 
(Ikejima et al., 2012; Yue et al., 2016) had robust methodology involving clinical 
assessments. One study sought to identify DLB specifically and found a slightly higher 
rate of 10%. The other study did not and found a similar rate to the earlier reviews of 
4.6%.   
A DLB prevalence rate of about 5% would be substantially lower than the 15-20% rate 
found in autopsy studies. However, as this latter autopsy rate is for LBD, we would also 
need to look at the clinical prevalence of PDD as a proportion of dementia cases as they 
would also contribute to the number reported. 
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1.7 PDD Clinical Prevalence 
Aarsland and colleagues carried out a systematic literature review of both the prevalence 
of dementia in Parkinson’s disease and also the prevalence of PDD as a percentage of 
dementia cases as a whole (Aarsland, Zaccai and Brayne, 2005). From the 12 studies 
on the former that satisfied their inclusion criteria, a mean proportion of 24.5% had a 
diagnosis of dementia in Parkinson’s disease. A further 24 studies looked at PDD as a 
proportion of dementia, with a mean proportion reported of 3.6%.  
This was a thorough review using wide search criteria as well as of references in the 
articles found, with no restrictions on language or time frame.  The authors noted that 
several studies included in the review did not differentiate DLB from PDD, or the timing 
of the onset of parkinsonian symptoms and cognitive impairment, leading to the 
possibility that some patients reported as PDD should have been diagnosed with DLB or 
vice versa, that some patients with DLB should have been diagnosed as PDD. It should 
also be noted that the current MDS criteria for PDD (Dubois et al., 2007; Emre et al., 
2007) had not been established at the time of the review. 
Interestingly, in the studies reviewed by Aarsland and colleagues the rate of dementia 
did not correlate significantly with the mean age of PD subjects. It was noted however 
that these studies rarely stratified dementia incidence in PD according to age (Aarsland, 
Zaccai and Brayne, 2005). In addition, it is well established that dementia risk increases 
with age, an association that has previously been reported in PD specifically (Levy et al., 
2002). 
 
1.8 Recent PDD Clinical Prevalence Studies 
Since the publication of this review, the literature search described above discovered a 
further eleven studies that assessed the rate of dementia in PD (see Table 1.3) at a 
certain point in time. Nine out of the eleven reported a prevalence of dementia in PD 
patients of 20-30% (the two outliers were one study which reported a rate of 12% and 
another of 38%). This range is consistent with the 24.5% reported by Aarsland in his 
earlier review.  
Only one study used the established MDS criteria for dementia in PD (Dubois et al., 
2007; Emre et al., 2007). This clinic based study (Wang et al., 2014) of 901 PD patients 
found a dementia prevalence of 21%, again largely consistent with the figure of 24.5%. 
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The range of 20-30% was consistent despite the diverse methods used in these studies. 
Variations occurred in searching for PD cases (including clinic based and population 
based studies as well as an insurance record survey) as well as the means by which 
dementia was assessed. The latter could be a simple cognitive assessment with no 
regard to functional ability but also a more comprehensive full neurological exam, 
cognitive battery and brain imaging carried out by clinical specialists. Additionally, there 
were demographic differences in the sample population in terms of age groups and also 
geographical regions in the world and subsequently their social environment and 
education status.  
This would suggest that the consistent estimate of 20-30% of PD patients having 
dementia at any given time, is likely to be very close to the true prevalence.  This would 
not conflict with longitudinal studies that look at the number of patients with PD who are 
eventually affected by dementia. Of 130 PD patients that were followed up for 20 years, 
75% developed dementia. In total only 30 survived the entire period of 20 years and 25 
(83%) of these were diagnosed with dementia (Hely et al., 2008).   
There were no further studies more recent than the review that looked specifically at 
Parkinson’s disease dementia as a proportion of all dementia cases. Three studies 
stated the combined LBD prevalence as a proportion of dementia, not making a 
distinction between DLB and PDD, these are also listed in Table 1.3 and further 
discussed below. 
Goodman and colleagues’ (Goodman et al., 2017) survey of Medicare claims in the US, 
found a combined LBD rate of 5.4% within dementia cases as a whole. However, 
diagnoses were obtained from insurance information where diagnoses were coded 
according to ICD-9, which lists dementia with Lewy bodies as a dementia subtype but 
does not have a code for dementia in PD. The study team did not independently verify 
each diagnoses. In addition, a number of cases were entered in more than one 
diagnostic category. The study team also used the terms LBD and DLB interchangeably 
and therefore it is not clear whether the authors intended to include PDD within their 
figures. Nevertheless, over 3 million cases of dementia were included, making this an 
unusually large data set.   
A study of dementia in rural Japan found an LBD prevalence rate in the under 65s of 
6.2% using a postal survey (Ikejima et al., 2009). Both DLB and PDD were stated to be 
diagnosed using the “revised criteria for the clinical diagnosis of dementia with Lewy 
bodies”. Which would suggest that the authors have not looked for PDD within the study, 
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but have instead assumed that both diseases are the same and are diagnosed using the 
same criteria (this study is also summarised in Table 1.2).  
A study of clinical records and death certificates in a large health service in London 
reported LBD as making up 0.8% of patients with dementia (Perera et al., 2016). 
However, there were also a large proportion who had unspecified dementia (25.6%) and 
the results did not include clinical verification of the diagnosis by the study team. PDD 
was not specifically mentioned and it is likely that most of these patients had DLB. 
Indeed, Parkinson’s disease was not mentioned in the study report at all with the authors 
omitting to look for PD in the health records or on death certificates.  
Despite their methodological issues, the newer studies suggest the combined DLB and 
PDD rates of 5.4%, 6.2% and 0.8%. With the latter figure likely to be low due to the large 
number of cases that did not have a dementia subtype in their findings. Excluding this, 
the other results would not conflict with the figure for PDD as a proportion of all dementia 
cases of 3.6% found in Aarsland’s review published in 2005.   
 
1.9 Lewy Body Dementia Pathological Rates Are Higher Than Clinically Diagnosed 
Rates 
If the 3.6% found in Aarsland’s review is a reasonable estimate of clinically diagnosed 
PDD as a proportion of dementia cases and similarly the 5% from the review by Hogan 
and colleagues represents a reasonable estimate of clinically diagnosed DLB cases, the 
combined LBD clinical prevalence rate would be 8.6%. A figure that is significantly lower 
than the reported 15-20% of dementia cases ascribed to LBD at autopsy. 
For DLB, the reasons for a large discrepancy between clinically diagnosed and 
pathologically confirmed cases are likely to include the following: 
a) the lack of awareness by clinicians of how common DLB is and/or the symptoms 
of DLB, 
b) the lack of coding of the DLB diagnosis under major classification systems such 
as ICD or DSM, until very recently (2012 and 2013 respectively), 
c) the difficulties in diagnosing the condition clinically: features such as REM sleep 
behaviour disorder and cognitive fluctuation require careful clinical assessment 
(with currently no validated or widely used scales), subtle extra-pyramidal signs 
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may be missed, and the assessment of visual hallucinations has to be by the 
patient’s (or carer’s) history alone,   
d) that although biomarkers for DLB exist, for example: an abnormal DaTscan has 
been shown to have a higher than 80% specificity and sensitivity in differentiating 
LBD from other dementia subtypes (Brigo, Turri and Tinazzi, 2015), and the 
myocardial scintigraphy SPECT tracer 123I-MIBGiodine-123-meta-
iodobenzylguanidine has also been shown to have high specificity for DLB 
(Watson and Colloby, 2016), these are not widely available or commonly used in 
many countries, again making diagnosis harder, 
e) the complex nature of the relationship between AD pathology and Lewy body 
pathology and the resultant clinical syndrome – some DLB patients may not 
prominently display the classic DLB features and so appear to have AD,  
f) the perceived lack of specific treatment options for DLB reducing the motivation 
for clinicians to look for the DLB diagnosis, when the treatment will just be the 
same as for AD, and 
g) the higher proportion of DLB cases (compared to other dementia subtypes) which 
may be referred for autopsy, due to the complex nature of their symptoms, and 
possibly a higher mortality, leading to an over-representation in the autopsy 
figures.  
A study of the current rates of diagnosis of DLB in clinical practice, together with the 
diagnostic and management pathways associated with the diagnosis compared to other 
non-LBD subtypes, would show how clinicians currently approach the condition in clinical 
practice and therefore reveal which of the possible reasons discussed above (or any 
other reason) are the main drivers behind this mismatch.  
Similarly, with respect to PDD, from the clinical studies on the prevalence of dementia in 
idiopathic Parkinson’s disease, it would be expected that between 20-30% of PD patients 
would have PDD. There are 127,000 reported patients with PD in the UK (Parkinson’s 
UK, 2009). Hence about 25,000 – 38,000 people in the UK should have PDD. In terms 
of the proportion of all dementia cases that have PDD, if there are 800,000 dementia 
patients in the UK (Prince et al., 2014) and 25,000-38,000 have PDD, this would be 3.1-
4.8% in percentage terms). This would be very consistent with the PDD prevalence rate 
(as a proportion of all dementia cases) found by Aarsland and colleagues of 3.6%.  
Alternatively, if the autopsy rates are correct and 15-20% of dementia cases have LBD, 
it is possible that there are many more people with PDD as the underlying cause of their 
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dementia than the higher estimate of 4.8% (i.e. even if 30% of all PD patients are 
diagnosed with dementia). However, as previously stated, despite the large differences 
in methodology, 20-30% was consistently found as the proportion of PD cases with 
dementia, suggesting that this is close to the true prevalence rate of dementia in PD.  
Nevertheless, it would be important to know if in clinical practice 20-30% of PD patients 
are indeed being diagnosed with dementia. If so, this would suggest that the discrepancy 
may have a different cause. It could be for example that cases of idiopathic Parkinson’s 
disease dementia may be being diagnosed inaccurately as other forms of dementia - for 
example: vascular parkinsonism combined with vascular dementia.   
 
1.10 Conclusion 
In summary, the clinical literature suggest that DLB forms 5% of all dementia cases and 
PDD 3.6%, meaning LBD as a whole forms 8.6% of all dementia. At autopsy, the 
proportion is 15-20%, hence half or more of cases do not appear to be diagnosed 
clinically.  
The next chapter explores this further and describes a study of the clinical diagnostic 
rates of DLB and dementia in Parkinson’s disease in the East Anglia region of the UK. A 
detailed further analysis of the diagnostic pathway and management in individual cases, 
compared to non-DLB and non-dementia PD cases respectively, will be carried out to 
understand what may be the key drivers behind the mismatch between pathological rates 
of LBD and clinically diagnosed rates.  
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2.1 Introduction 
This chapter describes the method used to undertake a study of the clinical diagnostic 
rates of dementia with Lewy bodies (DLB) and dementia in idiopathic Parkinson’s 
disease (PDD) in the East Anglia region of the UK, prompted by the apparent 
discrepancy between the autopsy rate and clinical diagnostic rate of Lewy body dementia 
(LBD) discussed in Chapter 1. It will also describe a study analysing the diagnostic 
pathway and management of individual DLB and PDD cases, compared to non-DLB 
dementia cases and non-dementia idiopathic Parkinson’s disease (PD) cases 
respectively.  
 
2.2 Hypothesis 
a) That the proportion of dementia cases diagnosed with DLB in dementia 
assessment services in East Anglia is lower than that expected on the basis of 
autopsy studies of 15-20% (Oinas et al., 2007)(Perry et al., 1989). 
b) That a diagnosis of PDD as a proportion of all PD cases in PD and movement 
disorder services in the same region will be less than the reported figure of 20% 
(Aarsland, et al. 2005). 
c) The diagnosis of DLB is more difficult compared to non-DLB dementia subtypes, 
as indicated by DLB diagnoses taking longer and requiring more clinical 
investigations and appointments. 
d) That dementia in PD is under-diagnosed, being made late in the disease when 
symptoms are moderate to severe. 
 
2.3 Methods 
The study was split into two parts one focussing on DLB and the other on PDD as they 
are mostly seen in separate services. DLB is largely seen in memory clinics or old age 
psychiatry services and PDD is seen in movement disorder or PD clinics. 
  
Chapter 2: Lewy Body Dementia Diagnosis - Methods 
34 
 
2.3.1 Dementia with Lewy Bodies Diagnosis Survey 
To investigate the frequency of diagnosis of DLB as a proportion of all dementia cases, 
six services in two different trusts (Cambridgeshire and Peterborough Foundation Trust 
(CPFT) and Cambridge University Hospitals Foundation Trust (CUH)) within East Anglia 
were surveyed (see Table 2.1). These were chosen as they were representative of the 
services and Trusts within the East Anglia region. 
 
Table 2.1 Clinical services investigated for DLB diagnoses   
Service Trust Screening period 
South Rural, Old Age Psychiatry (OAP) CPFT 1/1/2013 to 30/6/2014 
City, OAP CPFT 1/1/2013 to 30/6/2014 
Fenland, OAP  CPFT 1/1/2013 to 30/6/2014 
Ely, OAP CPFT 1/7/2013 to 31/12/2014 
Peterborough, OAP  CPFT 1/7/2013 to 31/12/2014 
Cambridge, Memory Clinic CUH 1/7/2013 to 31/12/2014 
 
All new cases referred and assessed within these selected services in an 18-month 
period (“screening period”) during 2013 and 2014, were surveyed for diagnoses made. 
This entailed a brief review of the medical notes of each case from that service to detect 
if dementia was diagnosed. If so, further demographic and diagnostic details were 
recorded (Table 2.2). Patients were considered to have a DLB diagnosis if their last 
diagnosis in the medical notes was either “probable” or “possible” DLB or mixed 
dementia with DLB specifically mentioned. As one of the purposes of this process was 
to identify patients for further analysis of diagnostic and management pathways, the 
screening period was shifted to a later six-month period for the second set of three sites 
as they were investigated six months later or more. Identification of patients earlier on in 
their diagnostic pathways and therefore earlier on in their disease, would ideally mean 
fewer patients had died or had such severe impairment that participation was deemed 
inappropriate by their clinician.  
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Table 2.2 Demographic and diagnostic data collected for each patient with dementia 
Patient demographics collected 
Diagnosis - dementia subtype  
Age at presentation to clinic  
Gender  
Cognitive score  (e.g. Mini Mental Test Score)  
Date of initial cognitive test  
Date last seen in clinic & date first seen in clinic  
Prevalent or incident diagnosis  
Whether deceased in screening period 
 
 
2.3.2 Parkinson’s Disease Dementia Diagnosis Survey 
Similarly, to investigate the frequency of diagnosis of dementia as a proportion of all PD 
cases three PD services in three different trusts (CUH, CPFT and Norfolk and Norwich 
University Hospitals Foundation Trust (NNUH)) were identified to provide a sample of 
PD services in East Anglia (see Table 2.3).  
 
Table 2.3 Clinical services investigated for PDD diagnoses  
Service Trust Screening period 
Addenbrooke’s PD and 
movement disorders clinics 
CUH 1/1/2014 to 30/6/2015 
Elderly Medicine PD clinics NNUH 1/1/2014 to 30/6/2015 
Brookfields PD clinics  CPFT 1/1/2014 to 30/6/2015 
 
All patients seen in those services in an 18-month period within 2014 and 2015, aged 65 
and over, were surveyed for whether a PD diagnosis was made. Demographic details 
were then collected for such patients - see Table 2.4 for the data obtained. Patients were 
recorded as having PDD where the notes specifically stated “dementia” as a diagnosis, 
“cognitive impairment” or similar terms were not sufficient. 
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Table 2.4 Demographic and diagnostic data collected for each patient with PD  
Patient demographics collected 
Date of PD diagnosis  
Age at PD diagnosis  
Gender  
Whether dementia diagnosed 
Date of PDD diagnosis  
Disease duration before dementia 
diagnosis 
Cognitive test score   
Date first seen in clinic  
PD prevalent/ incident 
PDD prevalent/ incident  
Whether deceased in screening period 
 
 
2.3.3 Diagnostic and Management Pathway Analysis for DLB and PDD 
Where medical notes recorded a patient’s diagnosis as DLB or, in the case of the PDD 
survey, where the notes stated that dementia had being diagnosed in PD, such patients 
were selected for further detailed analysis of their diagnosis and management pathway. 
Patients were not approached for consent if:  
a) their clinician deemed they were unsuitable,  
b) the research team deemed they were unsuitable for social reasons apparent 
from the medical notes,  
c) their contact details were not available, or  
d) they had died.  
If written consent was obtained, a matched control patient was identified for that 
participant from the next consecutive non-DLB dementia case or non-dementia PD case 
(as appropriate) seen in the service who satisfied the matching criteria (see Table 2.5 for 
exact criteria). If the next case declined or was not suitable, the next case that matched 
criteria was identified, and so on until a control patient was recruited. For DLB patients, 
a PDD diagnosis was an exclusion criteria for control subjects. For PDD patients, 
treatment with rivastigmine during the screening period was an exclusion criteria for 
control subjects as prescription of this drug would suggest significant cognitive 
impairment and possible de facto dementia despite dementia not being formally 
diagnosed by the clinician in the notes hence such subjects would not be suitable control 
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patients. A panel of three expert clinicians reviewed the clinical data collected from the 
CRFs and applied consensus criteria (McKeith et al., 2005; Emre et al., 2007) to each 
consented case to validate the clinical diagnosis with the aim of excluding cases from 
the analysis if the LBD diagnosis were incorrect in the LBD cases or if LBD cases were 
identified in the controls.   
 
Table 2.5 Matching criteria 
DLB PDD 
Gender Gender 
Age at dementia diagnosis  (+/-5 years) Age at referral for PD symptoms (+/-5 
years)  
Within similar MMSE score range at 
dementia diagnosis: 0-9; 10-20, 21-30  
 
 
 
2.3.4 Recruitment  
23 DLB cases were recruited. Three DLB subjects could not be matched despite an 
extensive search for a control subject in each case, leaving 20 matched controls. 18 PDD 
cases were recruited, with similarly 3 subjects unmatched, leaving 15 control subjects. 
Following completion of case report forms (CRFs) (as detailed below), individual 
participant’s diagnoses were verified by two experts. One matched case for the DLB 
group was subsequently excluded as they were deemed by both experts to have PDD 
rather than AD as was diagnosed by the clinical team, hence leaving 19 control subjects 
(see figures 2.1 and 2.2 for the full details of participant recruitment). The experts 
achieved consensus and agreed with all other diagnoses. 
 
2.3.5 Case Report Forms  
CRFs were created to collect data for the in-depth medical notes review and were divided 
into sections as stated in Table 2.6 below.  
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Table 2.6 CRF description 
Section Data Collected 
Patient Details  Details of the patient’s diagnosis and living 
conditions 
Clinical Features The various clinical symptoms the patient was 
reported to have by clinicians 
Medical History All the reported medical history the patient was 
reported as having 
Drug History   Entire drug history including changes 
Family History Family history as reported by patient 
Physical Examination  Details of any examination findings 
Investigations All investigations carried out  
Pathway to Diagnosis Details of clinic appointments and home visits pre-
diagnosis 
Post-Diagnostic 
Management 
Details of clinic appointments and home visits post-
diagnosis plus further referrals and management 
steps 
 
 
 
2.4 Sample Size 
To identify the proportion of dementia cases that had a DLB diagnosis, a diagnostic rate 
below 10% was expected. If the rate found were 5%, a sample size of about 600 would 
enable a confidence interval of between 3.3% and 6.7%, as per the calculation below: 
 
2
2 )1(
d
ppz
x


 or  (1.96)2 x (.05(1-.05))/(.0172) = 631 
To identify the proportion of cases of PD with dementia, a diagnostic rate below 20% 
was expected. If the rate found were 10%, a sample size of about 300 would enable a 
confidence interval of between 6.6% and 13.4%, as per the calculation below: 
(1.96)2 x (0.1(1-.01))/(.0362) = 267.  
The actual number of dementia cases screened exceeded this figure as it became clear 
that the diagnostic rate was below even the low rate of 5% that was predicted. This was 
to enable sufficient DLB cases to be identified for detailed analysis of their diagnosis and 
management. Even after identifying over 2300 dementia cases, only 23 cases of DLB 
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were recruited for detailed notes analysis due to the low diagnostic rate and the small 
number of cases that were actually eligible for recruitment (see Figure 2.1).  
A higher number of PD cases were also identified than planned as there was a similar 
difficulty in recruitment for further detailed analysis of diagnosis and management, 
although not to the extent of the DLB subjects since the diagnostic rate was slightly 
higher for PDD (see Figure 2.2). 
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Figure 2.1 Recruitment diagram for DLB recruits 
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PDD cases 
not 
approached 
for notes 
review = 22
(deceased = 
9, unsuitable 
for approach 
=3,
clinical team 
did not 
authorise 
approach = 9, 
unable to 
establish 
contact = 1) 
PDD cases 
declined 
participation 
= 9
Total cases screened = 993
PD cases identified = 589
PDD Cases 
identified = 49
PD cases without 
dementia identified = 540
PD cases suitable as 
matches for PDD cases = 
35
PD cases not 
matched to PDD 
cases = 505
Matched PD cases 
not approached for 
notes review = 16 
(unsuitable for 
approach =5,
clinical team did 
not authorise 
approach = 7, 
unable to establish 
contact = 4) 
PDD cases 
approached for 
notes review = 
27
Matched PD cases 
approached for in-depth 
notes review = 19
PDD cases 
recruited for 
notes review = 
18
Matched PD cases 
recruited for notes review 
= 15
Matched PD cases 
declined 
participation = 4
Matched PD CRFs 
completed and entering 
analysis = 15
PDD CRFs 
completed and 
entering analysis 
= 18
Figure 2.2 Recruitment diagram for PDD recruits 
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2.5 Ethics 
The Confidentiality and Advisory Group provided permission to screen medical records 
for the surveys without obtaining patient consent. Approval was also obtained from each 
individual Trust (CPFT, CUH, NNUH) Research and Development (R&D) departments. 
Access to electronic records was also obtained at each Trust to enable the surveys. Data 
was collected in a standardised spreadsheet and stored on secure password protected 
files within each Trust’s NHS server or on secure encrypted devices. For the detailed 
notes study, potential patients and matched controls were identified and contacted by 
post and provided with a patient information sheet. Following a two week period (to allow 
sufficient time to consider the information and to provide a written reaction if they chose), 
they were contacted by telephone to arrange to discuss the study in further detail. If in 
agreement, each patient (or carer if the patient was assessed as not having capacity to 
consent) signed a written consent form permitting access to their medical records for an 
in-depth analysis of their management and diagnosis. Appendix 3 contains an example 
consent form and patient information sheet for each of the two parts of the diagnostic 
and management pathway study.  
 
2.6 Data Analysis 
Data were analysed using the Statistical Package for the Social Sciences software 
version 25 (SPSS; IBM Corporation, Armonk, NY, USA). Differences in demographic and 
clinical data were assessed using either t-tests, analysis of variance (ANOVA), or rank-
sum tests (Mann-Whitney U) as appropriate for continuous variables and χ2 test for 
categorical data. Correlations were carried out using Spearman’s rank correlation. For 
each test statistic, p<0.05 was regarded as significant. 
 
2.7 Funding 
All studies mentioned in this chapter and chapter 3 and 4 were part of the Diamond Lewy 
study, funded by the NIHR (Grant Reference Number DTC-RP-PG-0311-12001). 
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3.1 Introduction 
This chapter sets out the results from the study described in Chapter 2, starting with the 
diagnostic rates of both dementia with Lewy bodies (DLB) and Parkinson’s disease 
dementia (PDD) and concluding with the analysis of the diagnostic and management 
pathways of both conditions compared to control patients.  
 
3.2 DLB Prevalence  
1929 cases of dementia were identified, with the proportions of each subtype listed in 
Table 3.1. The proportion of dementia cases diagnosed with DLB was 3.3% (95% 
confidence interval (CI) 2.6% to 4.2%, calculated using the Wilson method). As expected, 
Alzheimer’s dementia (AD) was the most common form of dementia diagnosed, followed 
by “mixed” dementia - the vast majority of which did not have any further details given, 
with a few where the diagnosis was explicitly stated as AD and vascular dementia.   
 
Table 3.1 Dementia subtype proportions within the 1929 cases 
 
*These are all the deaths that were recorded in the medical notes and is the minimum 
figure. Other deaths may not have been recorded in the notes, hence the figure 
could be higher for each subtype. 95% confidence intervals were calculated using 
the Wilson method. MMSE = Mini mental state examination. 
 
PDD was diagnosed in 2.0% of dementia patients seen (CI: 1.5% to 2.8%). Vascular 
dementia was third most common and frontotemporal dementia (FTD) was the rarest 
type. 8.6% of patients did not have a specified type of dementia, with clinicians simply 
diagnosing “dementia”. Figure 3.1 shows a bar chart of the frequencies of each type. 
Dementia Subtype
Number Proportion (%) 95% 
Confidence 
Interval
Mean Age at 
Presentation
Males (%) Mean MMSE 
Score at 
presentation
Proportion (%) 
deceased during 
Screening Period*
Alzheimer's dementia 888 46.0% 43.8 to 48.3% 81.0 34.8% 20.1 6.3%
Vascular 286 14.8% 13.3 to 16.5% 83.6 46.5% 20.0 17.5%
Mixed 455 23.6% 21.8 to 25.5% 84.4 44.2% 20.6 9.0%
Dementia with Lewy bodies 63 3.3% 2.6 to 4.2% 81.1 52.4% 20.1 15.9%
Parkinson's disease dementia 39 2.0% 1.5 to 2.8% 80.0 74.4% 20.0 25.6%
Fronto-temporal 32 1.7% 1.2 to 2.3% 69.4 56.3% 24.9 3.1%
Unspecified 166 8.6% 7.4 to 9.9% 83.5 34.9% 19.0 16.9%
1929 100.0% 82.2 40.5% 20.3 10.2%
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Figure 3.1 Frequency of dementia subtypes recorded. Error bars = 95% 
confidence intervals calculated using Wilson method 
 
There was no significant variation in the prevalence rate across the six services (P=0.43, 
Chi Squared test) sampled (Figure 3.2) with the proportion of DLB cases ranging from 
2.4% to 5.1%.  
At the time of presentation to the relevant service, the mean age of patients diagnosed 
with DLB was 81.1. Comparison of the mean ages across groups showed significant 
differences (F(6,198) = 24.7, P= <0.001, Welch F-test/ANOVA as there was no 
homogeneity of variance between groups). Post-hoc analysis with the Games-Howell 
test revealed DLB patients were significantly older than FTD patients at presentation, but 
no significant differences were found between DLB and other dementia subtypes 
(Figures 3.3 and 3.4). FTD patients presented at a much younger age then patients of 
all other dementia subtypes (P<0.001). AD patients were also significantly younger than 
patients with vascular dementia (P<0.001), mixed dementia (P<0.001) or those with an 
unspecified dementia (P=0.02) at presentation to the service. Similarly PDD patients 
were younger than vascular dementia (P=0.04) and mixed dementia (P=0.005) patients 
at presentation.  
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The mean age of female patients with dementia was significantly higher (P<0.001, t-test) 
than males at presentation to the clinical service (Figure 3.5): 83.1 years compared to 
80.9 years.  
52.4% of patients with DLB were male (Figure 3.6), higher than in AD (34.8%) and 
vascular dementia (46.5%) but lower than in both FTD (56.3%) and PDD (74.4%).  
 
  
Figure 3.2 DLB prevalence for each service. No significant variation was found. 
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Figure 3.3 Mean age at presentation of each dementia subtype 
 
 
Figure 3.4 Box plots of age at presentation of each dementia subtype  
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Figure 3.5 Age at presentation in years according to gender (***= P<0.001) 
 
 
Figure 3.6 Gender distribution for each dementia subtype 
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3.3 PDD Prevalence 
The prevalence of dementia as recorded in the medical notes of idiopathic PD cases was 
8.3% (CI: 6.4% to 10.8%), with the proportion varying between services, ranging from 
4.5% to 10.0% (Table 3.2). However the variation was not found to be statistically 
significant (chi squared test, P=0.11). There was no variation found in the gender 
distribution of patients with PD, between the services (chi squared test, P=0.25).  
 
Table 3.2 PDD prevalence figures and demographics across difference services.  
 
CIs were calculated using the Wilson method. Mortality figures were unavailable for 
service 3.  
 
The mean age at PD diagnosis was however significantly higher in one service compared 
to the others, with a mean age of 78.3 years compared to 71.4 and 70.8 (ANOVA, 
F(2;557) = 40.4, P<0.001). The same service had the lowest rate of PDD diagnosis at 
4.5% but the mean disease duration (the time between PD diagnosis and PDD 
diagnosis) was similar to the other services at a mean of 5.4 years (ANOVA, F(2,35) = 
0.118, P=0.89). There was no mortality data (the percentage of all patients to have 
deceased during the screening period) available for this service, but the combined 
mortality rate was 11.1% for the remaining two services and was not significantly different 
between each (chi squared test, P=0.63). 
Different cognitive tests were used by the services. Service 1 used a combination of  
Addenbrooke’s Cognitive Exam – Revised 2005 (ACE-R) and Mini Mental State 
Examination (MMSE) and service 3 used a combination of MMSE and Montreal 
Cognitive Assessment (MOCA). Service 2 did not record test results, suggesting no 
formal tests of cognition were carried out as part of that clinic. A comparison of MMSE 
Service
Number PDD 
number
Proportion 
PDD (%)
95% 
Confidence 
Interval
Mean Age 
at PD 
Diagnosis
Mean 
disease 
duration 
(yrs) before 
PDD
Males 
(%)
Died in 
Screening 
Period
Mean 
MMSE 
Scores 
(PD only)
1 359 36 10.0% 7.3%-13.6% 71.4 6.1 58.5% 11.4% 21.3
2 74 6 8.1% 3.8%-16.6% 70.8 5.3 52.7% 9.5% -
3 156 7 4.5% 2.2%-9.0% 78.3 5.4 51.0% - 28.0
All 589 49 8.3% 6.4%-10.8% 73.1 5.9 55.8% 11.1% 25.1
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scores between service 1 and service 3 in PD patients without dementia showed 
significantly higher scores in service 3: 28.0 v 24.0 (Mann-Whitney U, P<0.001).  
Table 3.3 shows a comparison of the age at diagnosis, gender and mortality of PD 
patients with and without dementia. There was significantly more male patients (71.4%) 
with dementia (chi squared test, P=0.02) than females. Both groups had a similar 
mortality rate (Fisher’s Exact Test, P=0.37) and near identical ages at diagnosis of PD. 
However it was not possible to detect whether patients in service 3 had died as this was 
not recorded in their paper medical notes – the other services used electronic records 
which recorded whether a patient was deceased by reference to the NHS spine. 
 
Table 3.3 Comparison of PD and PDD patients from all three services 
 
Note: mortality data was not available for service 3. 
 
There was a significant negative correlation between the age of diagnosis of PD and the 
time before the diagnosis of dementia in PDD patients (Spearman’s correlation, P=0.003, 
= -0.47) as seen in Figure 3.7. 
 
Diagnosis
Number Mean Age at 
PD Diagnosis
%Died in Screening 
Period
Males 
(%)
PD 540 73.1 9.9% 54.4%
PDD 49 73.0 11.9% 71.4%
All 589 73.1 11.1% 55.8%
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Figure 3.7 Correlation between age at PD diagnosis and disease duration before 
dementia (P=0.003, Spearman’s Rho). 
 
3.4 Summary of Prevalence Results 
The proportion of dementia cases diagnosed with DLB was 3.3% and Alzheimer’s 
disease, was the commonest form of dementia diagnosed, at 46.0%.  DLB patients were 
found to be significantly older than FTD patients at presentation but there were no 
significant age differences at presentation with other dementia subtypes. Also, a higher 
percentage of DLB subjects were male compared to AD and vascular dementia subjects.  
The proportion of PD subjects diagnosed with dementia was 8.3% and significantly more 
patients with PDD were male (71.4%) than female. There was also a significant negative 
correlation between the age at diagnosis of PD and the time before the diagnosis of 
dementia.    
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3.5 DLB Diagnostic and Management Pathway 
3.5.1 Demographics 
Twenty three patients diagnosed with DLB and 19 patients diagnosed with a dementia 
subtype other than DLB or PDD were recruited for analysis of their diagnostic and 
management pathway. The demographics of the recruits in the two groups are shown in 
Table 3.4 and revealed no significant differences in age at dementia diagnosis, MMSE 
score at diagnosis or gender. The control group consisted of the following subtypes of 
dementia: 13 AD, 5 mixed AD and vascular and 1 vascular. The matching process is 
further described in Chapter 2. 
 
Table 3.4 Demographics of recruits to DLB diagnostic pathway analysis 
 
Both the age and MMSE scores are at the time of any dementia diagnosis. Chi Sq = Chi 
Squared statistical test. 
 
3.5.2 Comparison of Diagnostic Pathways 
Comparisons were made between the two groups with respect to the number of 
diagnoses made prior to their last diagnosis, the number of home visits and clinic 
appointments required before their final diagnosis was made, as well as the time period 
between the final diagnosis being made and (i) their first referral to the service, and (ii) 
their first appointment at the service, both for their cognitive complaint. Additional 
comparisons were also made between the number of clinic appointments and home 
visits made after their final diagnosis.  The results are shown in Table 3.5. 
The comparison between groups showed that before a final diagnosis was made, DLB 
participants on average had more alternate diagnoses, home visits and clinic 
appointments. They also had a longer time period on average until their final diagnosis 
was made from both (i) the date of referral to a service and (ii) the time seen in the 
service for the first time. Of these, the number of dementia diagnoses before the final 
Demographic DLB Non-DLB Group Difference
Gender: males/females 14/9 11/8 ChiSq=0.04; p=0.85
Age in years: mean +/-SD 80.3 +/- 9.4 78.0 +/- 9.2 t=0.81; p=0.43
MMSE: mean +/- SD 20.2 +/- 5.5 19.3 +/-5.3 t=0.57; p=0.57
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diagnosis (P=0.007) and also the number of clinic appointments faced by DLB patients 
(P=0.03) before a final DLB diagnosis was made, were statistically significant (with the 
Mann-Whitney U test) between the groups.     
After a final diagnosis was made, the number of home visits faced by both groups was 
similar, but DLB patients had on average significantly higher clinic appointments (Mann-
Whitney U, P=0.04).  
 
Table 3.5 Comparison of the diagnostic pathways in DLB and non-DLB patients 
 
 
Old Age Psychiatrists made the majority of diagnoses in both groups, although DLB 
patients were slightly more likely to have a diagnosis made by a Neurologist (see Table 
3.6).  
 
 
 
 
Group Mean Std Dev
p value (Mann-
Whitney U) 
Number of diagnoses made before final diagnosis DLB 0.7 0.76 * p=0.007
Non-DLB 0.2 0.50
Home visits before final diagnosis DLB 4.6 7.70 p=0.14
Non-DLB 2.0 2.20
Clinic appointments before final diagnosis DLB 2.0 2.00 * p=0.034
Non-DLB 0.6 0.81
Total (home visits and clinic) appointments DLB 5.2 7.60 p=0.050
     prior to final diagnosis Non-DLB 2.3 2.69
Home visits after final diagnosis DLB 7.3 6.40 p=0.75
Non-DLB 7.1 7.30
Clinic appointments after final diagnosis DLB 1.4 1.40 * p=0.041
Non-DLB 0.4 0.74
Total (home visits and clinic) appointments DLB 7.3 6.20 p=0.95
     after final diagnosis Non-DLB 7.4 7.10
Time from referral to service to final DLB 11.8 21.9 p=0.30
     diagnosis (months) Non-DLB 8.6 13.9
Time from 1st appointment at service to final DLB 10.0 21.8 p=0.35
     diagnosis (months) Non-DLB 7.4 14.0
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Table 3.6 Comparison of the clinicians who made the final diagnosis in both groups  
 
 
3.5.3 Comparison of Symptomatology 
A comparison of the symptomatology of the groups (see Table 3.7), showed that, as 
expected, the core features of DLB (parkinsonism, visual hallucinations, fluctuating 
cognition) were all much more present in the DLB group, each at a highly significant level 
(chi squared test, P≤0.001). The supportive feature of rapid eye movement (REM) sleep 
behaviour disorder was also much more prevalent in the DLB group, though the 
difference was not as statistically significant (each at P<0.05, Fisher’s test). There were 
no patients in either group with recorded severe neuroleptic sensitivity.  
 
3.5.4 Diagnostic Threshold 
The majority of patients (61%) exceeded the diagnostic threshold for “probable” DLB as 
set out in the 2005 consensus criteria (McKeith et al., 2005), with 44% of these having 
at least three core features (see Table 3.8).     
 
Table 3.7 Comparison of the core and suggestive features of DLB as seen in both groups 
at time of final diagnosis 
 
Clinician Making 
Diagnosis
Old Age 
Psychiatrist Neurologist Geriatrician 
DLB 18 4 1
non-DLB 17 2 0
At time of final diagnosis Group Present Statistic p value
Parkinsonism DLB 70% ChiSq=15 p<0.001
Non-DLB 11%
Visual Hallucinations DLB 78% ChiSq=22 p<0.001
Non-DLB 5%
Fluctuating Cognition DLB 65% ChiSq=10 p=0.001
Non-DLB 16%
REM sleep behaviour disorder DLB 39% Fishers p=0.038
Non-DLB 11%
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Table 3.8 Presence of core and suggestive features of DLB in DLB group at the time of 
diagnosis 
 
 
Table 3.9 Comparison of the imaging carried out in each group 
Imaging Carried 
out 
CT 
Scan MRI DaTscan Refused 
No 
Data 
DLB 16 4 1 0 2 
non-DLB 10 4 0 1 4 
DaTscan = Dopamine transporter scan 
 
3.5.5 Comparison of Imaging, Carer Stress and Co-morbidities 
All patients underwent neuro-imaging – either CT head or MRI head, or in one DLB case 
– a dopamine transporter scan (DaTscan), unless they explicitly refused (Table 3.9).   
Episodes of stress related to the patient’s care expressed by their carer at an 
appointment were also compared, with DLB patients’ carers experiencing more episodes 
on average (0.6 v 0.4), but this difference was not statistically significant (Mann Whitney 
U, P=0.26).  
Co-morbidities such as repeated falls, constipation, urinary incontinence and orthostatic 
hypotension were more common in the DLB group, however only repeated falls were 
statistically significantly higher in the DLB group (Table 3.10). However, many of the non-
Symptoms at Final Diagnosis %
3 CORE +1 or more suggestive 17.4%
3 CORE 26.1%
2 CORE + 1 or more suggestive 17.4%
2 CORE 21.7%
1 CORE + 1 or more suggestive 4.3%
1 CORE 8.7%
1 or more suggestive 4.3%
0 features 0.0%
100.0%
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DLB group’s notes did not state whether the clinician considered the presence of the 
symptoms. 
 
Table 3.10 Comparison of co-morbid symptoms including autonomic symptoms in both 
groups 
 
 
3.6 PDD Diagnostic and Management Pathway 
3.6.1 Demographics 
Eighteen patients diagnosed with PDD and 15 PD patients not diagnosed with dementia 
(controls) were recruited for analysis of their diagnostic and management pathway. The 
demographics of the recruits in the two groups are shown in Table 3.11 and revealed no 
significant differences in age at referral for PD symptoms or gender. The matching 
process is further described in Chapter 2. 
 
Table 3.11 Demographics of recruits to PDD diagnostic pathway analysis  
 
The age is at the time of referral for PD symptoms. 
 
 
Group
Number with 
symptom Statistic p value
Repeated Falls DLB 18 ChiSq=6 p=0.016
Non-DLB 8
Constipation DLB 9 ChiSq=0.9 p=0.47
Non-DLB 4
Urinary Incontinence DLB 12 ChiSq=1.83 p=0.26
Non-DLB 5
Orthostatic Hypotension DLB 4 Fishers p=0.56
Non-DLB 3
Demographic PDD PD Group Difference
Gender: males/females 15/3 13/2 Fisher's; p =0.56
Age at referral for PD symptoms: mean +/- SD 69.2 +/-16.6 71.5 +/-6.4 t=-.49; p=0.63
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3.6.2 Functional impairment before diagnosis 
Seven PDD patients (39%) were found, either at a clinic appointment or at a home visit, 
to have cognitive impairment that impaired their activities of daily living (ADLs) before a 
PDD diagnosis was made, with a mean duration of 1.5 years between the impairment 
and a dementia diagnosis. Six PDD subjects (33%) had impairments in two or more 
cognitive domains before their dementia diagnosis, with a mean duration of 0.3 years 
between the two events. However, only two (11%) of these patients had both: 
impairments in multiple cognitive domains and impaired ADLs due to their cognitive 
impairment, noted in the records prior to a dementia diagnosis being made.  
 
3.6.3 Treatment before diagnosis 
Five PDD patients (28%) were started on rivastigmine before a diagnosis of PDD was 
made (the diagnosis was made at a later clinical appointment), with a mean of 0.9 years 
before their diagnosis. One such patient had an intervening time period of 4.4 years prior 
to their diagnosis of PDD.   
 
3.6.4 Investigations 
A comparison of the two groups showed that PDD patients had significantly more 
cognitive tests than the PD control group (Mann-Whitney U, P=0.011) and a larger 
number of imaging tests (Mann-Whitney U, P=0.009) – see Table 3.12.  
 
Table 3.12 Group comparison of assessments and carer stress events recorded 
 
 
Group Mean Std Dev
p value (Mann-
Whitney U) 
Number of imaging tests PDD 1.7 1.36 p=0.009
PD 0.6 0.63
Number of cognitive assessments PDD 2.8 1.60 p=0.011
(MOCA, MMSE, ACE-R, ACE-III) PD 1.3 1.60
Carer Stress Events Recorded PDD 0.6 0.70 p=0.048
PD 0.1 0.52
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3.6.5 Carer stress 
Significantly higher numbers of carer reported stress events were recorded in the 
medical notes of PDD patients, compared to PD control patients (Mann-Whitney U, 
P=0.048), see Table 3.12. 
 
3.6.6 Symptomatic PD subjects without dementia 
Seven of the control PD subjects (47%) had cognitive impairment noted in their medical 
records, of which four (27%) had impairments in multiple cognitive domains and one 
separate subject (7%) was sufficiently impaired that their cognitive impairment impacted 
on their ADLs.   
Two of the control patients (13%), both of whom had recorded cognitive impairment, had 
been treated with rivastigmine in the past, prior to the screening period, though they were 
never formally diagnosed with dementia.  Note however that patients who were on 
treatments for cognitive impairment during the screening period were excluded from 
recruitment to the PD control group. 
 
3.6.7 Clinicians making the diagnosis 
Neurologists and geriatricians were found to make the PD diagnosis, however dementia 
diagnoses were made mostly by Old Age Psychiatrists (10 out of 18 subjects), see Table 
3.13. 
 
Table 3.13 Group comparison of the speciality making the final diagnosis 
 
 
 
 
Clinician Making 
Final Diagnosis
Old Age 
Psychiatrist Neurologist Geriatrician No Data
PDD 10 2 4 2
PD 0 6 9 0
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3.6.8 Symptomatology 
Visual hallucinations, fluctuating cognition and REM sleep behaviour disorder were all 
recorded at a significantly higher frequency in PDD patients compared to PD patients 
(see Table 3.14 and Figures 3.8-3.10).  
 
Table 3.14 Presence of symptoms characteristic of dementia with Lewy bodies within 
PD and PDD subjects 
 
 
 
   
 Figure 3.8 Frequency of fluctuating  cognition in each group 
 
 
Symptom Group Present Statistic p value
Visual Hallucinations PDD 88% ChiSq=12.5 p<0.001
PD 27%
Fluctuating Cognition PDD 92% ChiSq=18.6 p<0.001
PD 7%
REM sleep behaviour disorder PDD 59% ChiSq=3.3 p=0.07
PD 27%
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Figure 3.9 Frequency of visual hallucinations in each group 
 
 
Figure 3.10 Frequency of REM sleep behaviour disorder in each group 
 
Impairment in each of the cognitive domains was recorded at a significantly higher 
frequency in the PDD group (see Table 3.15). Memory impairment was ubiquitous in the 
PDD group and present in a third of the control group. Attentional impairment was absent 
Chapter 3: Lewy Body Dementia Diagnosis - Results 
62 
 
in the control group and was the least frequently impaired of all the domains in the PDD 
group.   
 
Table 3.15 Presence of impairments in cognitive domains  
 
 
Similarly, other symptoms associated with PD and LBD were recorded at significantly 
more frequency in the PDD group: excessive daytime sleepiness, swallowing difficulties, 
repeated falls, anxiety, orthostatic hypotension and changes in personality (see Table 
3.16). Constipation and bladder instability was noted at similarly high levels in both 
groups and there was no statistical difference seen. Depression was more frequent in 
the PDD group, however the difference was not significant.  
 
  
Cognitive Domain Impaired Group Present Statistic p value
Attention PDD 62% Fisher's p=0.002
PD 0%
Executive PDD 85% ChiSq=9 p=0.003
PD 25%
Visuo-spatial PDD 79% ChiSq=9.9 p=0.002
PD 17%
Memory PDD 100% Fisher's p<0.001
PD 33%
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Table 3.16 Presence of associated symptoms 
 
 
3.7 Summary of Diagnostic and Management Pathway Results 
DLB patients on average had a longer time period in secondary care, plus more home 
visits, and significantly more clinic appointments and alternate diagnoses, than their non-
DLB dementia counterparts, before their final diagnosis was made. The majority of all 
dementia diagnoses, including DLB, were made by Old Age Psychiatrists.  
The core features of DLB were present at much higher levels in the DLB group as would 
be expected; however 61% exceeded the threshold for probable DLB at the time of final 
diagnosis and 44% had at least three core features as per the 2005 consensus criteria.   
In PDD patients, time lags were found between functional impairment, such as cognitive 
impairment affecting ADLs, before a dementia diagnosis was made and more than a 
quarter of PDD patients were started on rivastigmine before a dementia diagnosis. 
Cognitive impairment was also noted in several control subjects and two were started on 
treatment for dementia without a dementia diagnosis. 
Significantly higher numbers of carer reported stress events were recorded in PDD 
patients’ notes compared to PD patients. Visual hallucinations and fluctuating cognition 
Symptom Group Present Statistic p value
Excessive Daytime Sleepiness PDD 81% ChiSq=7.3 p=0.007
PD 33%
Swallowing Difficulties PDD 65% ChiSq=4.6 p=0.03
PD 27%
Repeated Falls PDD 77% ChiSq=6.0 p=0.01
PD 33%
Anxiety PDD 77% ChiSq=6.0 p=0.01
PD 33%
Depression PDD 59% ChiSq=1.1 p=0.29
PD 40%
Orthostatic Hypotension PDD 87% ChiSq=11.5 p<0.001
PD 23%
Changes in Personality PDD 53% Fisher's p=0.007
PD 7%
Constipation PDD 89% Fisher's p=1
PD 87%
Bladder Instability PDD 72% Fisher's p=0.41
PD 87%
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were also recorded at significantly higher frequency in PDD patients compared to PD 
patients.   
In addition, cognitive impairment in the memory domain was present in 100% of PDD 
subjects and impairments in visuospatial skills, executive function and attention were 
also present at a significantly higher level in PDD compared to PD, as expected. Other 
symptoms common to PD and LBD, such as swallowing difficulties, orthostatic 
hypotension and repeated falls, were also found at a significantly higher level in the PDD 
group. 
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4.1 Introduction 
In this chapter the prevalence rates of dementia with Lewy bodies (DLB) and Parkinson’s 
disease dementia (PDD) identified in the results of the notes review are discussed, 
together with the differences found in the diagnosis and management of both compared 
to non-DLB dementia subjects and Parkinson’s disease (PD) subjects respectively.   
 
4.2 DLB Prevalence  
DLB was diagnosed in only 3.3% (95% confidence interval (CI) 2.6% to 4.2%) of subjects 
diagnosed with dementia, which is lower than that found in systemic reviews of the 
clinical prevalence rate of DLB: 5% was reported by Hogan and colleagues (Hogan et 
al., 2016) from combined community and secondary care studies and 7.5% was reported 
in secondary care populations by Vann-Jones and O’Brien (Vann Jones and O’Brien, 
2014). It is much lower than that found in neuropathological studies (Fujimi et al., 
2008)(Jellinger and Attems, 2011), which report at least 15% of dementia patients meet 
pathological criteria for DLB. 
This study intentionally aimed to identify frequency of diagnosis in routine clinical 
practice, reflecting the experience of patients being assessed in secondary care. This 
would likely result in lower rates than if DLB was prospectively sought with re-
examination of all subjects with this in mind. The majority of other studies within the 
systematic reviews required the research team to assess dementia patients clinically for 
subtypes which could increase diagnostic rates of DLB as the research team are paying 
increased attention to symptomatology, particularly in studies investigating DLB 
prevalence specifically.  
Hence the results may indicate a lower rate of disease detection, rather than true disease 
prevalence in the region. Differences in detection are supported by the range in 
prevalence of DLB observed between services (2.4% to 5.1%), though the differences 
were not statistically significant.  
Another potential reason for lower rates than expected, is that the services studied 
receive mainly community based referrals and hence reflect a broader dementia 
population than the specialist centres often studied in secondary care prevalence papers. 
Services in this study were selected primarily as they were similar to psychiatry, 
neurology and geriatric medicine practices within the NHS throughout the UK.  
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Variation in true disease prevalence cannot be entirely ruled out however, the low rates 
seen in the region sampled could simply reflect the degree of exposure to causative or 
precipitating biological factors, although as yet there is no evidence of an environmental 
causative factor.  
The prevalence of Alzheimer’s dementia (AD) of 46.0% in this study was lower than 
found in a European wide systemic review of the prevalence of different dementia 
subtypes in those older than 65, at 53.7% (Lobo et al., 2000) and a Japanese community 
study which reported 67.4% (Ikejima et al., 2012). Vascular dementia prevalence here 
(14.8%) was consistent with that found in the studies stated (15.8% and 18.9% 
respectively).  A UK survey of dementia prevalence commissioned by the Alzheimer’s 
Society and based on an expert Delphi process, found AD to make up 62% of all 
dementia cases and vascular dementia to make up 17% (Knapp et al., 2014). 
However, 24% of dementia cases were found to be “mixed” in the current study and this 
excluded cases which specifically stated a combination of LBD with another subtype, 
which were recorded as DLB. In addition, 8.6% of patients were diagnosed with dementia 
without a subtype being given in the notes (hence classified as “unspecified”). This is a 
combined 32.6%, and could mean some cases of DLB (as well as other dementia 
subtypes) fell into these categories due to diagnostic uncertainty and could also explain 
a lower rate of AD than found in the prevalence studies stated. Indeed the percentage of 
cases recorded as mixed was much higher than reported in the aforementioned 
Japanese study (at  4.2%) (Ikejima et al., 2012). Mixed cases were not explicitly stated 
in the European systematic review. It is also higher than reported by a recent report from 
the Alzheimer’s Society – 10% (Knapp et al., 2014), where “other” dementia cases were 
also reported to make up 3%. In addition, the study by Ikejima and colleagues (Ikejima 
et al., 2012), reported 3.3% of cases  as “other illnesses” but did not elaborate on whether 
these included those with an unspecified subtype of dementia. In contrast, a survey of 
death certificates specifying dementia in South London, reported a high level of 
unspecified dementia at 25.6% (Perera et al., 2016), but is difficult to interpret as death 
certificates are often completed by doctors who have known the patient over a short 
admission and the diagnoses were not combined with any form of clinical assessment 
by the research team. 
 
Frontotemporal dementia (FTD) patients made up 1.7% of all dementia subjects in this 
study, which falls between the rates found in the Japanese prevalence study of 1.1% 
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(Ikejima et al., 2012) and the report by the Alzheimer’s society, of 2%. The European 
study did not report FTD rates. FTD patients were also significantly younger than patients 
with other dementia subtypes but an average of 69 is still older than the typical mean 
age of presentation of FTD patients, which is in their 50s (Woollacott and Rohrer, 2016), 
however the higher age is likely to be due to this study being conducted on an older 
sample of patients within mainly old age psychiatry services.  
Female dementia patients were older at presentation than males (83.1 years compared 
to 80.9 years), which is consistent with a faster rate of increase in the proportion of 
females (compared to males) developing dementia as age increases (Van Der Flier and 
Scheltens, 2005). Interestingly AD patients were younger at presentation than their 
vascular dementia counterparts, as well as those with mixed and unspecified dementia. 
AD prevalence is typically reported to increase steeply with age, more so than vascular 
dementia (Van Der Flier and Scheltens, 2005). The older age of presentation of the 
mixed and unspecified dementia patients adds support for some AD patients to have 
fallen within these two non-specific groups. 
In summary, DLB prevalence was lower than reported in clinical prevalence studies, 
which are in turn lower than that reported in pathological studies. This study looked at 
routine clinical practice, whereas the majority of other studies within the systematic 
reviews required the research team to assess dementia patients clinically for subtypes 
and hence points to poor detection of DLB in clinical practice and also indicates a clear 
need for future work to address ways this could be increased. The subsequent diagnostic 
pathway analysis, which tries to understand other possible causes, is discussed further 
in this chapter. In addition, the large group of mixed and unspecified dementias within 
this study would be consistent with DLB patients (and to an extent AD patients) being 
given these diagnoses which are associated with uncertainty (the unspecified group 
more so than the mixed group) and lowering the figure specifically diagnosed with both 
DLB and AD subtypes.  
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4.3 PDD Prevalence 
Dementia was diagnosed in only 8.3% (CI 6.4% to 10.8%) of patients with Parkinson’s 
disease , much lower than the figure reported in clinical prevalence studies of between 
20-30% (Aarsland, Zaccai and Brayne, 2005) (Wang et al., 2014). Whilst there was some 
variation between the three services that were reviewed, the differences were not 
significant statistically.  
Methodological differences are likely to have been the most significant factor in the lower 
rate of dementia found. The majority of recent studies aiming to ascertain the proportion 
of PD patients with dementia were clinic based and used a form of clinical assessment - 
see Chapter one. The systematic review by Aarsland and colleagues in 2005, only 
included papers where the study team carried out a prospective clinical examination. 
There was however one recent study which used similar methodology – a retrospective 
notes analysis, but in an Italian regional movement disorders clinic, and this showed a 
similar low rate of dementia in PD of 12% (Cereda et al., 2016). The differences seen 
here may indicate that routine clinical practice does not reflect the ‘true’ prevalence of 
dementia in PD. 
This study also shows service variation. One service (service 3) had a significantly higher 
age at diagnosis of PD at 78 (compared to 71 in the other two) and also a lower rate of 
dementia diagnosis at 4.5% (compared to 8.1% and 10%) though the latter was not 
significant. The length of time between the diagnosis of PD and the subsequent dementia 
was however similar to the other services. All three services recorded a mean of between 
5.3 and 6.1 years. This suggests that the older age at presentation likely reflects an older 
population within that clinic rather than clinicians diagnosing PD later in the disease 
course - service 3 was a geriatrics movement disorders clinic, whereas the other two 
were combined neurology and geriatrics movement disorder clinics. An older population 
could also mean that fewer patients survived long enough for a dementia diagnosis 
leading to the lower prevalence of dementia in that service, but this could not be verified 
as mortality data was not available for this service.  
Mini mental state examination (MMSE) scores were the only tests that were used in more 
than one service and hence comparable between services. A comparison between 
services 1 and 3 showed service 3 patients had significantly higher scores at dementia 
diagnosis (28 v 24). As stated, the lack of difference in disease duration between PD and 
dementia in this service, suggests that the higher cognitive scores are unlikely to 
represent clinicians having a lower threshold for dementia in that service, a point 
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supported by the lower rate of dementia diagnosis in this service compared to service 1, 
but it may mean that other markers of dementia were being used to make the diagnosis.  
A higher proportion of patients with dementia were male (71%) than female. PD is 
thought to be more common in males than females, with meta-analysis of both incidence 
and prevalence studies of PD reporting evidence of higher rates in men (Twelves et al., 
2003; Pringsheim et al., 2014), a 2:1 male predominance has been reported in one large 
study (Baldereschi et al., 2000). A higher incidence of dementia in males with PD has 
also been found of 62.7% (Cereda et al., 2016), with male gender thought to be a risk 
factor for dementia overall due to hormonal differences, as oestrogen is thought to be 
protective (Vest and Pike, 2013). However, it is far from clear that this interesting 
observation will translate into clinical benefit, as there is no evidence that hormone 
replacement therapy protects against dementia. Indeed, the largest randomised control 
trial undertaken thus far actually showed an increase in dementia incidence with therapy 
(Uchoa, Moser and Pike, 2016).  
The results also showed a significant correlation between age at PD diagnosis and time 
before dementia, which is consistent with age being a very well established risk factor 
for dementia (Van Der Flier and Scheltens, 2005). A tendency for clinicians to diagnose 
dementia more readily in older patients cannot be excluded however, though the 
opposite could also be argued as older patients are far more likely to be diagnosed 
initially with a severe dementia, which clinicians have failed to diagnose in its earlier 
stages.  
In summary, dementia was diagnosed in this study of clinical practice at much lower 
levels than other studies using clinical assessments by the research team, suggesting 
that either an inability by clinicians to diagnose dementia or perhaps a reluctance to do 
so. The subsequent diagnostic pathway analysis tries to understand which of these 
scenarios is more likely and is discussed further in this chapter. 
Strengths of this DLB and PDD prevalence study include the large sample size (>5000 
cases sampled) compared to previous studies, its representativeness, in that access to 
all cases within a service was allowed and, since clinical diagnoses were used, its clinical 
relevance. A potential limitation was the inability to verify the diagnoses which would 
have required full clinical examination of all cases and was therefore not feasible.  
However, cases were reviewed with respect to diagnosis by an expert panel, for the 
purposes of the subsequent in-depth notes study, and a diagnosis of LBD was validated 
in each case recruited as such. This provides a degree of confidence that those patients 
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in whom LBD was diagnosed in the prevalence study, are likely to have a diagnosis of 
LBD. One participant recruited as a control for the DLB diagnostic pathway study, as he 
was diagnosed with AD by the clinical team, was however considered to have PDD by 
the panel, and therefore excluded from the analysis.  This is also consistent with the 
notion that LBD cases are being misdiagnosed as other dementia subtypes. 
 
4.4 DLB Diagnostic Pathway 
DLB patients needed a significantly greater number of clinic appointments and had 
significantly more diagnoses before their final diagnosis than patients with other subtypes 
of dementia. The mean number of home visits before final diagnosis and the total number 
of appointments (clinic attendance and home visits) were also higher for DLB patients 
but these differences were not statistically significant. A higher number of both clinical 
contacts before diagnosis and alternate diagnoses, would suggest difficulty on the part 
of clinicians to reach the diagnosis. The mean times experienced by patients from both 
referral to the secondary care service and their first appointment in that service, to the 
establishment of a final diagnosis, were also higher for those with DLB, but these 
differences were again not statistically significant. Post diagnosis, the number of clinic 
appointments attended by DLB patients was also higher than non-DLB patients. Home 
visits were however similar in number. 
The results of this study are consistent with the retrospective study by Galvin and 
colleagues (Galvin et al., 2010) of caregiver experience of patients with LBD, which found 
that two-thirds of patients saw more than 3 doctors before an LBD diagnosis was made 
and a third needed more than six clinic visits. In 78% of cases, a diagnosis of another 
disorder was made first (39% with another form of parkinsonism, 26% with AD and 24% 
with a primary psychiatric disorder).  However the Galvin study was entirely based on 
caregiver perception with no independent observations or objective information to verify 
the diagnostic pathway. It could also be subject to recall bias especially where patient’s 
experience is mostly negative. In addition, the study did not differentiate DLB from PDD, 
the latter diagnosis, in theory, should be more straightforward than a DLB diagnosis, with 
dementia presenting on the background of established PD. In contrast, the current study 
used objective information collected from medical notes written contemporaneously.   
The majority of all diagnoses were made by psychiatrists, not a surprising finding as the 
study was mainly conducted in psychiatry services. Some patients were seen by 
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neurologists, who were a smaller proportion of the clinicians within the services. 
Psychiatrists were responsible for a similar number of DLB (78%) and non-DLB (89%) 
diagnoses, as were neurologists (17% of DLB diagnoses and 11% of non-DLB 
diagnoses).  For comparison, in the study by Galvin et al., 62% of LBD diagnoses were 
made by neurologists and only 9% by psychiatrists, the differences may simply reflect 
that the current study surveyed mainly Old Age Psychiatry services.   
There were, as expected, significantly more core features (parkinsonism (70%), visual 
hallucinations (78%) and fluctuating cognition (65%)) in the DLB group than the non-DLB 
group (11%, 5%, and 16% respectively). REM sleep behavior disorder (RBD) was also 
significantly more common in the DLB group, but to a lesser extent (39% v 11%). The 
latter could be due to clinicians not asking about the symptom or patients and carers not 
reporting or being aware of the typical features of this condition.  
At the time of diagnosis, 61% of patients diagnosed with DLB had more clinical features 
than required by the criteria to meet the diagnostic threshold for “probable” DLB as set 
out in the 2005 criteria (McKeith et al., 2005), with 41% having all three core criteria or 
all three core criteria plus a suggestive feature, which would be in line with clinicians 
needing to feel very confident about a DLB diagnosis before assigning it to patients. Very 
few patients were diagnosed based just on two core criteria (21%) or just one core and 
one suggestive (4%), both of which would satisfy the criteria for “probable” DLB. There 
were 12% however who only had sufficient diagnostic features for “possible” DLB. 
Interestingly only one DLB case had a dopamine uptake scan (DaTScan), and in this 
subject the scan was abnormal. A DaTScan or Dopamine SPECT (Single-photon 
emission computed tomography) is an imaging test shown using autopsy validation to 
have good sensitivity (>80%) and specificity (>90%) for DLB (Walker and Walker, 2009; 
Thomas et al., 2017). An abnormal DaTScan is a suggestive feature in the 2005 criteria 
(McKeith et al., 2005) and an indicative biomarker in the updated 2017 criteria (McKeith 
et al., 2017), which is discussed below. The low rate of use of the scan may be due to 
lack of funding or lack of availability for the services studied. An abnormal scan may have 
increased the likelihood of clinicians diagnosing “probable” DLB, as just one more criteria 
is required: a single core feature.  
The higher threshold that appears to be set by clinicians is despite the excellent 
specificity of the diagnostic criteria. Intriguingly, the 2005 criteria have lower sensitivity 
(32%) than specificity (98%) in diagnosing DLB according to the largest study to use 
autopsy data to assess the 2005 criteria, with 2868 cases (Peter T. Nelson et al., 2010) 
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(Huang and Halliday, 2013). This suggests that setting a higher threshold than the 2005 
consensus criteria is unlikely to increase the diagnostic accuracy, but would reduce the 
numbers detected even further. Hence the high threshold used by clinicians may well 
explain the relatively low proportion of DLB cases identified in this study. 
A recent pooled meta-analysis of DLB diagnosis accuracy showed 20% of DLB patients 
were diagnosed incorrectly as DLB (Rizzo et al., 2017), however that review  (in the case 
of the 2005 criteria) only looked at studies where the criteria were applied to late stage 
(severe) DLB patients, and in this group sensitivity was increased to 88% but specificity 
fell to 80%. The latter is consistent with increasing numbers of late stage AD patients 
developing hallucinations, fluctuations and parkinsonism (Peter T Nelson et al., 2010). 
A lack of a viable biomarker may be hindering clinicians in the diagnosis of DLB and 
leading them to use higher thresholds for symptomatology. This study shows that despite 
DaTScans being a very accurate and hence useful determinant of DLB pathology, they 
are not being used widely. A more accessible biomarker, which is also sensitive, may 
narrow the gap between clinical and pathological prevalence rates.  
The importance of making a DLB diagnosis is underlined by the experiences of patients 
and carers. This study showed that DLB patients’ carers experienced more stress than 
carers of non-DLB dementia patients (though this was not statistically significant).  There 
were also higher levels of co-morbidities in DLB patients, who had a higher rate of falls. 
Other symptoms of constipation, urinary incontinence and orthostatic hypotension were 
also more common in the DLB group, but these differences were not statistically 
significant.  
High levels of care giver stress have been identified in LBD previously and this was 
associated with behavioural problems, impaired activities of daily living and isolation 
(Leggett et al., 2011), though that study did not compare DLB with other dementia 
subtypes. A review by Zweig and Galvin (Zweig and Galvin, 2014) looked in more detail 
at the experiences of patients and carers and identified far-reaching consequences of 
having LBD that may not be appreciated without a diagnosis being made. The gravest 
danger being the inadvertent use of neuroleptics, which can be fatal in DLB if neuroleptic 
malignant syndrome is triggered, and can more commonly lead to worsening of their 
debilitating movement disorder, something which may not even be realised by doctors 
or patients if thought of as a natural deterioration of their dementia.    
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LBD patients also report lower quality of life scores than AD patients, often due to 
autonomic and neuropsychiatric symptoms that are common in LBD. Higher care giver 
stress was also reported in DLB patients compared to AD patients, in association with 
delusions, hallucinations, anxiety and apathy in DLB patients. The multitude of symptoms 
can complicate the provision of clinical care for clinicians who may not appreciate which 
symptoms are most troubling and hence need addressing. There is also a suggestion of 
a higher mortality risk of DLB than AD (Zweig and Galvin, 2014). In addition, if 
parkinsonism is not recognized, patients may not receive beneficial symptomatic 
treatment for bradykinesia or rigidity.  
Hence making the diagnosis of DLB is an important step in appreciating the potential 
complications from the condition and for providing the necessary level of support and 
clinical care to the patient and their care giver. 
Newer criteria to try and improve the diagnosis have been published since this study was 
conducted (McKeith et al., 2017), see Table 4.1.  RBD has been upgraded to a core 
criteria and both polysomnography for detecting RBD and MIBG (123Iodine- 
metaiodobenzylguanidine myocardial scintigraphy) scanning for detecting cardiac 
sympathetic nerve loss, have become indicative biomarkers. Neuroleptic sensitivity is no 
longer part of the criteria. Whilst the addition of two new biomarkers will make it easier 
for clinicians to make the diagnosis where core clinical features are not present, both 
scans have their difficulties. MIBG scans for example are popular in Japan but in the UK 
their use is limited and they are not always available, though this may change if the new 
draft National Institute for Health and Care Excellence guidelines for dementia, which 
recommend their use, are accepted (National Institute for Health and Clinical Excellence, 
2018). In the case of polysomnography, it would currently be impracticable to refer 
everyone suspected of DLB for an overnight sleep study – as it would overwhelm the 
limited services available. Patients would need to be carefully selected, for example 
where there is a suspicion but the history is not clear cut and if an abnormal study would 
assist in making the DLB diagnosis from “possible” to “probable” - say if the patient only 
had one core feature such as visual hallucinations and no other features. In addition, 
such patients could be identified with a careful history from their partner without the need 
for a sleep study, but on the flip side this is inherently inaccurate as it is based on a 
subjective experience. Hence, whilst RBD and polysomnography for its detection are 
proven to be accurate biomarkers, they both have their limitations in terms of usefulness. 
This also highlights another difficulty with the criteria as they stand: –a patient with only 
parkinsonism and an abnormal DaTScan will fall into the “probable” DLB category, 
Chapter Four: Lewy Body Dementia Diagnosis - Discussion 
76 
 
similarly those with only RBD and an abnormal sleep study. However, from a clinical 
perspective they represent only one clinical abnormality in each case, and using them 
twice is likely to diminish diagnostic accuracy.   
Hence in summary there is a need for a simple biomarker that is easily available and 
easy to conduct. If such a biomarker were also sensitive, this would be a major step in 
narrowing the difference in clinically diagnosed and pathologically prevalent rates of 
DLB. A recent study suggested phosphorylated alpha-synuclein in autonomic nerves 
supplying the skin could indeed be such a biomarker, proving to be sensitive and specific 
for DLB (Donadio et al., 2017). Whilst the study shows promise, it was limited to very few 
non-autopsy confirmed subjects (18 DLB, 13 non-DLB dementia and 25 healthy 
controls), and therefore requires further validation, and is not close to being introduced 
into routine clinical practice.  
The lack of an accessible sensitive biomarker leads to a reciprocal cause and effect as 
it means a difficulty in recruiting DLB patients, as many are misdiagnosed, hence they 
often do not enter research trials that are trying to identify a viable biomarker for such 
patients, meaning a perpetuation of this issue. 
Another factor that may lead to fewer DLB diagnoses, is the perceived lack of specific 
treatments for DLB. The current cognitive therapies for DLB of donepezil, rivastigmine, 
galantamine and memantine are the same treatments given to AD patients (Stinton et 
al., 2015) (O’Brien et al., 2017). Hence clinicians may be less motivated to differentiate 
the two disorders, where the clinical history has overlapping features. This simplistic 
approach overlooks the additional complications (movement disorders, autonomic, 
psychiatric and neuroleptic related) that are associated with DLB, but nevertheless may 
be a factor in the gap between clinical and neuropathological rates of DLB. Whilst 
education and awareness of these complications is increasing, a disease specific 
treatment for DLB, is likely to increase the need to not miss a DLB diagnosis.    
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Table 4.1 The latest diagnostic criteria for DLB (McKeith et al., 2017) 
Diagnostic Criteria 
 For a patient with dementia (defined as a progressive cognitive decline of sufficient 
magnitude to interfere with normal social or occupational functions or with activities of 
daily living):  
1. A “probable” DLB diagnosis requires at least two core features or one core 
feature and at least one indicative biomarker, whereas  
2. A ”possible” DLB requires only one of the seven from the list of core features or 
indicative biomarkers.  
Supportive biomarkers are helpful in making the diagnosis but their specificity to 
DLB is not clear. 
 In addition, a patient must have either developed dementia before, or within one year, of 
the onset of parkinsonian symptoms; hence if more than a year passes before the onset 
of dementia following parkinsonism, the alternative diagnosis of Parkinson’s disease 
dementia (PDD) is made. 
Core Features Indicative Biomarkers Supportive Biomarkers 
1. Recurrent visual 
hallucinations 
2. Fluctuating 
cognition 
3. Spontaneous 
features of 
parkinsonism 
4. Rapid eye 
movement (REM) 
sleep behaviour 
disorder (RBD) 
1. Polysomnography 
confirming RBD by 
showing REM sleep 
without atonia 
2. Abnormal dopamine 
transporter (DAT) 
imaging revealing 
reduced DAT uptake 
in the basal ganglia 
3. 123Iodine- 
metaiodobenzylguani
dine (MIBG) 
myocardial 
scintigraphy revealing 
loss of postganglionic 
sympathetic cardiac 
innervation 
1. Relative preservation of medial 
temporal lobe structures on CT 
or MRI 
2. Generalized low uptake on 
Single Photon Emission 
Tomography (SPECT)/ 
Positron Emission Tomography 
(PET) perfusion/metabolism 
scan with reduced occipital 
activity ± posterior cingulate 
island sign on 
Fluorodeoxyglucose (FDG)-
PET imaging 
3. Prominent posterior slow-wave 
activity on EEG with periodic 
fluctuations in the pre-alpha/ 
theta range 
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4.5 PDD Diagnostic Pathway 
 
The results of this study suggest that a diagnosis of dementia is often delayed in PD 
patients. The diagnostic criteria for PDD (Emre et al., 2007) as published by the 
Movement Disorder Society (MDS) is shown in Table 4.2. Subsequent to its release, a 
follow-up paper described how to interpret the criteria (Dubois et al., 2007) and suggests 
two levels of certainty: a lower level (“level 1”) for clinicians and a higher (“level 2”) for 
the purposes of research.  The level 1 algorithm as set out by Dubois and colleagues for 
diagnosis is shown in Table 4.3.  
 
 
Table 4.2 Clinical diagnostic criteria for PDD as published by the Movement Disorders 
Society (Emre et al., 2007) 
 
Probable PDD requires both 1 and 2 to be present, with a clear history of dementia 
established in the context of motor symptoms, and no other plausible causes of 
dementia syndrome including systemic disease, drug intoxication, major 
depression or probable vascular dementia.  
 
 
Table 4.3 Suggested algorithm for diagnosis of PDD (Dubois et al., 2007) at level 1 that 
could be used by clinicians. 
 
MDS Criteria for Diagnosis of Dementia in Parkinson's Disease
1.PD diagnosed in accordance with UK PD Brain Bank criteria
2.Dementia syndrome with insidious onset & slow progression, in the context of established PD and 
diagnosed by history, clinical and mental examination, defined as:
(i)Impairment in at least 2 domains (attention, executive function, visuospatial function and memory)
(ii)Representing a decline from premorbid level
(iii)Deficits severe enough to impair daily life (social, occupational, or personal care),               
independent of the impairment ascribable to motor or autonomic symptoms
Level 1 Algorithm for PDD diagnosis
1. A diagnosis of Parkinson's disease based on the UK Brain Bank Criteria for PD
2. PD developed prior to the onset of dementia
3. Mini mental state examination score (MMSE) below 26
4. Cognitive deficits severe enough to impact daily living
5. Impairment in at least two of the following tests (as further described in the paper):
-Months reversed or Sevens backward (Attention)
-Lexical fluency or Clock drawing (Executive Function)
-MMSE pentagons (Visuospatial skills)
-3 Word recall (Memory)
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Seven of the 18 PDD patients recruited to this study were found, either at a clinic 
appointment or at a home visit, to have cognitive deficits that impaired daily life as 
measured by activities of daily living (ADLs), for a mean duration of 1.5 years, before a 
dementia diagnosis was made. Six PDD subjects had impairments in two or more 
cognitive domains before their dementia diagnosis, with a mean duration of 0.3 years 
between the two events. Two of these patients had both: impairments in multiple 
cognitive domains and impaired ADLs due to their cognitive impairment, noted in their 
records prior to a dementia diagnosis being made. This suggests that there was a lag 
between satisfaction of the dementia criteria and the formal diagnosis. 
 
Another five PDD patients were being treated with Rivastigmine before a diagnosis of 
dementia. The mean length of time before the diagnosis was made in these patients was 
0.9 years. One of these patients (but none of the other four) had evidence of psychosis 
prior to the onset of dementia, and for this patient, rivastigmine was started at the same 
time as the onset of these psychotic symptoms. Visual hallucinations were present in two 
of the other four patients prior to dementia and to the commencement of rivastigmine, 
and it is possible they were started on rivastigmine for visual hallucinations. Rivastigmine 
is licenced only for the treatment of dementia and hence its use for these indications 
would be “off-licence”. 
 
The results from the diagnostic study also suggest that some PD patients that fit the 
criteria for dementia in PD, were not being diagnosed with dementia. Four of the 15 PD 
subjects in the control group had cognitive impairment noted in their medical records in 
multiple cognitive domains. One separate subject was sufficiently cognitively impaired 
for their ADLs to be affected.  Two of the control patients, both of whom had recorded 
cognitive impairment, had been treated with rivastigmine in the past, prior to the 
screening period, though they were never formally diagnosed with dementia. Neither 
patient had evidence of psychosis or visual hallucinations. The study actively excluded 
patients who were on rivastigmine during the screening period, from the control group, 
hence the number of patients on rivastigmine without a dementia diagnosis in these 
services is likely to be higher.  
 
Interestingly, whilst geriatricians and neurologists made the initial PD diagnosis, a 
dementia diagnosis was made in the main by old age psychiatrists (in 10 out of 16 PDD 
patients). PD patients are regularly followed up by neurologists and geriatricians (as well 
as specialist nurses), who would be able to make a dementia diagnosis, but the results 
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suggest that most PD patients were referred to psychiatry services for diagnosis of PDD. 
As noted earlier, DLB diagnoses were also made by psychiatrists, though most DLB 
patients were seen by psychiatrists initially.  Hence, in this study LBD was made primarily 
by psychiatrists, irrespective of whether the initial referral to specialist services was to 
neurology or psychiatry.  
 
Clinicians also used more cognitive and imaging tests with respect to PDD patients than 
PD patients, but as dementia is an additional condition in the PDD group, on the baseline 
of PD  that is found in both groups, this is not unexpected. 
 
All four of the cognitive domains that are typically impaired in PDD (attention, executive 
function, visuospatial skills and memory) were much more impaired in the PDD group. 
Memory impairment was a feature in all PDD patients, and executive dysfunction in 85%. 
However memory impairment and executive dysfunction was also found in more than a 
quarter of patients with PD. None of the PD patients were found to have attentional 
impairment however.  
 
Visual hallucinations and fluctuating cognition were present significantly more in PDD 
(88% and 92% respectively) than PD control subjects (27% and 7%), suggesting these 
clinical features could be surrogate markers, used by clinicians to make a dementia 
diagnosis – they are not part of the MDS criteria. Both are core features of DLB, which 
shares many of the pathological features of PDD (Jellinger and Korczyn, 2018), hence it 
is possible clinicians are making the dementia diagnoses with this in mind, or perhaps 
from their own clinical experience that PDD is often associated with these features. 
Visual hallucinations are less frequent in PDD than DLB, but have been found to be a 
strong predictor for the onset of dementia (Anang et al., 2014). In addition, fluctuations 
in cognition have been reported at a similar frequency in DLB and PDD patients but were 
not found at all in PD patients (Ballard et al., 2002).  
 
RBD was also found at higher levels in PDD compared to PD patients (59% v 27%) but 
the difference was not significant. RBD is also reported to be a strong predictor for 
dementia in PD subjects (Anang et al., 2014). 
The implications of a dementia diagnosis on the patient and carer can also be seen within 
the results with increased orthostatic hypotension and psychiatric features (anxiety and 
changes in personality) in PDD patients compared to those without dementia. 
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Swallowing difficulties, repeated falls and excessive daytime somnolence were also 
more frequent in the PDD group.  The increase in carer stress in PDD compared to PD 
patients, could easily be explained by these differences and subsequent increase in care 
burden.  
Hence overall, the results suggest a delay in diagnosis of dementia in some PD patients, 
where clinically the patient has features consistent with dementia, but they are not 
diagnosed promptly, only later on in the disease course, if at all. This may lead to a lower 
rate of diagnosis clinically and explain the low proportion of patients with dementia found 
in the earlier prevalence study. The longitudinal study by Hely and colleagues (Hely et 
al., 2008) which observed PD patients over 20 years from diagnosis, found 83% of 
survivors developed dementia and 75% who had not survived to 20 years also developed 
dementia before they died. It also found neurologists were more likely to underestimate 
than overestimate the prevalence of dementia in PD patients, recommending that 
dementia should be actively sought and excluded rather than assumed to be absent. 
Neurologists and geriatricians in this study appeared to defer diagnosing dementia to 
their psychiatry colleagues.       
A lower rate of diagnosis in clinical practice has important implications for the patients 
and their care givers who benefit from a diagnosis being made as the consequences of 
its development has a profound effect on the patient and carer, as described. A diagnosis 
allows for the provision of support services to cater for these. Dementia, together with 
the increased carer stress and an increased falls risk we report here, also leads to loss 
of insight, impaired driving skills, poor judgement and poor financial decision making, 
amongst other difficulties (Aarsland et al., 2001). Health care providers would also need 
to adapt their services to cater for a higher population of their patients experiencing the 
difficulties of having dementia. 
Hely and colleagues suggest serial brief regular assessments throughout the disease 
course to detect cognitive decline as a means to ensure that diagnosis is not missed 
(Hely et al., 2008). A simple biomarker, sensitive for dementia, in the context of PD would 
be another means of increasing detection. Disease modifying treatment specific for 
dementia in PD, similar to DLB, would also increase the vigilance by clinicians (especially 
neurologists and geriatricians who carry out the regular follow-ups) for its features and 
increase detection.  
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4.6 Conclusion and Next Steps 
This study revealed low clinical prevalence rates of DLB and dementia in PD, which are 
likely to be as a result of low detection rates. In DLB, clinicians appear to be requiring a 
high threshold before making a diagnosis and many cases may be being missed due to 
diagnostic uncertainty. In PDD, there appears to be a lag in the diagnosis, beyond the 
onset of symptoms of dementia. Hence both subgroups of LBD patients appear to be 
being underdiagnosed. A sensitive, easily accessible biomarker is therefore needed as 
are disease modifying treatments to try and increase detection rates through making the 
diagnosis process easier and by increasing motivation, and hence vigilance, to make an 
LBD diagnosis.      
One source of a potential biomarker or a possible avenue for disease modifying 
treatment is inflammation in association with these conditions, if inflammation was found 
to be increased in Lewy body dementia. It is now increasingly recognised that 
inflammation plays a part in the pathology of dementia (Amor et al., 2014) (Lee et al., 
2010), though it’s not clear whether that is beneficial, detrimental or both. The next part 
of this thesis looks at whether inflammation plays a part in LBD pathology, hence 
potentially providing a source of a biomarker or a route for disease modifying treatment, 
starting with a review of the current evidence of inflammation in LBD. 
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5.1 Introduction 
The etiology of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia 
(PDD)  remains unclear, but a role for inflammation has been proposed, extrapolating 
from the emerging evidence for inflammation in the etiology of Alzheimer’s disease (AD) 
and other neurodegenerative conditions. In AD neuropathological studies report 
evidence of brain inflammation (McGeer and McGeer, 2013), positron emission 
tomography (PET) imaging reveals microglial activation in vivo (Hamelin et al., 2016, 
2018; Fan et al., 2017), genetic studies implicate polymorphisms in genes involved in 
the inflammatory response as risk factors, epidemiological studies indicate a protective 
effect of non-steroidal anti-inflammatory drugs (NSAIDs) and mouse models of AD 
suggest NSAIDs reduce neuroinflammation and protein deposition (Lee et al., 2010; 
Latta, Brothers and Wilcock, 2014; Morales et al., 2014).  
In light of the gathering evidence for neuroinflammation in AD, we reviewed the literature 
for evidence that inflammation also plays a role in the etiology of Lewy body dementia 
(LBD). 
 
5.2 Literature Search Strategy  
References were identified using searches of PubMed with key words. The following 
combinations were used in a search of titles and abstracts in June 2015 and updated in 
March 2018 (the number of articles yielded is noted in brackets): 
1. ‘Lewy’ and (‘inflammation’ OR ‘neuroinflammation’) (186 articles)  
2. (‘Parkinson's disease dementia’ OR ‘PDD’ OR ‘DLB’ OR (‘Dementia AND 
Parkinson*’)) AND (‘neuroinflammation’ OR ‘inflammation’) (361 articles)  
3. ‘synuclein’ AND ‘microglia’ (295 articles) 
4. ‘synuclein’ AND (‘inflammation’ OR ‘neuroinflammation’) (410 articles) 
The abstracts of these articles were screened and full texts obtained of those articles 
which were potentially relevant to this review. In order to ensure that all relevant 
references were sourced, references were in turn reviewed for other relevant articles, 
supplemented by articles known to the authors.  
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5.3 Neuroinflammation  
Neuroinflammation describes the response to injury within the central nervous system 
(CNS) leading to the activation of microglia and astrocytes, release of cytokines and 
chemokines, invasion of circulating immune cells and complement activation. Microglia 
are the resident macrophages of the CNS, originating from progenitors in the embryonic 
yolk sac (Ginhoux et al., 2013). They provide the innate immune response to invading 
pathogens and also initiate the adaptive response through antigen presentation (Nayak, 
Roth and McGavern, 2014). Microglia are also involved in non-immunological roles, 
including synapse formation and maintenance.  
Microglia are resting or “inactivated” under physiological conditions with characteristic 
ramified morphology and distributed within brain regions, such that rami are close but 
not touching, implying each cell has its own distinctive territory. But even in this inactive 
state, they have been shown using two-photon microscopy to be vigilant: continuously 
monitoring the extracellular spaces with their processes and protrusions in adult mice 
(Nimmerjahn, Kirchhoff and Helmchen, 2005). Activation leads to morphological change 
with microglia assuming a more rounded amoeboid shape, with targeted movement of 
processes towards sites of injury or stimuli to initiate phagocytosis (Nimmerjahn, 
Kirchhoff and Helmchen, 2005) and also leads to production of chemokines, that amplify 
the response by recruiting other microglia, plus cytokines, free radicals and proteases 
which destroy infectious organisms and infected neurons. 
The potential role of microglia as primary contributors to neurodegeneration was 
highlighted by the discovery that null mutations of triggering receptor expressed on 
myeloid cells 2 (TREM2), which is only expressed in microglia within the CNS, cause 
Nasu-Hakola disease, a rare condition leading to a degenerative mid-life dementia, 
amongst other impairments (Dardiotis et al., 2017). TREM2 suppresses inflammatory 
processes and promotes phagocytosis of cell debris and bacteria, lending support for a 
generally protective function (Ransohoff, 2016). TREM2 variants have been associated 
with increased risk of developing a number of degenerative conditions including 
Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease (Yeh, Hansen 
and Sheng, 2017). Intriguingly, ApoE has been found to be a high affinity ligand to 
TREM2 and can coat apoptotic neurons to promote phagocytosis through this 
interaction, though there was no variation in binding based on the different isoforms of 
ApoE, which can alter risk of developing AD. However mutations in TREM2 associated 
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with AD, can block the binding between TREM2 and ApoE (irrespective of isoform) (Atagi 
et al., 2015).   
Microglia appear to have an important part both in MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, a neurotoxin that leads to parkinsonism) disease progression and 
idiopathic PD (Gao et al., 2003), suggesting a central role for these glia in nigro-striatal 
degeneration, irrespective of etiology. Microglia may be especially susceptible to 
mechanisms of aging. Their maintenance is proposed to be dependent on self-renewal 
rather than replenishment by peripheral blood precursors (Ajami et al., 2011; Prinz and 
Priller, 2014), and their phagocytic function could diminish with age (Bliederhaeuser et 
al., 2016), which could be highly significant in age dependent neurodegenerative 
conditions such as LBD. Systemic infections or disease, which rise in number with age, 
could also lead to priming of microglia, such that their response is exaggerated and 
damaging to nearby neurons leading to cognitive decline (Perry and Holmes, 2014). It 
has also been proposed that an initial stimulus that triggers microglial activation could 
persist in neurodegenerative disorders leading to repeated cyclical chronic 
neuroinflammation causing neuronal dysfunction and cell death (Gao and Hong, 2008; 
Tansey and Goldberg, 2010). The specificity of these changes to Lewy body dementias 
is unclear. 
Astrocytes are the primary glial cells of the CNS, involved in brain homeostasis: 
supporting neurons and regulating the extracellular balance of fluid, ions and 
neurotransmitters. They also have an inflammatory response, with an ability to secrete 
cytokines and chemokines and activate the adaptive immune system.  In comparison to 
microglia, astrocytes have been less well studied in neurodegeneration, however 
evidence is emerging of their potential as regulators of inflammation, in both protective 
and detrimental roles (Colombo and Farina, 2016).    
 
5.4 Alpha Synuclein and Neuroinflammation 
Alpha-synuclein is the main component of Lewy bodies (Spillantini et al., 1997) which 
characterize LBDs pathologically, and the likely driving force behind the disease process, 
hence the interaction between this protein and microglia appears to be critical. Alpha-
synuclein inclusions in neurons and glia are associated with DLB and PDD, as well as 
PD and multiple system atrophy. In DLB and PDD, the inclusions are neuronal and in 
the form of Lewy bodies (Spillantini et al., 1997). Lewy neurites are also common in these 
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disorders, consisting of coarse dystrophic neurites immunoreactive for α-synuclein within 
affected neurons.  With 140 amino acids, α-synuclein’s possible intracellular forms 
include monomeric (Fauvet et al., 2012; Lashuel et al., 2013) or a relatively stable folded 
tetramer (Bartels, Choi and Selkoe, 2011; Wang et al., 2011).  
Many studies have found evidence of α-synuclein’s ability to activate microglia and 
induce dopamine cell loss (Zhang et al., 2005, 2007; Theodore et al., 2008; Hoffmann et 
al., 2016), including monomeric wild-type and mutant forms as well as extracellular 
oligomeric conformations and fibrils. Indeed, neuron-glia cultures depleted of microglia 
have been shown to be resistant to α-synuclein induced dopaminergic neurotoxicity 
(Zhang et al., 2005). The initiation of the innate response occurs through pattern-
recognition receptors (PRRs) expressed on CNS cells (for example the toll-like receptor 
(TLR)) through activation by pathogen associated molecular patterns or danger 
associated molecular patterns. 
Recently the focus has been on possible mechanisms of interaction. Models of PD have 
been used to study this relationship rather than models of DLB, with overexpression of 
α-synuclein in the substantia nigra using viral vectors, the most common. A survey of the 
literature shows several potential mechanisms (see Table 5.1).  
A number of immunomodulatory proteins and compounds are implicated in α-synuclein 
microglial recognition, chemotaxis, activation and response. TLRs 1 (Daniele et al., 
2015), 2 (Kim, Kågedal and Halliday, 2014; Daniele et al., 2015) and 4 (Fellner et al., 
2013) are PRRs key to the innate response machinery and have been reported as having 
a role in recognition of α-synuclein by microglia. Microglia exposed to higher-ordered 
oligomers (but not monomers) of α-synuclein changed to an amoeboid, phagocytic 
morphology with increased secretion of tumor necrosis factor α (TNF-α) that was 
reduced by inhibition of the TLR 1/2 complex (Daniele et al., 2015). A separate study 
found only β-sheet rich oligomeric conformations of α-synuclein could activate microglia 
via TLR 2, but both aggregated and non-aggregated forms could activate microglia 
through TLR 4. Furthermore pro-inflammatory cytokine/chemokine release was 
completely eliminated in TLR 2 knockout mouse microglia exposed to α-synuclein, but 
remained unaffected in TLR 4 knockout mouse microglia (Kim et al., 2013). Selective 
activation of TLR 4 rather than TLR 2 receptors in transgenic α-synuclein mouse models 
also led to increased clearance of α-synuclein, improved motor performance and rescue 
of nigro-striatal neurons (Venezia et al., 2017). In addition, human oligomeric α-synuclein 
injected into mouse hippocampi inhibited memory function, which was prevented by TLR 
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2 inhibition but not TLR 4 knockout (La Vitola et al., 2018). This suggests recognition of 
oligomeric α-synuclein by TLR 2 leads to inflammation and dysfunction, whereas TLR 4 
receptors respond with phagocytosis and cellular protection.  
Another molecule which could feature in the initiation of microglia activation is fractalkine, 
a membrane bound chemokine which acts on its receptor (CX3CR1) on microglia to 
suppress production of inflammatory molecules. The soluble secreted form of fractalkine 
had a protective function in an animal model of α-synuclein overexpression, suggesting 
loss of this membrane bound chemokine could lead to neuronal loss through microglia 
mediated cell damage (Nash et al., 2015). Deletion of CX3CR1 reduces microglial 
phagocytosis and MHC class II (MHCII) expression in response to α-synuclein, but does 
not increase neuronal loss (Thome, Standaert and Harms, 2015).   
Αlpha-synuclein, in extracellular aggregated form, has been shown to be a 
chemoattractant through CD11b receptors on microglia (S. Wang et al., 2015). Also, the 
β1-integrin subunit, which forms transmembrane adhesion molecules has been reported 
as being required for the morphological changes and migration of microglia seen in the 
presence of extracellular α-synuclein (Kim et al., 2014).  
Once microglia are activated, interleukin-1 (IL-1) appears to be a key cytokine in 
promoting an inflammatory response. IL-1α and β knockout mice did not show loss of 
dopamine neurons or behavioral deficits seen in wild-type mice in a PD model, utilizing 
lipopolysaccharide (LPS) injections into the substantia nigra.  LPS injections have been 
shown to produce microglial activation, cytokine release and subsequent dopaminergic 
cell loss in the substantia nigra (Sharma and Nehru, 2015). TNF-α knockout mice 
however showed similar results to wild-type mice (Tanaka et al., 2013), indeed TNF-α  
may have a role in promoting α-synuclein accumulation (M.-X. Wang et al., 2015). 
Galectin-3 has also been shown to be important for the inflammatory effect of α-
synuclein. Its inhibition significantly reduced cytokine release by microglia in response to 
aggregated α-synuclein (Boza-Serrano et al., 2014).  
Leucine-rich repeat kinase 2 (LRRK2) is a protein expressed on microglia when they are 
in their inflammatory state and has been shown to have a significant role in α-synuclein 
mediated microglial activation and subsequent cell loss, with LRRK2 knockout mice 
being protected from α-synuclein overexpression (Daher et al., 2014) as were mice 
treated with LRRK2 inhibitors (Daher et al., 2015). LRRK2 knockout mice also exhibited 
increased clearance of α-synuclein compared to wild-type mice (Maekawa et al., 2016). 
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Yet mutations in LRRK2 are associated with PD (see Genetics section), suggesting the 
contribution of this kinase to PD pathology is unclear. 
Another protein involved is NRF2, a transcription factor for a number of cell protection 
proteins that appears to have a protective role in the interaction (Lastres-Becker et al., 
2012) - activation leads to protection from α-synuclein toxicity and inflammation (Lastres-
Becker et al., 2016).  
Several studies suggest the adaptive immune response is engaged by microglia 
following their activation. Knockout mice without Fc gamma receptors (FcγR), which are 
found on microglia and involved in facilitating phagocytosis through binding of IgG, 
showed reduced pro-inflammatory signaling in the presence of aggregated α-synuclein. 
Suggesting the latter could be triggering inflammation and antibody mediated cell 
damage through FcγR (Cao, Standaert and Harms, 2012). However, one specific 
subtype FcγRIIB, in the presence of aggregated α-synuclein, inhibits microglial 
phagocytosis, suggesting an alternative means of microglial dysfunction through these 
receptors in  synucleinopathies (Choi et al., 2015).  
A knockout of all four murine MHCII complex genes prevented α-synuclein induced 
dopaminergic cell loss in a mouse model, strongly suggesting that CD4 T lymphocytes 
are critical to α-synuclein cell damage. Microglia, as the only resident cells expressing 
MHCII in the CNS, would be candidates for their recruitment, although infiltrating antigen 
presenting cells such as macrophages (or their precursors, monocytes) may also be 
involved (Harms et al., 2013)(Harms et al., 2018). Furthermore, mice with microglia 
deficient in prostaglandin E2, which is thought to have a role in lymphocyte proliferation, 
have increased resistance to MPTP mediated pathology (Jin et al., 2007). In addition, 
inhibiting the JAK/STAT pathway that is known to underlie many aspects of the immune 
response, suppresses microglial activation, T-cell infiltration in the substantia nigra and 
neurodegeneration in mouse models of  α-synuclein over-expression (Qin et al., 2016). 
Inflammatory stimuli can also lead to truncation of α-synuclein, through activation of an 
inflammatory enzyme – caspase 1, and subsequent aggregation and neurotoxicity in 
neuronal cell cultures (Wang et al., 2016). Such a pathway could lead to cell death 
independently or synergistically with microglial activation. 
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5.5 Imaging of Neuroinflammation and Neuronal Dysfunction  
Imaging studies have shown an association between neuroinflammation in vivo and 
cognitive dysfunction. Microglial activation as a marker of neuroinflammation has been 
identified in PD and PDD (Fan et al., 2015) (see Table 5.2), in the majority of cases using 
11C-RPK11195 (PK11195), a PET ligand that binds to a translocator protein (TSPO) 
found on microglia in their activated state. Extensive microglial activation has similarly 
been identified in another α-synucleinopathy: multiple systems atrophy (Gerhard et al., 
2003), as well as other degenerative conditions, including AD, a condition which shares 
some of the pathological features of LBD (Cagnin et al., 2001; Edison et al., 2008; Colom-
Cadena et al., 2013) 
An association between microglial activation in the midbrain and dopaminergic loss in 
the dorsal putamen has been found in the early stages of PD (disease duration less than 
2.5 years), both contralateral to the clinically affected side, with levels of activation 
correlating with severity of motor impairment measured by the Unified Parkinson’s 
Disease Rating Scale (UPDRS) (Ouchi et al., 2005). In the later stages of disease 
(disease duration range 0.5 - 21 years), there is extensive microglial activation, with the 
basal ganglia, cortex and pons all showing significantly increased levels. The substantia 
nigra was however spared. Follow-up scans in eight of these subjects (after 18-28 
months) showed no significant change in microglial activation from baseline despite a 
clear deterioration in disability as measured using the UPDRS. Cognition was however 
not assessed longitudinally (Gerhard et al., 2006). The authors also noted a clear overlap 
in the areas of microglial activation and the regions proposed by Braak et al. (Braak et 
al., 2003) in their study of PD pathology. Another longitudinal study, this time with a 
second generation TSPO ligand [11C]-DPA713, found increased microglial activation 
(compared to controls), spreading in cortical regions (temporal and occipital) in the same 
subjects over one year, despite no change in mini mental state examination (MMSE) 
scores (Terada et al., 2016). Second generation ligands are reported to have a higher 
sensitivity to TSPO (Kobayashi et al., 2018), however their affinity to TSPO depends on 
the expression of a polymorphism in the gene for this receptor unlike PK11195 (Owen et 
al., 2012). Yet participants in this latter study were not assessed for genotype, calling 
into question the validity of the differences between patients and controls. 
In PDD subjects, there is increased cortical microglial activation compared to control 
subjects, however levels of activation were also increased in comparison to PD cases, 
but just in the left parietal lobe (Edison et al., 2013).  
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In DLB, increased microglial activation in the substantia nigra and putamen, plus several 
cortical regions was found in a pilot imaging study of six cases of less than one year’s 
disease duration (Iannaccone et al., 2013). That microglial activation occurs in more 
widespread regions in early DLB, where there is greater cognitive dysfunction compared 
to early PD, strengthens the link between microglial activation and cognitive function.  
A relationship between microglial activation and cognitive function has been found in 
PDD, where cortical activation levels inversely correlated with MMSE in temporo-parietal, 
occipital, and frontal cortical regions (Edison et al., 2013; Fan et al., 2015). Fan et al. 
(Fan et al., 2015) also demonstrated a significant negative correlation between whole 
brain levels of microglial activation and glucose metabolism. Within the temporo-parietal 
cortex there was voxel by voxel significant inverse correlation between levels of 
microglial activation and glucose metabolism in the immediate vicinity suggesting local 
damage, but the areas of correlation were small. Femminella et al. went further and 
demonstrated microglial activation within cortical and subcortical areas in PDD subjects 
correlated inversely with hippocampal volume and negatively with hippocampal glucose 
metabolism (Femminella et al., 2016). 
Small clusters of positive correlations were also found between PK11195 binding and 
amyloid load (as determined by [11C]Pittsburgh compound B (PIB), a marker of fibrillary 
amyloid load) in PDD subjects, but only in the parietal lobe and anterior cingulate, as 
opposed to AD subjects in whom there was a stronger correlation between amyloid load 
and microglial activation. There was however little amyloid deposition found in PDD 
cases overall (Fan et al., 2015). Proteins other than amyloid, such as α-synuclein or tau, 
could be triggering microglial activation in PDD, however currently there are no α-
synuclein PET ligands available to demonstrate this and tau ligand imaging is in its early 
stages and as yet there are no studies investigation the relationship between tau and 
inflammation.  
Overall small scale studies with in vivo imaging have suggested that in PD, PDD and in 
a small preliminary report of DLB, there is early microglial activation. But, this does not 
appear to increase over time in regions once it is established. Early microglial activation 
in synucleinopathies is further supported by PK11195 studies in patients with rapid eye 
movement (REM) sleep behaviour disorder - a condition now considered to be a 
prodromal stage of synucleinopathies(Högl, Stefani and Videnovic, 2018), which show 
increased binding in the substantia nigra (Stokholm et al., 2017) and occipital cortex 
(Stokholm et al., 2018), prior to any motor or cognitive impairment . 
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The evidence for extensive microglial activation in LBDs, in an immunologically privileged 
site such as the brain, is highly significant. Immune responses are tightly controlled and 
yet there is widespread inflammatory cell activation, starting early and present chronically 
during the disease.  
 
5.6 Pathological Studies 
Pathological studies further support a role for inflammation. Large numbers of microglia 
were reported to be HLA-DR-positive, which can indicate activation, in the substantia 
nigra of PD and PDD cases together with Lewy bodies in association with a reduction in 
dopaminergic cells. In the PDD cases HLA-DR positive microglia were also found in the 
hippocampus, though this was associated with neuritic plaques and tangles suggestive 
of AD pathology (McGeer et al., 1988). Increased microglial expression of MHCII has 
also been reported in  transenterohinal, cingulate and temporal cortices in PD (Imamura 
et al., 2003).  
In a post-mortem study of controls, idiopathic Lewy body disease patients and PD 
subjects, different patterns of inflammatory cytokine changes were found in the 
substantia nigra and striatum. Microglial HLA DR expression in the substantia nigra was 
found to be both intense and reduced in PD cases. In the striatum, tyrosine hydroxylase 
fibers were lower in PD compared to controls, but those which survived had particularly 
intense microglial HLA DR staining (Walker et al., 2016).     
The presence of CD4 (as well as CD8) T lymphocytes within the substantia nigra of PD 
cases at post-mortem has also been found (Brochard et al., 2009). In addition, 
concentrations of interleukin-1β, interleukin-6 and transforming growth factor-α were 
higher in the striatal regions of post-mortem PD brains compared to controls (Mogi, 
Harada, Kondo, et al., 1994). Complement proteins were also found with Lewy bodies 
within this region in PD (Loeffler, Camp and Conant, 2006). Furthermore TLR 2 
expression is increased in PD brains and correlate with α-synuclein deposits. TLR 2 was 
found on neurons and microglia, the former correlating with disease duration (Dzamko 
et al., 2017). Alpha-synuclein deposits have also been reported in the astrocytes of PD 
patients within the brainstem (Wakabayashi et al., 2000) and cortex, adjacent to Lewy 
bodies and Lewy neurites (Braak, Sastre and Del Tredici, 2007).  
In DLB cases, both complement proteins and MHCII positive microglia are associated 
with Lewy body containing degenerated neurons on autopsy, suggesting microglial 
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involvement (Togo et al., 2001). An increase in MHCII positive microglia has also been 
reported, positively correlating with the number of Lewy bodies regionally (Mackenzie, 
2000). However this was not as high as in those cases with concomitant senile plaques 
and a second study has shown a lack of MHCII positive microglia in the absence of 
neuritic plaques in DLB (Shepherd et al., 2015). Indeed, Streit and Xue report that Iba1 
staining which identifies all microglia, did not identify hypertrophic microglia suggestive 
of activation in DLB compared to controls in the frontal or temporal cortices. CD68 
staining was raised in DLB cases, however this is a label for lipofucin deposits in 
microglial cells, that could indicate activated phagocytic microglia or senescent microglia 
that have accumulated lipofucin with age (Streit and Xue, 2016). Bachstetter and 
colleagues found that dystrophic microglia, rather than hypertrophic microglia were the 
predominant subtype in the hippocampus of DLB cases, suggesting hypofunction rather 
than a pro-inflammatory role (Bachstetter et al., 2015). 
In addition a recent study showed a correlation between changes in the anti-inflammatory 
marker CD200 or pro-inflammatory marker intercellular adhesion molecule-1 with 
amyloid plaques and tau tangles but not Lewy bodies in patients with DLB (Walker et al., 
2017). A comparison of middle aged healthy controls, rapidly progressive (less than two 
years between first symptom and death) DLB and other DLB cases, found no change in 
expression of a limited set of inflammatory genes between groups, but did find TNF-α 
protein levels were higher in the rapidly progressive group compared to controls (Garcia-
Esparcia et al., 2017).  
Hence, there is some evidence of inflammation but so far there is an absence of a link 
between microglia and pathological protein deposition in both PDD and DLB. 
Pathological studies in DLB vary in their findings dependent on the marker used to 
identify microglia. Whilst there is no evidence of morphological change suggestive of 
activation, MHCII expression and possibly phagocytosis and dystrophic changes appear 
to be increased in patients with DLB. It should however be noted that autopsy studies 
are by definition at the end-stage of the disease process and may not be reflective of 
active disease mechanisms, especially those relevant at early stage of disease. 
 
5.7 Genetic Studies 
Genetic studies have identified polymorphisms in genes coding IL-1β, TNF-α and 
TREM2  as risk factors for PD. Up to a doubling of risk has been reported amongst 
Chapter 5: Inflammation In Lewy Body Dementia – Background Literature Review 
 
100 
 
carriers of a genotype of IL-1β that is associated with increased gene expression 
(McGeer, Yasojima and McGeer, 2002; Wahner et al., 2007). Those carrying the 
homozygous variant genotype TNF-α-308, a variant which is thought to be a stronger 
transcriptional activator, experience doubled risk (Wahner et al., 2007). Overall the 
results from these two small studies are consistent with a gene dosing effect for these 
two powerful cytokines. A rare variant of the microglial receptor TREM2, that leads to 
loss of function, was found to be another risk factor for PD in a study of 1493 cases 
compared to 1957 controls (Rayaprolu et al., 2013). Missense mutations in the LRRK2 
gene are found in 1-2% of patients with PD, which codes for a kinase that is highly 
expressed in immune cells, and could play a role in the formation of the inflammasome 
- signaling complexes that play an important role in the inflammatory response (Alessi 
and Sammler, 2018).   
Genome wide association studies (GWAS) provide further evidence for inflammatory 
pathology in PD. Polymorphisms in HLA regions that code segments of the MHCII 
molecule present increased risk. A strong association was found within non-coding intron 
1 of HLA-DRA (in a study of 2000 cases and 1986 controls) by Hamza and colleagues 
(Hamza et al., 2010), with subsequent large-scale meta-analyses of single nucleotide 
polymorphisms (SNP) confirming associations amid the HLA-DR locus, with both HLA-
DRB5 (Nalls et al., 2011) and HLA-DQB1 (Nalls et al., 2014) identified. Wissemann and 
colleagues (Wissemann et al., 2013) found loci that predisposed to, as well as protected 
from, PD within the same 2000 PD and 1986 control GWAS dataset initially analyzed by 
Hamza et al. (Hamza et al., 2010), and replicated these in a further 843 cases and 856 
controls. The strongest association was again intron 1 of the HLA-DRA region, which 
regulates gene expression and linked to increased risk. This suggests HLA expression 
levels may play a key role in determining risk for PD. Indeed subjects homozygous for 
the G allele in this SNP, were found to have significantly increased MHCII expression, 
compared to subjects who did not have a single G allele. In addition, exposure to a 
common insecticide, pyrethroid, when combined with possession of the GG allele, 
significantly increased PD risk (Kannarkat et al., 2015), suggesting a combination of 
environmental triggers and inflammatory processes may play a part in PD pathology. 
Polymorphisms in genes associated with inflammation are yet to be identified as risk 
factors for PDD specifically. However in a GWAS study of 788 pathologically confirmed 
DLB cases and 2624 controls, ApoE, which may be involved in immune signaling, was 
identified as increasing risk (Guerreiro, Owen A. Ross, et al., 2018). This was further 
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confirmed in a larger study of 1743 DLB (1324  pathologically confirmed) and 4454 
controls (Guerreiro, Owen A Ross, et al., 2018).  
 
5.8 Blood Biomarkers 
Elevated peripheral inflammatory markers both before and after the onset of PD, suggest 
inflammation is concurrent with the disease. Increased plasma interleukin-6 (IL-6), 
measured on average 4.3 years before diagnosis, is associated with increased risk of 
developing PD, with higher levels associated with higher risk (Chen et al., 2008). After 
disease onset, levels of IL-6 (Dobbs et al., 1999; Hu et al., 2015), IL-1β (Hu et al., 2015) 
and TNF-α (Dobbs et al., 1999) are elevated compared to controls in PD, as are RANTES 
(regulated on activation, normal T cell expressed and secreted), a chemokine which 
attracts T-cells and high sensitivity CRP. RANTES levels also correlated with motor 
symptom severity (Rentzos et al., 2007) and CRP with subsequent progression of motor 
impairment (Umemura et al., 2015).  
A change in peripheral blood lymphocyte subsets further suggests a role for the adaptive 
immune system. A decrease in the overall level of T-helper CD4 cells but a rise in the 
subset of activated T-helper cells is reported in PD cases compared to controls (Bas et 
al., 2001).  
In PDD, high sensitivity CRP is increased compared to controls, but a significant 
elevation was not found in PDD compared to PD (Song et al., 2013). In DLB, one study 
has assessed inflammatory blood biomarkers in DLB and prodromal DLB, the latter 
defined as the presence of two core or suggestive features of DLB, in the absence of 
dementia. Whilst no changes were found in established disease, interleukin-10, 
interleukin-1β, interleukin-4 and interleukin-2 were higher in prodromal DLB than in 
controls (King et al., 2017)   
 
5.9 Cerebrospinal Fluid Biomarkers 
Attempts to identify a reliable cerebrospinal fluid (CSF) biomarker for PD or PDD have 
so far been inconsistent. The main candidates include total α-synuclein, Aβ42, and β-
Glucocerebrosidase (Parnetti et al., 2013). Inflammatory cytokines TNF-α (Mogi, 
Harada, Riederer, et al., 1994; Delgado-Alvarado et al., 2017), IL-6 (Blum-Degen et al., 
1995; Müller et al., 1998) and IL-1β (Blum-Degen et al., 1995; Hu et al., 2015)  have also 
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been investigated with raised levels seen in the CSF of PD cases compared to controls. 
IL-1β levels in the CSF were associated with raised α-synuclein oligomers also in the 
CSF, suggesting a direct link with protein deposition (Hu et al., 2015). 
In a study of 22 cases of PD, IL-6 was found to associate inversely with disease severity 
as assessed by the UPDRS (Müller et al., 1998). In a larger study of 62 cases, IL-6 was 
elevated in cases of PD with cognitive impairment compared to those without, the levels 
being negatively correlated to cognitive function. TNF-α and Interferon γ levels were 
however reduced in those with cognitive impairment in PD compared to control subjects 
(Yu et al., 2014). A rise in the fractalkine:Aβ42 ratio in CSF is also associated with motor 
severity of PD (again measured by UPDRS) but not with disease duration (Shi et al., 
2011). An increase in this ratio could suggest increased inflammatory signaling and 
microglial activation. An increase in Leucine rich α2-glycoprotein (LRG), thought to be a 
marker of inflammation, is reported in the CSF and post-mortem tissue of PDD and DLB 
cases, compared to controls (Miyajima et al., 2013). 
In a longitudinal study of PD cases, the inflammatory protein YKL-40 was found to rise 
over 2 years in the CSF (Hall et al., 2016). However when compared to AD cases, DLB 
and PDD subjects have lower levels of YKL-40 in their CSF (Wennström et al., 2015; 
Janelidze et al., 2016). 
The focus in DLB however has been on the variations of Aβ peptides and tau as well as 
α-synuclein; a combination of biomarkers may be the best route to increase specificity 
and sensitivity (Mollenhauer and Trenkwalder, 2009; Schade and Mollenhauer, 2014).  
The inflammatory marker Procalcitonin has been found to be significantly raised in 
dementia subjects within the CSF, compared to controls, with the highest median level 
found in DLB cases (Ernst et al., 2007).  
 
5.10 Epidemiological Studies  
There is limited support for neuroinflammation in PD from epidemiology studies. A meta-
analysis of the association of NSAIDs and the risk of developing PD, showed a 15% 
reduction in incidence among users of non-aspirin NSAIDS, with analysis of ibuprofen 
alone showing a stronger protective effect. This effect was more pronounced among 
regular users (Gagne and Power, 2010). Whether PDD incidence was lower in those 
who developed PD despite taking NSAIDS was not considered.  
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A further meta-analysis showed conflicting results with no overall protective effect, 
however there were methodological differences including the inclusion of aspirin and 
studies where NSAID exposure was entirely within a 1 year of the diagnosis of PD. 
Nevertheless a slight protective effect for ibuprofen in lowering the risk of PD was still 
confirmed (Samii et al., 2009). The evidence from these studies is however difficult to 
interpret because of variations in the drugs investigated, the duration of the drug 
treatment and the timing of administration in relation to disease onset.  
Whether NSAIDs could reduce the risk of developing DLB has not yet been established. 
 
5.11 A Role for the Adaptive Immune System 
Despite the evidence of microglial activation and an interaction between α-synuclein and 
microglia, the precise mechanism and whether it is always detrimental to neurons 
remains unclear. A paucity of the relationship between Lewy bodies and antigen 
presenting activated microglia in post mortem studies was reported by Imamura et al. 
(Imamura et al., 2003), indeed there was only a 20% association. This would suggest 
that Lewy bodies alone are not sufficient in themselves to trigger antigen presentation 
by microglia. In addition, increasing neuronal loss in the substantia nigra with lengthening 
disease duration was not associated with an increase in microglial activation, which is 
also reflected by in vivo PET studies (see above), implying a steady rather than 
escalating inflammatory response (Orr et al., 2005), 
Orr and colleagues (Orr et al., 2005) also demonstrated that substantia nigra neurons 
were immunopositive for IgG in PD, whereas control cases’ substantia nigra neurons as 
well as the visual cortex of PD cases showed negative immunoreactivity. Neuronal IgG 
labelling related to the degree of neuronal loss and microglial activation, with the authors 
suggesting humoral immune system involvement in the selective destruction of 
substantia nigra neurons.  
Given that the MHCII complex has also been shown to be key in dopamine neuronal cell 
loss in mouse models (Harms et al., 2013), it may be that an adaptive immune response 
is the final path to neuronal loss, following a switch in microglia function from protective 
to deleterious. Consistent with this theory is the genetic risk associated with HLA class 
II gene variation previously described, as well as the alteration in peripheral lymphocyte 
subsets found in PD cases (Bas et al., 2001), and the evidence that T lymphocyte 
infiltration of the substantia nigra is found at post mortem in PD subjects (Brochard et al., 
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2009) and in a mouse model of α-synuclein overexpression (Theodore et al., 2008). In 
addition α-synuclein fibrils lead to striatal degeneration and invasion of MHCII positive 
monocytes in mouse models (Harms et al., 2017) and increased microglial MHCII 
expression has been repeatedly found at post-mortem in Lewy body disorders 
(Mackenzie, 2000; Shepherd et al., 2015).  
It is possible initial protein clearance by microglia could be switched to a more harmful 
toxic function involving recruitment of the adaptive response ultimately leading to 
neuronal degeneration. For example due to peripheral inflammation or increased 
vulnerability of microglia through ageing, the latter supported by the identification of 
increased dystrophic microglia in DLB (Bachstetter et al., 2015). The timing of treatment 
initiation would be key in such circumstances.  
 
5.12 Conclusion 
Evidence for the role of neuroinflammation in LBDs continues to accumulate, building on 
the evidence of neuroinflammation in AD and PD. Imaging studies lead the way in 
supporting neuroinflammation as a key part of the pathogen process in LBDs, supported 
by pathological and biomarker evidence. Future studies are required to further establish 
the presence of inflammation in DLB including imaging and peripheral biomarker studies. 
Involvement of microglia in LBDs is signified by the presence of activation years before 
neuronal death as revealed by in vivo imaging. Microglial involvement is also supported 
by evidence of the activation of microglia by α-synuclein. Levels of activation however 
appear to remain relatively stable, which could indicate initiation and propagation of the 
disease process by microglia or alternatively a protective function that is eventually 
overcome (see Figure 5.1). In order to understand how inflammation affects disease 
progression in Lewy body dementia, studies need to try and link the nature and extent of 
microglial activation with peripheral markers and important indicators of disease severity 
such as protein deposition and the onset and progression of key cognitive and non-
cognitive symptoms through longitudinal studies in established disease and in those at 
risk. A better understanding of these mechanisms and the stage within the disease at 
which they operate, could potentially lead the way to trials of novel immunomodulatory 
therapies. 
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6.1 Introduction  
Neuroinflammation is increasingly considered as a contributor to dementia pathogenesis 
(Amor et al., 2014), and a potential target for novel disease-modifying therapeutic 
strategies. The previous chapter reviewed the literature for evidence of inflammation in 
Lewy body dementia (LBD) and Parkinson’s disease (PD), a condition with which it 
shares common pathology. There is evidence that α-synuclein aggregates are able to 
interact with a range of components of the immune system including microglia, potentially 
providing the substrate for an inflammatory response (Zhang et al., 2005, 2007; 
Theodore et al., 2008; Hoffmann et al., 2016). In PD, inflammation has been identified 
with a range of methodologies, including pathological, genetic, epidemiological and 
cytokine assessment (Dobbs et al., 1999; Imamura et al., 2003; Wahner et al., 2007; 
Brochard et al., 2009; Hamza et al., 2010). Similar evidence has also been identified in 
Alzheimer’s disease (AD) (Lee et al., 2010; McGeer and McGeer, 2013; Morales et al., 
2014; Latta, Brothers and Wilcock, 2015; Lai et al., 2017; Passamonti et al., 2018). 
Recent studies suggest inflammation may occur early. Inflammation is reported in the 
early stages of Alzheimer’s disease as well as in mild cognitive impairment (MCI) even 
before the onset of dementia (Okello et al., 2009; Hamelin et al., 2016), though there is 
a need for further evidence as some studies of patients with MCI report no differences in 
inflammation relative to controls (Wiley et al., 2009; Kreisl et al., 2013; Schuitemaker et 
al., 2013).  
In Parkinson’s disease, PET imaging shows early inflammation in vivo in the brain stem 
before extending cortically as the disease progresses. By the onset of dementia, 
increased microglial activation appears to be widespread (Ouchi et al., 2005; Gerhard et 
al., 2006; Fan et al., 2015). Persons affected by rapid eye movement (REM) sleep 
behaviour disorder, that is now recognised as a prodromal stage of synucleinopathies 
(Högl, Stefani and Videnovic, 2018), show elevated microglial activation in the substantia 
nigra (Stokholm et al., 2017). 
In addition, direct evidence of inflammation in Lewy body disease is growing, with MHC 
class II positive activated microglia closely associated with Lewy body positive neurons 
at post-mortem (Mackenzie, 2000)(Togo et al., 2001), though not all studies report 
inflammation (Streit and Xue, 2016), meaning further pathological evidence is needed. 
Activated microglia were also identified in vivo on PET in one small case series of 
dementia with Lewy body (DLB) subjects (Iannaccone et al., 2013). Exploratory next 
generation gene sequencing indicates an inflammatory component in DLB pathology, 
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with specific antigen presentation alleles (HLA-DPA1/DPB1) increasing risk (Peuralinna 
et al., 2015). Elevated interleukins have also been reported in prodromal DLB, although 
not the established disease (King et al., 2017). In Parkinson’s disease dementia (PDD), 
another form of dementia associated with Lewy bodies, a rise in c-reactive protein has 
been identified, after the onset of dementia (Song et al., 2013). 
Inflammation represents a potential means of modifying disease progression in 
dementia. Whether central or peripheral, therapies attenuating inflammation may be able 
to slow or even halt progressive neurodegeneration. Anti-inflammatory treatments 
already exist (Martin et al., 2016), meaning that in contrast to the disappointing results 
thus far for the discovery of therapies targeting protein accumulation in dementia (Mo et 
al., 2017), therapies targeting inflammation could be brought into clinical practice more 
quickly. The identification of inflammation as an early part of the disease process would 
increase its usefulness as a target with treatment then possible in the prodromal phase.  
However, more definitive evidence of peripheral and central inflammation in vivo in DLB 
is needed, as well as further evidence of the stage(s) in the disease process at which 
inflammation occurs, essential information to plan future therapeutic studies. A deeper 
understanding of the in vivo relationship between central and peripheral inflammation in 
the same patients is also required, to better elicit the role of inflammation in the 
pathophysiology of the disease and its effect on the clinical syndrome. 
To assess for these differences, this study undertook PET imaging with 11C-PK11195 
(PK11195), a marker of microglial activation in vivo within the brain, and tested for 
peripheral inflammatory cytokines in patients with DLB and healthy controls.  
If consistent with the studies in the closely related conditions of PD and AD, patients with 
DLB would have increased central and peripheral inflammatory changes when compared 
to controls. These changes would also likely vary according to disease severity, with 
more pronounced changes early in disease as has been found in Parkinson’s disease 
and, in some studies, Alzheimer’s disease. Accordingly, cognitive and motor 
performance in each subject was assessed for comparison with any central or peripheral 
inflammatory changes.  
Finally, in view of the concurrent beta-amyloid pathology found in many DLB patients 
(Colom-Cadena et al., 2013), concomitant amyloid protein deposition was also tested 
using 11C-Pittsburgh compound B (PiB) PET to assess whether amyloid load correlated 
with inflammation centrally or peripherally. 
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6.1.1 Hypotheses 
This study tested the following hypotheses - that: 
1) there is an increase in brain microglial activation in DLB as measured by 
PK11195,  compared to similarly aged healthy controls, that varies according to 
disease severity, with more pronounced changes seen early in disease, 
2) there is an increase in peripheral inflammation in DLB compared to similarly aged 
healthy controls as seen in AD and PD, as measured by blood inflammatory 
marker levels, 
3) levels of microglial activation correlate with: 
a) key clinical symptoms in cognition and motor function, 
b) peripheral markers of neuroinflammation, 
c) the cortical amyloid load as assessed with PiB PET, and 
4) the differences in microglial activation between DLB and controls would be in 
regions predicted by known anatomical correlates of the clinical syndrome. 
 
6.1.2 Sample size  
The present study aimed to recruit DLB subjects with a range of disease durations and 
similarly aged controls to investigate PK11195 binding in relation to disease severity. 16 
DLB patients and controls would provide a power of 80% power to detect a standardised 
effect size of 1.0 between the groups, with an alpha of 0.05 (Hulley et al., 2007): 
N = 2 (zα + zβ)2 / (δ/σ) 2 ; where α=0.05, β=0.20, δ/d = 1.0 
 N = 2(1.96 + 0.84)2/(1.0)2  
 N = 15.68 or 16 rounded up. 
 
The preliminary data from the small case series by Iannaccone et al. (Iannaccone et al., 
2013) showed that the mean PK11195 binding potential in the caudate was 0.08 for 
controls, and 0.19 for DLB subjects and that the standard deviation of the binding 
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potential in controls was 0.03. Hence the level in the DLB subjects was more than one 
standard deviation above the mean in the controls. Similar values were reported in the 
majority of the other regions tested, including the precuneus, putamen, occipital lateral 
cortex and occipital medial cortex.  However the study by Iannaccone did not have 
similarly aged controls (no mean age was given - only a range of 29 to 60 years, 
compared to a mean of 72 years for the DLB group) which could explain the low mean 
binding potential and standard deviation in the control group. It also only studied early 
(of less than one year disease duration) DLB subjects, for whom PK11195 binding is 
also expected to be high as hypothesised. The mean levels of binding and standard 
deviation in controls could be higher in older control patients and also closer to DLB 
patients with severe disease; hence a standardised effect size of 1.0 has been used for 
this study.  
This study aimed to recruit 16 controls and between 16 and 20 DLB subjects, allowing 
for any attrition in patients between scans and any loss of quality in the scan data (due 
to patient movement for example). 
 
6.2 Methodology 
6.2.1 Participants 
All participants were aged over 50 years and had sufficient proficiency in English for 
cognitive testing. Nineteen patients with “probable” DLB as defined by both 2005 and 
2017 consensus criteria (McKeith et al., 2005, 2017), and 26 healthy controls with similar 
ages and gender were recruited. Exclusion criteria were (1) acute infection, (2) a contra-
indication to MRI, or a history of any of the following: (3) major psychiatric disorder (e.g. 
major depression), (4) neurological disorder (except a diagnosis of DLB in DLB subjects), 
(5) head injury, or (6) systemic inflammatory disorder (e.g. systemic lupus 
erythematosus, rheumatoid arthritis or Crohn’s disease).  
Patients were identified from the specialist memory clinic at the Cambridge University 
Hospitals NHS Trust (CUH), other local memory clinics, from the Dementias and 
Neurodegenerative Diseases Research Network (DeNDRoN) volunteer registers or the 
Join Dementia Research platform (https://www.joindementiaresearch.nihr.ac.uk). 
Healthy controls were recruited via DeNDRoN or Join Dementia Research as well as 
from spouses and partners of patient participants.   
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6.2.2 Clinical Assessments 
All participants underwent an initial assessment that included neuropsychological and 
cognitive testing (including Mini Mental State Examination (MMSE) and Addenbrooke’s 
Cognitive Examination-Revised (ACE-R)), severity of parkinsonism (Unified Parkinson’s 
Disease Rating Scale part III - motor (UPDRS)) and demographic measures. 
 
6.2.3 MRI and PET Imaging  
All participants underwent MRI on a 3 Tesla Siemens Magnetom Tim Trio, Verio or Skyra 
scanner (www.medical.siemens.com).  Each MPRAGE (magnetization-prepared rapid 
acquisition gradient-echo) T1-weighted sequence was non-rigidly registered to the 
ICBM2009a template brain using ANTS (http://www.picsl.upenn.edu/ANTS/) and the 
inverse transform was applied to the modified Hammers atlas (resliced from MNI152 to 
ICBM2009a space) to bring the regions of interest (ROI)s to subject MRI space, to which 
the PET data described below was co-registered. The T1 scanning protocol was as 
follows: 176 slices of 1.0 mm thickness, TE= 2.98 ms, TR = 2300 ms, flip angle =9°, 
acquisition matrix 256x240; voxel size = 1x1x1 mm3. 
19 DLB and 16 control group participants underwent PK11195 PET imaging to assess 
the extent and distribution of microglial activation, using a GE Advance PET scanner (GE 
Healthcare, Waukesha, WI) or a GE Discovery 690 PET/CT, with attenuation correction 
provided by a transmission scan or a low dose CT scan, respectively. The emission 
protocol for PK11195 were 75 minutes of dynamic imaging consisting of 55 frames 
starting concurrently with a 500 MBq PK11195 injection. Binding in each ROI was 
quantified using non-displaceable binding potential (BPND) determined with the simplified 
reference tissue model previously validated for PK11195 (Turkheimer et al., 2007) and 
corrected for cerebrospinal fluid (CSF) partial volumes. 16 of the DLB participants also 
underwent PiB  imaging to determine cortical amyloid burden, with 550 MBq of PiB 
injected as a bolus and imaging performed for 30 minutes starting at 40 minutes post-
injection. PiB data were quantified using standardized uptake value ratio (SUVR) by 
dividing the mean CSF-corrected radioactivity concentration in each Hammers atlas ROI 
by the corresponding mean CSF-corrected radioactivity concentration in the reference 
tissue ROI. Participants were considered amyloid positive if the average SUVR value 
across the cortical ROIs was > 1.5 (Hatashita and Yamasaki, 2010). The radiotracers 
were produced at the Wolfson Brain Imaging Centre (WBIC) Radiopharmaceutical 
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Chemistry laboratories.  Both of the 11C-labelled compounds were produced using the 
GE PETtrace cyclotron, a 16MeV proton and 8MeV deuteron accelerator.  PK11195 was 
prepared using the “Disposable” synthesis system or GE TRACER lab FX-C module, 
whereas PiB was prepared using the GE TRACER lab FX-C module. 
 
6.2.4 Cytokine Assessments 
Blood samples were obtained from all participants, allowed to clot for at least 30 minutes,  
centrifuged to isolate serum, then aliquoted and stored at -70 degrees until further 
analysis as below.  
Assays were carried out by the Core Biochemical Assay Laboratory, Cambridge 
University Hospital using the MesoScale Discovery V-Plex Human Cytokine 36 plex 
panel and five additional cytokine assays: high sensitivity c-reactive protein (using 
Siemens Dimension EXL autoanalyser), tumor necrosis factor receptor 1 (using the 
electrochemiluminescence immunoassay from MesoScale Discovery) and interleukin-34 
(IL-34), YKL-40 (Chitinase-3-like protein 1), plus macrophage colony stimulating factor 1 
(all using BioTechne R&D Systems kit, ). Dilutions were made in accordance with 
manufacturer recommendations. Each assay was performed in duplicate, with the mean 
taken for the purposes of analysis.  
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6.2.5 Statistical Analysis 
Statistical analysis was completed using IBM SPSS Statistics software (version 25) and 
the support vector machine (SVM) analysis carried out with R:  R Foundation for 
Statistical Computing, Vienna, Austria (URL https://www.R-project.org/). 
Demographics were compared using student’s t-test for continuous variables and chi-
squared test or Fisher’s exact test for categorical variables. To compare cytokine levels 
between the DLB and cytokine control group, a repeated measures general linear model 
tested for the effect of group and group cytokine interaction, with age and gender 
included as covariates of no interest. The majority of the cytokine assay results were 
positively skewed, hence all cytokine measurements were transformed with log10 (x +1) 
prior to analysis to improve normality for the general linear model. PK11195 binding 
between the DLB and PET control group was also compared using a repeated measures 
general linear model, with age, gender and education included as covariates of no 
interest. 
To study further whether cytokine profiles or PK11195 binding in regions of interest could 
differentiate subjects according to group, a support vector machine was used, with 
feature selection to select the best variables from these datasets and identify the highest 
rate of accuracies that could be obtained for classification into groups. The SVM model 
was trained with leave one out cross-validation and a linear kernel tuned to provide the 
optimum balance between a wide margin between support vectors in the hyperplane and 
a small number of misclassified data points. Application of the SVM across different 
training group partition sizes, where each subject was randomly allocated to testing or 
training identified: (i) the training and testing split that provided the highest accuracies, 
and (ii) an order of influence of each variable as support vectors. Next feature selection 
was carried out, similar to that previously used to identify optimum blood biomarker 
panels in Alzheimer’s disease (Long et al., 2016). Features were individually added in 
order of increasing influence to create an enlarging panel of variables. For each panel, 
the SVM was repeated 5000 times, each with randomly allocated training groups from 
the full list of sample subjects, to obtain the mean accuracy for classification into groups. 
Once the panel with the highest accuracy was obtained, features were further selected 
within this subset based on changes in accuracy following their removal from the panel, 
to identify a set of features that recorded the peak accuracy.  
Correlations between clinical factors (disease duration and disease severity measured 
through ACE-R, and UPDRS), regional PK11195 BPND, amyloid SUVR, and cytokine 
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levels, were assessed with Pearson partial correlation, with age, gender and education 
as co-variates of no interest. To correct for multiple comparisons, the Benjamini-
Hochberg false detection rate method was applied, with an alpha of 0.05.  
 
6.3 Ethics  
The study received a favourable opinion from the East of England (Cambridge Central 
Research) Ethics Committee (reference: 13/EE/0104). Approval was also obtained from 
Cambridge University Hospitals NHS (CUH) Trust, Cambridgeshire and Peterborough 
NHS Trust, Norfolk and Suffolk NHS Foundation Trust and North Essex NHS Foundation 
Trust, Research and Development departments.  
Potential participants identified, as described above, who showed a willingness to take 
part in the research were provided with information about the study in the form of a 
patient information sheet.  Following a period of time to consider the information, a follow-
up phone call was made to inquire as to their interest in participation and to ask for further 
information to ensure they were eligible to take part.  An appointment was then made at 
the study premises or at their home to provide an opportunity to ask further questions 
and obtain formal written informed consent from the participant or, in cases where the 
participant did not have capacity, from an appropriate consultee in accordance with the 
Mental Capacity Act 2005 (England and Wales).  Consent was for participation in the 
study and publication of findings. Appendix 4 contains an example consent form and 
patient information sheet for this study.   
All data collected for the study was kept securely with imaging data stored on security 
protected computer systems, accessible only to authorised users with log-in identities 
and passwords, on University of Cambridge servers, within the Wolfson Brain Imaging 
Centre and University of Cambridge Medical School and CUH Department of Radiology 
servers.  Administration and neuropsychology test data was stored in paper form under 
lock-and-key and in computer-readable form in encrypted volumes securely hosted on 
the University of Cambridge Medical School servers. 
The study was also ARSAC (Administration of Radioactive Substances Advisory 
Committee) approved.  
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7.1 Demographics 
There were no differences in age or gender between the dementia with Lewy bodies 
(DLB) group and the two control groups (both the smaller 11C-PK11195 (PK11195) 
cohort and the expanded cytokine cohort (see Table 7.1)), though the DLB group had 
fewer years of formal education than the two control groups. As expected DLB 
participants had lower cognitive scores as measured by the Addenbrooke’s cognitive 
exam-revised (ACE-R) and mini mental state examination (MMSE) and higher motor 
scores on the unified Parkinson’s disease rating scale - section III (UPDRS) compared 
to the control participants. 
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Table 7.1 Participant Demographics.  
 
DLB  
(n=19) 
Control 
Group – PET 
Imaging 
 (n=16) 
Control 
Group – 
Cytokines 
(n=26) 
Group 
Difference 
(DLB v 
Control 
Group - PET) 
 
Group 
Difference 
(DLB v 
Control 
Group – 
Cytokines) 
 
Gender 
(males/females) 
15/4 8/8 15/11 P=0.09 P=0.20  
Age in years:  
mean (± SD) 
73.0(± 6.1) 70.0 (± 6.5) 69.9(± 6.4) t=1.4; P=0.17 t=1.6; P=0.11 
Education in 
years: mean (± 
SD) 
11.7(± 1.9) 14.1(± 3.0) 14.7(± 2.8) t=-2.9; 
P=0.007 
t=-4.1; 
P=<0.001 
MMSE scores: 
mean (± SD) 
21.9(± 4.5) 28.9(± 1.1) 29.1(± 0.9) t=-6.7; 
P<0.001 
t=-6.9; 
P<0.001 
ACE-R scores: 
mean (± SD) 
65.7(± 12.9) 92.5(± 5.6) 94.0(± 5.0) t=-8.2; 
P<0.001 
t=-9.1; 
P<0.001 
UPDRS scores: 
mean (± SD) 
32.5(± 20.6) N/A N/A   
Disease 
duration in 
years: mean (± 
SD) 
4.2(± 2.7) N/A N/A   
11C-PK11195  
PET scan 
19 16 16   
11C-PiB  
PET scan 
16 0 0   
The control groups for Position Emission Tomography (PET) and cytokines (the latter 
consisting of 10 additional participants) were not significantly different to the DLB 
group with respect to gender and age. SD = standard deviation. ACE-R = 
Addenbrooke’s Cognitive Examination-Revised. MMSE = Mini-Mental State 
Examination.  PiB = Pittsburgh B Compound.  
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7.2 Cytokine Results 
A total of 41 cytokines were assayed. Nine were removed from the analysis as follows. 
In three assays (interleukin (IL)-34, IL-23, IL-1β) there were no cytokines detected in any 
sample. In three further assays (IL-17A Gen B assay, IL-21, IL-31), between 1 and 3 
samples had detectable levels - all within DLB subjects. For a further three assays less 
than a third of subjects in both groups had detectable levels (IL-1α, IL-5 and IL-4). 
Additionally, in two subjects there was a greater than 20% variation when the assay was 
duplicated (one DLB IL-17A assay and one control IL-12p70 assay), hence the mean for 
the group was substituted. Where a cytokine assay result was below the detectable 
threshold, zero was substituted in as the result.  
 
7.2.1 Repeated-Measures General Linear Model 
The repeated measures general linear model found no main effect of group (F(1,41) = 
0.24, P=0.63) however a significant group by cytokine interaction was found F(12,500) 
= 1.92, P =0.029 following Greenhouse-Geisser correction (ε=0.39), (as Mauchly’s test 
of sphericity was significant (P<0.001) indicting that variances of the differences were 
not equal). Post-hoc ANCOVAs of each cytokine, with age and gender as co-variates, 
showed that macrophage inflammatory protein 3α (MIP-3α) (F (41,1) = 13.29, P =0.001),  
IL-17A (F (41,1) = 7.75, P =0.008), and IL-2 (F (41,1) = 4.23, P =0.046) were higher in 
DLB and that IL-8 (F (41,1) = 5.46, P =0.024) was lower (see Table 7.2 for remaining 
results). 
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Table 7.2 Cytokine Results 
 Control Participants DLB Participants Log10 (x+1) transform  
Cytokine 
(all pg/ml) 
except 
where 
stated 
Mean  Standard 
Error 
Mean  Standard 
Error 
F P value % 
difference 
in means 
IL-12p70 0.228 0.229 6.06 25.7 0.732 0.397 2553% 
IL-2 0.140 0.218 0.496 0.637 4.234 *0.046 254% 
IL-22 0.907 0.805 1.91 3.62 0.867 0.357 111% 
IL-17A     3.04 1.58 5.67 6.19 7.747 *0.008 87% 
MIP-3a 3.09 2.59 5.74 3.27 13.298 **0.001 86% 
YKL-40 43034 28357 64150 46616 1.821 0.185 49% 
IP10         324 147 434 368 0.976 0.329 34% 
IL-12      151 119 174 90.6 1.894 0.176 15% 
TNFR1 
(CD120a) 
3186 949 3527 737 1.446 0.236 11% 
TNF α 2.92 1.02 3.16 0.99 0.033 0.856 9% 
IL-7 17.5 5.55 18.7 8.55 0.139 0.711 7% 
MCSF1 358 319 380 181 0.720 0.401 6% 
TNF-β     0.367 0.139 0.385 0.213 0.061 0.807 5% 
IL-27 2590 1421 2615 934 0.042 0.839 1% 
IL-6 0.975 0.704 0.974 0.531 0.163 0.689 0% 
IL-16       211 64.0 209 79.3 0.874 0.355 -1% 
IL-15       2.46 0.812 2.41 0.325 0.033 0.856 -2% 
hsCRP mg/l 3.19 5.05 3.10 3.79 0.001 0.981 -3% 
GM-CSF 0.588 0.371 0.567 0.246 0.010 0.920 -3% 
MCP-1     282 100 268 81.3 0.004 0.951 -5% 
Eotaxin   181 52.4 171 83.0 1.726 0.196 -6% 
MIP1a      17.1 9.08 15.7 4.78 0.812 0.373 -8% 
MIP1b     130 74.6 119 35.8 0.158 0.693 -8% 
IL-10 0.463 1.10 0.420 0.281 0.550 0.463 -9% 
IFN gamma 11.4 8.19 10.2 7.26 0.503 0.482 -10% 
MCP-4     197 59.4 175 58.8 1.498 0.228 -11% 
Eotaxin 3 21.0 7.51 18.6 5.90 2.255 0.141 -11% 
IL-13 0.594 0.749 0.512 0.697 0.723 0.400 -14% 
TARC  320 241 272 146 0.094 0.761 -15% 
IL-8 11.9 7.75 8.83 2.44 5.455 *0.024 -26% 
VEGF     178 115 116 56.3 1.455 0.235 -35% 
MDC         1644 2290 1018 161 0.899 0.349 -38% 
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Results of post-hoc ANCOVAs with age and gender as covariates of no interest 
(*=significant at P<0.05, **=significant at P<0.005). Cytokines are ordered 
according to differences in means between groups, with those cytokines highest 
in the DLB participants at the top. Abbreviations:  IL = interleukin, TNF = tumour 
necrosis factor, MIP = macrophage inflammatory protein, MCP = monocyte 
chemotactic protein, MCSF = macrophage colony-stimulating factor, hsCRP = 
high sensitivity c-reactive protein, GM-CSF = granulocyte-macrophage colony-
stimulating factor, IP-10= interferon gamma-induced protein 10, IFN = interferon, 
TARC = thymus- and activation-regulated chemokine, TNFR = tumour necrosis 
factor receptor, MDC = macrophage derived chemokine, VEGF = vascular 
endothelial growth factor. Showing four cytokines were significantly different 
between the groups.  The largest difference in means was observed in IL-12p70, 
but one result in the DLB group was a high outlier, meaning overall there was no 
significant difference. 
 
7.2.2 Support Vector Machine Analysis 
With the support vector machine (SVM) model, peak accuracy for the classification of 
subjects based on cytokines was recorded at 81% (sensitivity of 71% and specificity of 
87% in classifying DLB subjects correctly). MIP-3α, IL-8, IL-2, IL-13, vascular endothelial 
growth factor, YKL-40 (Chitinase-3-like protein 1) and IL-16 made up this discriminatory 
panel of cytokines. Cytokines were adjusted for age and gender prior to analysis by SVM. 
 
7.3 PET Imaging Results 
7.3.1 Repeated-Measures General Linear Model: DLB v Controls 
In the repeated measures general linear model between the control and DLB groups, 
there was no statistically significant main effect of group (F(30,1) = 0.13, P =0.91) or any 
significant group by region of interest interaction (F(8,238) = 1.48, P =0.165; 
(Greenhouse-Geisser correction (ε=0.20) as Mauchly’s test of sphericity was significant 
(P<0.001)).  
In view of the priori hypothesis, based on previous literature in PD and AD, that there 
would be greater inflammation in early stage DLB, the DLB group was split according to 
their median ACE-R score, resulting in nine “mild” cases with an ACE-R of >65 (Mild 
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DLB group) and ten “moderate-severe” cases with an ACE-R of ≤65 (Moderate-Severe 
DLB group), reflecting levels of cognitive impairment at the time of their PK11195 scans.  
All three groups (Mild and Moderate-Severe DLB, plus controls) were similar in gender 
and age (see Table 7.3). Education was also similar between the Mild and Moderate-
Severe DLB groups, but both DLB groups’ years of education were lower than controls. 
As expected, MMSE and ACE-R scores were significantly different between each of the 
three groups. Disease duration and UPDRS scores were higher in the Moderate-Severe 
DLB group than the Mild DLB group, but this was not statistically significant.   
Chapter 7: Inflammation In Dementia With Lewy Bodies - Results 
151 
 
Table 7.3 DLB Subgroup Demographics.  
 
The Mild and Moderate-Severe DLB groups were similar to the control group, as well as 
each other, with respect to gender and age. There were differences in education 
between the Mild and Moderate-Severe DLB groups and the controls but not 
each other. As expected, MMSE and ACE-R scores were significantly different 
between each of the three groups. Disease duration and UPDRS scores were 
however not significantly different between Mild and Moderate-Severe DLB 
 
Mild DLB  
(n=9) 
Moderate-
Severe 
DLB   
(n=10) 
Control 
Group – 
PET 
Imaging 
 (n=16) 
Group 
Difference 
(Mild DLB v 
Control - 
PET) 
 
Group 
Difference 
(Moderate-
Severe 
DLB v 
Control – 
PET) 
 
Group 
Difference 
(Mild DLB v 
Moderate-
Severe 
DLB) 
 
Gender 
(males/femal
es) 
6/3 9/1 8/8 P=0.68 P=0.09  P=0.30  
Age in years:  
mean (± SD) 
74.7(± 5.2) 71.5(± 6.7) 70.0 (± 6.5) t=1.87; 
P=0.07 
t=0.55; 
P=0.59 
t=1.17; 
P=0.26 
Education in 
years: mean 
(± SD) 
11.8(± 1.9) 11.7(± 2.1) 14.1(± 3.0) t=-2.2; 
P=0.04 
t=-2.3; 
P=0.03 
t=0.09; 
P=0.93 
MMSE 
scores: mean 
(± SD) 
25.9(± 2.7) 18.3(± 1.8) 28.9(± 1.1) t=-4.1; 
P<0.001 
t=17.2; 
P<0.001 
t=7.4; 
P<0.001 
ACE-R 
scores: mean 
(± SD) 
77.4(± 6.2) 55.2(± 6.2) 92.5(± 5.6) t=-6.2; 
P<0.001 
t=15.9; 
P<0.001 
t=7.8; 
P<0.001 
UPDRS 
scores: mean 
(± SD) 
28.2(±14.4) 36.4(±25.1) N/A N/A N/A t=-0.86; 
P=0.40 
Disease 
duration in 
years: mean 
(± SD) 
3.0(±0.7) 5.2(±3.4) N/A N/A N/A t=-1.9; 
P=0.07 
11C-PK11195  
PET scan 
9 10 16    
11C-PiB  
PET scan 
9 7 0    
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participants. 
 
7.3.2 Repeated-Measures General Linear Model - DLB Subgroups v Controls  
Repeated measures general linear model analysis of these three groups, with age, 
gender and education as covariates, showed a significant main effect of group (F(2,29) 
= 5.88, P=0.007), and a main effect of region (F(8,231) = 2.1, P=0.04), but no group by 
region interaction F(16,231) = 1.35, P =0.171 (Greenhouse-Geisser corrections 
(ε=0.198) to the degrees of freedom were required as sphericity was violated (P<0.001)). 
Pairwise comparisons showed the main group effect was due to a significant difference 
between the Mild and Moderate-Severe DLB groups (P=0.006).   
Post-hoc ANCOVAs with the same co-variates found 18 out of 41 regions to be 
significantly different between all three groups: caudate nucleus, cuneus, putamen, 
fusiform gyrus, lateral occipital lobe, inferior frontal gyrus, superior frontal gyrus, middle 
and inferior temporal gyrus, central superior temporal gyrus, anterior superior temporal 
gyrus, posterior temporal lobe, lateral orbital gyrus, anterior orbital gyrus, posterior orbital 
gyrus,  inferolateral parietal lobe, superior parietal gyrus, thalamus and midbrain. The 
caudate nucleus (F (29,2) = 12.702, P =0.0001) showed the highest level of significance 
(see Fig. 7.1).  
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Figure 7.1 Group differences in PK11195 BPND. PK11195 BPND between controls, Mild 
and Moderate-Severe DLB - significant differences were found in 18 regions. 
***=significant at P<0.001, **=significant at P<0.01 and *=significant at P<0.05. 
Error bars represent standard deviation. Abbreviations: med=medial, 
temp=temporal, ant=anterior, sup=superior, cent=central, inf=inferior, gy=gyrus, 
post=posterior, lat=lateral, par=parietal, orb=orbital, Mod-Sev=Moderate-Severe. 
 
7.3.3 Comparison Between DLB Groups 
Pairwise comparisons from the ANCOVAs found 14 individual regions had significant 
differences in binding between DLB groups, all with mean BPND higher in the Mild DLB 
group: superior and middle/inferior temporal gyri, anterior superior temporal gyrus, 
posterior temporal lobe, caudate, thalamus, anterior orbital gyrus, lateral orbital gyrus, 
inferior frontal gyrus, superior frontal gyrus, superior parietal gyrus, inferior lateral parietal 
lobe, cuneus, and lateral occipital lobe.  
 
7.3.4 Comparison Between Control Group and Each DLB Group 
In addition, comparing each DLB group with controls: 33 out of 41 regions showed higher 
binding in the Mild DLB group compared to controls (an exact sign test used to compare 
the differences found a significant increase in PK11195 BPND (non-displaceable binding 
potential) in the Mild group compared to controls, P = 0.00004), with five significantly 
higher (inferior and medial temporal gyrus, fusiform gyrus, putamen, inferior frontal gyrus 
and cuneus) in the ANCOVA.  33 out of 41 regions showed higher binding in the control 
group than the Moderate-Severe DLB Group (with an exact sign test finding a significant 
increase in the control group, P=0.00004), but only the caudate nucleus was significantly 
higher, when analysed as an individual region. 
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7.3.5 Support Vector Machine 
Peak accuracy for the classification of DLB subjects from controls using the SVM model, 
based on PK11195 binding in regions of interest, was recorded at 75% (sensitivity of 
68% and specificity of 84%) with the following five PK11195 regional BPND being the best 
for separating groups: caudate, putamen, midbrain, nucleus accumbens, and inferior 
frontal gyrus. For classifying Mild and Moderate-Severe DLB subjects, the peak accuracy 
was 83% (sensitivity 75% and specificity 89%), with the cuneus, lateral occipital lobe, 
caudate, superior frontal gyrus,  anterior superior temporal gyrus and anterior orbital 
gyrus best for separating the subgroups. BPND values were adjusted for age, gender and 
education prior to analysis by SVM. 
 
7.3.6 Amyloid status  
Eleven of the sixteen “probable” DLB subjects who underwent PiB imaging, had 
standardized uptake value ratio (SUVR) >1.5, indicating positive amyloid status.  
 
 
7.4 Correlation Analysis In DLB subjects 
Pearson’s correlations were carried out between the clinical features (ACE-R score, 
UPDRS score and disease duration) and amyloid SUVR, together with log transformed 
cytokines and PK11195 BPND values in regions of interest. Cytokines significantly 
different in DLB as identified using the repeated measures general linear model were 
selected for correlation, in addition to the ten regions with the highest significant 
differences in the repeated measures general linear model between DLB groups.  
ACE-R scores, were positively correlated with PK11195 BPND in four regions, with the 
caudate showing the strongest correlation (R=0.83, P=0.00008). Significant positive 
correlations were also found between ACE-R scores and binding in the cuneus (R=0.77, 
P=0.0005), superior frontal gyrus (R=0.69, P=0.003) and anterior orbital gyrus (R=0.67, 
P=0.004).  Whilst correlations with ACE-R scores in the remaining six regions were non-
significant, all showed positive correlations, ranging from R=0.25 to R=0.63 (see Fig. 
7.2).  
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Figure 7.2 Clinical, Imaging and Cytokine Correlations. Pearson’s partial correlations 
within the DLB group between clinical features, cytokines (log transformed) and 
PK11195 binding regions identified in the DLB group by the repeated measures 
general linear model.  Age, gender and education were used as covariates. 
Abbreviations: temp=temporal, ant=anterior, sup=superior, cent=central, 
inf=inferior, gy=gyrus, lat=lateral, orb=orbital.   
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There were also negative correlations between inflammatory cytokines IL-2 and IL-8 and 
BPND in the lateral occipital lobe: R=-0.55, P=0.03 and R=-0.53, P=0.04, respectively and 
between the caudate BPND and UPDRS scores (R=-0.49, P=0.05), though these did not 
survive correction for multiple comparisons, see Fig. 7.3.  
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Figure 7.3 Associations between clinical and inflammatory markers. A-D 
show strong positive associations between cognition and regional PK11195 
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binding. E shows a negative association between central inflammation in the 
occipital cortex and peripheral inflammation in the form of IL-8 levels in the blood. 
F shows a negative association between the caudate and motor performance as 
measured by UPDRS. A-D, but not E and F, were statistically significant after 
correction for multiple comparisons. 
 
 
 
Comparison of PK11195 binding in the caudate with disease duration and UPDRS 
scores, appeared to show that higher levels were associated with the Mild DLB group 
irrespective of disease duration and motor impairment (see Fig. 7.4). Further comparison 
of PK11195 binding in the caudate region and levels of MIP-3α, showed that low levels 
of caudate binding and high levels of MIP-3α appeared to be associated with severe DLB 
(see Fig. 7.5). 
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Figure 7.4 Clinical features and Caudate BPND. Comparison of caudate BPND with 
disease duration and UPDRS scores in the two DLB subgroups, showing that the 
association between microglial activation and the caudate was independent of 
disease duration and motor impairment. 
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Figure 7.5 Caudate BPND and MIP-3α. Comparison of caudate BPND and MIP-3α 
levels in controls and the two DLB subgroups. 
 
There was however no association between the level of PK11195 binding in the cuneus 
and the likelihood of the patient experiencing visual hallucinations (see Fig. 7.6). A 
comparison of binding potentials in the cuneus in DLB patients with and without visual 
hallucinations found no significant difference (t=-0.59, P=0.56) 
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Figure 7.6 Cuneus BPND, ACE-R Scores and Visual Hallucinations. Despite the 
correlation between PK11195 binding in the cuneus and cognitive performance, 
there does not appear to be a link between level of binding and the likelihood of 
visual hallucinations being experienced by the patient.     
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8.1 Introduction 
This study provides evidence of both central and peripheral inflammation in dementia 
with Lewy bodies and establishes a correlation between inflammation and clinical 
severity.   
 
8.2 Evidence of Early Central Inflammation in DLB 
11C-PK11195 (PK11195) binding, which is a marker of microglial activation, was found 
to be significantly elevated in dementia with Lewy body (DLB) cases with mild disease 
compared to those who had moderate-severe disease. Healthy adults had lower levels 
of inflammation than mild DLB cases, but higher levels than those with moderate-severe 
DLB, indicating a non-linear spectrum of microglial elevation, starting early in the 
condition or before and subsiding in the late stages. The strong association found 
between cognitive scores and microglial activation in several brain regions (caudate, 
cuneus, anterior orbital gyrus and superior frontal gyrus), as well as a positive correlation 
in all the regions tested, is consistent with such a continuum. 
Early microglial activation is consistent with results in prodromal and early Alzheimer’s 
disease where positron emission tomography (PET) studies have previously shown 
microglial activation in mild-cognitive impairment, before the onset of dementia (Okello 
et al., 2009) and early in dementia with a similar correlation with cognitive performance 
by means of mini mental state examination (MMSE) score (Hamelin et al., 2016). 
Inflammation has also been seen early in Parkinson’s disease in the brainstem, and 
cortical inflammation is seen before the onset of dementia (Ouchi et al., 2005; Gerhard 
et al., 2006; Edison et al., 2013).  In addition, inflammation has been reported even 
earlier, in subjects with no motor or cognitive impairment, only REM sleep behaviour 
disorder, a condition which is recognised as a prodromal stage of synucleinopathies, 
within the substantia nigra (Stokholm et al., 2017), and occipital cortex (Stokholm et al., 
2018).  
From this study, we cannot conclude at what point in the DLB process inflammation 
occurs, only that it is already present in mild disease. It remains possible subjects 
predisposed to develop DLB have lifelong increases in activated microglia, though from 
mouse models of a number of dementia subtypes, which suggest activation is a response 
to excess protein or protein accumulation (Schwab, Klegeris and McGeer, 2010), this 
seems unlikely. Early neuroinflammation that then plateaus has been reported in a 
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mouse model of Alzheimer’s disease (López-Picón et al., 2017), but to date a decline in 
central inflammation with disease progression has not been reported in human studies. 
Other studies in Alzheimer’s disease have reported an early and late peak (Fan et al., 
2017) (though these peaks were not demonstrated in the same subjects) or an increase 
in inflammation with disease progression  (Fan, Okello, et al., 2015)(Hamelin et al., 2018) 
but in only eight or six (respectively) demented Alzheimer’s subjects who individually had 
heterogeneous (both rises and falls in inflammation) on follow-up scanning. In addition, 
in Parkinson’s disease an inverse relationship between microglial activation and MMSE 
scores has also been found (Fan, Aman, et al., 2015), suggesting caution is indicated in 
the interpretation of this study’s result. This study provides cross-sectional data only and 
longitudinal studies are required to study the role of central inflammation as impairment 
progresses.  
The strength of the association between cognition and inflammation was highest in the 
caudate, which was also identified by the support vector machine (SVM) as a key 
classifier in determining differences between the control and DLB groups. The caudate 
is a core anatomical area involved in the pathology of DLB and caudate dysfunction could 
be caused by defects in the nigrostriatal pathway (Minoshima et al., 2002) and/or their 
targets, the medium spiny neurons (Zaja-Milatovic et al., 2006), both of which show 
selective degeneration in DLB, compared to Alzheimer’s disease. Early inflammation of 
the caudate, which declines with cognitive impairment, implicates a key component of 
the basal ganglia in the cognitive impairment seen in DLB. Indeed, hypometabolism in 
the caudate of DLB patients has previously been detected in early disease (Huang et al., 
2015). In addition, in a comparison with Parkinson’s disease patients, DLB patients are 
reported to have a more severe reduction in dopamine uptake within the caudate (Walker 
et al., 2004; Gomperts et al., 2016). The caudate has extensive cortical (as well as 
nigrostriatal) inputs, and is increasingly recognised for its role in higher cognition, 
particularly executive function and goal-directed action (Grahn, Parkinson and Owen, 
2008; Haber, 2016).  
A strong correlation between cognitive scores and PK11195 binding in the occipital lobe, 
within the cuneus, was also found, but no link between the level of binding and visual 
hallucinations being experienced by the patient. Occipital lobe pathology has been 
frequently reported in DLB, with both Fluorodeoxyglucose (FDG) PET and perfusion 
Single Photon Emission Tomography (SPECT) scans showing reduced metabolism 
(Minoshima et al., 2001; Kantarci et al., 2012) and perfusion (Yeo et al., 2013) 
respectively, distinguishing DLB cases from those with Alzheimer’s disease.  
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Visuospatial dysfunction is also a specific indicator of DLB pathology (Yoshizawa, 
Vonsattel and Honig, 2013). Our results suggest inflammation maybe linked to the 
underlying pathology of these cognitive impairments.  
Furthermore, higher levels of microglial activation in the caudate appeared to be 
associated with milder cognitive impairment independently of disease duration or level 
of motor impairment, which may indicate a stronger link between caudate dysfunction 
and cognitive performance in DLB and a protective effect of microglial activation, at least 
initially. A longitudinal study in brain trauma patients found evidence of a protective role 
for microglia clinically, with the drug minocycline reducing microglial activation over 12 
weeks, with an associated increase in neurodegeneration (Scott et al., 2018). However, 
early microglial activation that is then primed by systemic inflammatory factors towards 
chronic and deleterious inflammation has also been suggested as a potential mechanism 
in neurodegeneration (Perry and Holmes, 2014). 
 
8.3 Evidence of Peripheral Inflammation in DLB in Comparison to Controls 
As well as central inflammation, we report increased peripheral cytokines in DLB subjects 
as a whole compared to controls. A significant cytokine by group interaction was found, 
suggesting individual cytokines had a different effect depending on the group that they 
were in. DLB participants showed higher levels of macrophage inflammatory protein – 
3α (MIP-3α), interleukin (IL)-17A, IL-2 and lower levels of IL-8 in the serum compared to 
their healthy counterparts. MIP-3α, IL-2 and IL-8 were also identified by SVM as 
classifiers in separating the DLB group from controls. SVM was able to differentiate the 
groups with an accuracy of 81%, suggesting cytokine profiles between controls and DLB 
patients were indeed different. 
MIP-3α, also known as CCL20, and IL-17A share a close relationship, with MIP-3α 
regulating helper T cells that produce IL-17a. IL-17a is strongly implicated in the 
pathogenesis of a number of autoimmune disorders. In rheumatoid arthritis in particular, 
IL-17a appears to promote a chronic pro-inflammatory state leading to bone and cartilage 
destruction (Schutyser, Struyf and Van Damme, 2003; Onishi and Gaffen, 2010; Lee and 
Körner, 2014) and levels have been found to fall following treatment of rheumatoid 
arthritis with monoclonal antibodies such as Infliximab (Kawashiri et al., 2009). Whether 
these two cytokines play a destructive inflammatory role in DLB requires further 
investigation.   
Chapter 8: Inflammation In Dementia With Lewy Bodies - Discussion 
 
167 
 
IL-2 has a number of anti-inflammatory and pro-inflammatory roles within the immune 
system, but predominantly is a marker of T-cell activation (Boyman and Sprent, 2012), 
again suggesting a role for T-cells in DLB pathology. IL-8 is a mediator of inflammation 
through recruitment and degranulation of neutrophils, and can also promote 
phagocytosis in neutrophils (Waugh and Wilson, 2008).    
Only one prior study has investigated peripheral cytokine levels in DLB (King et al., 
2017). No differences were found compared to healthy controls, however MIP-3α, IL-17a 
and a large number of cytokines that were included in this current study were not 
investigated. IL-2 was not found to be raised in the DLB group but was raised in the 
prodromal DLB group and no differences in IL-8 results were found in either cohort. In 
Alzheimer’s disease, a systematic review of peripheral inflammatory markers showed IL-
2 but not IL-8 was consistently raised (Lai et al., 2017). MIP-3α and IL-17a were not 
mentioned in that review. Mouse models of Alzheimer’s disease however suggest T-
helper cell infiltration into the brain parenchyma is combined with elevated IL-17 levels 
in the serum, cerebrospinal fluid and hippocampus in association with amyloid pathology 
(Zhang et al., 2013). T-cells have also been implicated in the pathology of Alzheimer’s, 
through the IL-17 pathway (Sommer, Winner and Prots, 2017).  
 
8.4 Correlations between Central and Peripheral Inflammation 
Combined low levels of PK11195 binding in the caudate and higher levels of MIP-3α 
were associated with moderate-severe DLB, and hint at a link between falling central 
inflammation and rising peripheral inflammation, involving the adaptive immune system. 
In addition, a negative, though non-significant, association was found between IL-2 and 
IL-8 levels and PK11195 binding in the occipital lobe.  
Rising systemic inflammation could be associated with a fall in central inflammation. It is 
possible that microglia switch from being protective initially to destructive as the disease 
progresses - leading to the initiation of a peripheral response - before subsiding as 
neuronal death follows. There are suggestions that MIP-3α is released when microglia 
are in their pro-inflammatory (rather than anti-inflammatory state) in association with the 
release of free radicals (Orihuela, McPherson and Harry, 2016), but the evidence is 
limited. Further studies looking at this potential interaction are required. 
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8.5 No Correlations with Amyloid 
We did not find any correlation between amyloid load and clinical features, binding in the 
regions of interest or peripheral cytokine levels, suggesting either that amyloid is not a 
driver of inflammation or disease in DLB, or that any such association is weak. This is in 
contrast to other studies which have shown a local or regional correlation between 
amyloid and inflammation in Alzheimer’s disease (Fan, Okello, et al., 2015; Hamelin et 
al., 2016; Parbo et al., 2017) and to a lesser extent in Parkinson’s disease dementia 
(Fan, Aman, et al., 2015). 
 
8.6 Strengths and Limitations of this Study 
The strengths of this study include the novel use of the combined methodologies of PET 
imaging, serum inflammatory profiles and clinical assessments to assess the extent and 
nature of inflammation in DLB subjects. There are no studies in the literature which have 
correlated peripheral and central inflammation in the same dementia subjects. 
Another strength is the use of a machine learning technique to add to the standard 
parametric analysis used to compare groups. The support vector machine results were 
consistent with the parametric test results with respect to showing differences between 
groups and identifying key classifiers, adding further validity to the results. 
Potential limitations include the use of the PK11195 ligand as a measure of microglial 
activation, via binding to the peripheral benzodiazepine receptor. PK11195 is accepted 
to have a high signal to noise ratio and also displays non-specific binding, particularly to 
astrocytes (Vivash and OBrien, 2016). It nevertheless provides the best means currently 
available for assessing in vivo central inflammation as other ligands for the peripheral 
benzodiazepine receptor are affected by polymorphisms in the gene for the receptor 
(Owen et al., 2012), which would mean that subject recruitment would be limited to those 
with moderate to high affinity binding, diminishing the number of potential DLB 
participants that could be recruited. This is relevant for DLB studies where patient 
recruitment is already made difficult by the low clinical prevalence rate, but may be less 
relevant for studies in Alzheimer’s disease subjects.  
Another potential limitation is the inference of evolutionary changes in a cross-sectional 
study such as this. Whilst the correlations with cognitive performance were strong and 
provide some evidence of a correlation with disease severity, they are not substitutes for 
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a longitudinal study of PK11195 binding in the same subjects assessing inflammatory 
changes over time.  
The serum biomarker study tested a large number of inflammatory markers but was 
limited by the small sample size. However as this study was primarily focussed on the 
correlation between central and peripheral inflammation, the number of patients in the 
serum study was limited by the number who could carry out PET imaging. 
 
8.7 Conclusion 
Overall our results suggest that early DLB is associated with microglial activation in key 
areas affected by DLB pathology, which appears to decline as cognitive impairment 
progresses. Peripherally, cytokines associated with T-cell activation appear to be higher 
in DLB. The next step is for a longitudinal study of central and peripheral inflammation 
starting in early DLB, to understand if progressive disease is linked to both pathways, 
and hence if selectively targeting either could halt disease progression.  
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9.1 Objectives and Summary of Results 
This study aimed firstly to investigate the current clinical practice in relation to the 
recognition and diagnosis of Lewy body dementia, and the difficulties associated with 
both and then aimed secondly to investigate if inflammatory changes were present in 
Lewy body dementia, and whether these could thus assist in improving recognition and 
diagnosis of the condition. If present, inflammatory changes could potentially provide a 
biomarker to aid diagnosis or could potentially lead to a disease modifying therapy. Any 
novel treatment such as the latter could raise motivation to diagnose LBD and hence 
increase vigilance of these conditions clinically. 
A background literature review of studies assessing prevalence of both dementia with 
Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) found DLB forms 5% and 
PDD 3.6% of all clinically diagnosed dementia cases, meaning LBD accounts for 8.6% 
of all dementia cases. At autopsy however, this is a much higher 15-20%, suggesting a 
mismatch between clinical and pathological rates of LBD, where a half or more of LBD 
cases are not being diagnosed clinically. The rate of dementia in PD was found 
consistently to be 20-30% of PD cases. 
Rates of diagnosis of both DLB and PDD in routine practice within NHS trusts in East 
Anglia were found to be even lower than previously reported clinical prevalence rates. 
Only 3.3% of dementia cases were diagnosed with DLB, lower than that expected from 
the literature review and only 8.3% of patients with PD were diagnosed with dementia, 
less than half of the expected rate from the review. This study intentionally looked at 
routine practice to identify the actual rates of these conditions diagnosed clinically 
reflecting patient experience, whereas the vast majority of studies are based on a 
diagnosis made by the study team, actively seeking to identify dementia subtypes. Hence 
this study reflects actual practice in the NHS within the UK and found that far fewer cases 
are being detected clinically than are reportedly found to be LBD at autopsy, suggesting 
that a large number of patients with LBD are misdiagnosed as another dementia subtype 
or alternatively are not specifically diagnosed with any dementia subtype. 
Compared to patients with other dementia subtypes, DLB patients had more clinic 
appointments with more alternate diagnoses, prior to reaching a final diagnosis. In 
addition, the majority of patients who were diagnosed with DLB, exceeded the threshold 
for “probable” DLB, in terms of the core and suggestive features they experienced, as 
set out in the 2005 consensus criteria. In addition, only one DLB patient out of 23 had a 
dopamine transporter scan, suggesting this was a much under used biomarker. 
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In PD patients, delays were found between the onset of symptoms suggestive of 
dementia and an actual diagnosis and more than a quarter were started on treatment for 
dementia, in the form of rivastigmine, before being diagnosed. Carer stress was also 
higher in PD patients with dementia compared to those without, as were visual 
hallucinations and cognitive fluctuations.  
Cognitive impairment was frequently found in the control PD subjects, who were not 
formerly diagnosed with dementia and some had even had treatment for dementia. This 
suggests once more that there are delays in the diagnosis of dementia in PD. 
A literature review of studies examining inflammation in Lewy body dementia found 
imaging evidence of microglial activation early in disease in PD subjects and PDD 
subjects. However, pathological evidence in the form of autopsy studies in DLB found 
increased MHC class II expression, with some evidence of phagocytosis and dystrophic 
changes in microglia, but not hypertrophic change, at the latter stages of the disease. 
Over-expression of α-synuclein in mouse models, leads to microglial activation and 
neuronal loss, providing a substrate for a toxic inflammatory reaction, MHC class II 
molecules and toll like receptor (TLR) 2 appear to be key to this process. However a 
number of other inflammatory components are found to be neuroprotective in α-synuclein 
mouse models, including TLR 4, NF-E2-related factor 2 and fractalkine, hence the role 
of microglia in LBD and other synucleinopathies remains unclear. Cerebrospinal fluid 
and blood biomarker studies in DLB and PDD provide limited evidence of inflammation 
in these disorders.  
In a study of 11C-PK11195 (PK11195) PET imaging in DLB compared to controls, this 
study found increased PK11195 uptake in mild but not in moderate-severe cases of DLB, 
consistent with microglial activation in vivo occurring early in the disease process. The 
level of microglia activation in the caudate and cuneus correlated strongly (with an R of 
more than 0.7) with revised Addenbrooke’s cognitive exam (ACE-r) scores in DLB 
subjects, again suggesting central inflammation occurs early in disease. Assessment of 
a panel of serum inflammatory biomarkers revealed several inflammatory changes 
(macrophage inflammatory protein-3, interleukin-17A and interleukin-2 were elevated, 
and interleukin-8 reduced), in the serum of DLB patients compared to controls. There 
was no correlation between cortical amyloid load as measured by 11C Pittsburgh 
Compound B PET imaging in DLB and PK11195 uptake suggesting an association 
between central inflammation and cortical amyloid load. Nor was there a correlation 
between cortical amyloid load and clinical features or peripheral inflammatory markers. 
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9.2 Conclusions 
9.2.1 Diagnosing DLB 
In this study, the proportion of dementia cases given a diagnosis of DLB in clinical 
practice was much lower than studies suggest is the true prevalence of the disorder 
pathologically and also lower than previously reported clinical rates. Many dementia 
cases in routine clinical services were given a non-specific dementia diagnosis of either 
unspecified or mixed with no mention of possible underlying pathology. It is possible, and 
indeed likely, that some of these cases were DLB. Clinicians appear to find it difficult to 
diagnose DLB and have high thresholds for diagnosing the condition in practice, as 
evidenced by the fact that more clinic appointments and changes in diagnosis were made 
in subjects diagnosed with DLB, compared to non-DLB controls, prior to their final 
diagnosis and the majority of subjects who did receive the diagnosis exceeded the 
thresholds for “probable” DLB (McKeith et al., 2005). It is recognised that the 2005 DLB 
criteria are highly specific but not very sensitive (Nelson et al., 2010) (Huang and 
Halliday, 2013), hence opting to set a higher threshold than the DLB criteria is unlikely 
to improve the accuracy of the diagnosis. Whilst a sensitive and specific biomarker in the 
form of a dopamine uptake scan (Walker and Walker, 2009; Thomas et al., 2017) does 
exist, it was rarely used. The reasons for this could include the high cost and poor 
availability. The criteria have been updated since this study was undertaken (McKeith et 
al., 2017) and this may improve diagnosis rates. However the two new biomarkers of 
123Iodine- metaiodo-benzylguanidine (MIBG) myocardial scintigraphy and 
polysomnography which have been proposed may also be difficult to access and 
expensive, and hence may not provide what is needed: a biomarker that is easily 
available and specific yet also sensitive.   
 
9.2.2 Diagnosing PDD 
Compared to previous studies on the prevalence of dementia in PD, which consistently 
report between 20-30%, this study found a much lower rate in actual clinical practice. A 
possible reason for this difference could be a delay between the recognition of dementia 
symptoms and a formal diagnosis. This study also found that symptoms of dementia 
were noted in clinic, but the diagnosis was not made until later and treatment often 
started before a diagnosis, perhaps indicating an inability or reluctance to diagnose 
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dementia despite clinicians acknowledging that it was nevertheless present. Often 
patients were referred by neurologists and geriatricians to old age psychiatrists for 
diagnosis and the majority of dementia diagnoses were indeed made by old age 
psychiatrists, despite neurologists and geriatricians providing the majority of care 
through follow-ups. The importance of making the diagnosis however was highlighted by 
the increased presence of additional symptoms such as excessive daytime sleepiness, 
swallowing difficulties, repeated falls, anxiety, orthostatic hypotension and changes in 
personality in those with PDD together with increased levels of carer stress. In addition, 
a dementia diagnosis can open further avenues of support for patients and their carer-
givers but perhaps more importantly may mean increased recognition that the patient’s 
dementia has significant implications including loss of insight, poor judgement and poor 
financial decision making (Aarsland et al., 2001). Potential avenues to consider in order 
to increase the rates of formal dementia diagnosis include improved education of 
neurologists and geriatricians regarding dementia in PD and providing a biomarker of 
dementia. 
 
9.2.3 Central Inflammation in DLB 
DLB subjects also show evidence of increased PK11195 uptake, consistent with 
increased microglial activation in mild disease, and reduced levels in moderate to severe 
disease, suggesting that inflammation occurs early in the condition. A decline in cognitive 
performance was strongly associated with a fall in microglial activation in the caudate, a 
region which is recognised as important in the DLB pathology. Similarly, the cuneus in 
the occipital lobe, also showed a positive correlation as did many other regions. Early 
central inflammation  is consistent with previous studies in PD and PDD plus in a small 
case series in DLB (Ouchi et al., 2005; Gerhard et al., 2006; Iannaccone et al., 2013; 
Fan et al., 2015). High levels of microglial activation in the caudate were associated with 
higher levels of cognitive performance irrespective of how long subjects had the disease 
and how severe their motor impairment was, suggesting that microglia may be playing a 
key role in either maintaining cognition through neuroprotection or being the instigators 
of cognitive decline where high levels of activity are seen before the onset of dysfunction. 
The case for both scenarios has been made previously (Perry and Holmes, 2014; Scott 
et al., 2018), and it is not possible to make this distinction in a cross-sectional study such 
as this.  
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Comparison with autopsy studies is also difficult as most patients reaching autopsy are 
in the mid to late stages of disease, yet in small numbers of DLB subjects, previous 
pathological studies report a lack of hypertrophic change indicative of the classically 
defined activated pro-inflammatory microglia (Walker and Lue, 2015) within the temporal 
pole and superior frontal gyrus (Streit and Xue, 2016). Increased MHC class II 
expression, another marker of activation, have however been found, in the entorhinal 
cortex (Mackenzie, 2000) and amygdala (Togo et al., 2001), together with evidence of 
dystrophic change in the hippocampus (Bachstetter et al., 2015). The results of this study 
do not conflict with these pathological findings, as microglial activation was higher only 
in early disease. In addition PK11195 binding is a marker of activation and is not 
increased by further transformation of microglia into a hypertrophic or amoeboid shape 
(Banati, 2002).  The results of this study also suggest that any future trials of anti-
inflammatory therapy should only include mild cases, and that potential patients should 
have an ACE-R score of more than 65. In addition, inflammation in the milder stages of 
disease could mean targeted therapies are able to modify disease progression early and 
prevent further deterioration, highlighting the importance of unravelling the underlying 
mechanisms and their impact on disease. For this purpose, there is also a need to study 
inflammation even earlier, in the prodromal or pre-dementia stage of DLB. 
 
9.2.4 Peripheral Inflammation in DLB      
Inflammatory cytokines in the blood are also altered in DLB subjects as a whole 
compared to controls, with macrophage inflammatory protein-3, interleukin (IL) 17A and 
IL-2 elevated. All three are associated with T cell activation and hence recruitment of the 
adaptive immune system. The only prior study to have investigated serum inflammatory 
markers in DLB by King et al. found raised IL-2 in prodromal DLB, but not in established 
disease, macrophage inflammatory protein-3 and IL-17A were not tested (King et al., 
2017). There was no significant correlation between disease severity and IL-2 levels in 
the current study, hence this result needs further confirmation in a larger group of DLB 
patients. Acquired immune system involvement in the disease is consistent with 
increased MHC class II expression in microglia at autopsy as described earlier in DLB.  
If the adaptive immune system in the form of T cells are the final path in cell degeneration, 
they could represent a rich target for therapy. Drugs that attenuate this aspect of the 
immune system are already widely used clinically - in the neuroinflammatory disorder 
multiple sclerosis and include alemtuzumab, natalizumab, and glatiramer acetate (Martin 
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et al., 2016). T cell involvement in Lewy body disorders is supported by studies showing 
T cell infiltration in the substantia nigra of PD patients at post-mortem (Brochard et al., 
2009) and polymorphisms in HLA regions coding segments of the MHC class II molecule 
representing increased risk in PD (Hamza et al., 2010; Wissemann et al., 2013). 
Knocking out MHC Class II protein also prevents dopaminergic cell loss in mouse models 
of α-synuclein overexpression (Harms et al., 2013). 
IL-8 levels were lower in DLB subjects. IL-8 is a pro-inflammatory chemokine involved 
mainly in neutrophil recruitment and angiogenesis (Waugh and Wilson, 2008). It has also 
been reported to be secreted by microglia in response to pro-inflammatory stimuli 
(Ehrlich et al., 1998). The reduction seen in this study is not consistent with results of the 
study by King and colleagues (King et al., 2017) however, which found no differences in 
IL-8 between DLB subjects and controls. Hence this result also needs verification in 
larger studies.  
 
9.2.5 Could Inflammation Provide a Biomarker for the Diagnosis of DLB? 
This study supports the concept of identifying an accurate biomarker for DLB through 
inflammation. Both central and peripheral inflammation are detected in DLB, with central 
inflammation closely related to disease severity. Whilst this study provides evidence for 
the distinction of DLB from non-dementia subjects through inflammation, the next step is 
to identify variations between inflammatory pathways between DLB and other dementia 
subtypes and initially this must be focussed on Alzheimer’s dementia (AD), the most 
common dementia and one which is often hard to differentiate from DLB. However 
differentiation from other parkinsonian disorders must also be considered in the search 
for specific biomarkers.  
There is evidence to suggest that inflammation in AD and DLB have both common and 
divergent patterns, however the evidence for inflammation in AD is much better 
established than DLB, due to the much larger number of studies in AD, hence making 
comparisons is currently difficult. Early central inflammation as detected using 11C-
PK11195 PET imaging also occurs in AD and mild cognitive impairment (Okello et al., 
2009; Hamelin et al., 2016), however in AD there is also a reported late peak (Fan et al., 
2017), albeit this latter study reported early and late increases in different AD subjects. 
At post-mortem, increased HLA- DR positive hypertrophic microglia are found in the 
hippocampus (McGeer et al., 1988) and increased microglial density and fewer 
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dystrophic microglia compared to DLB has also been reported in the hippocampus 
(Bachstetter et al., 2015), suggesting different trajectories of microglial activation once 
established. In AD, a negative correlation between PK11195 whole cortical gray matter 
binding and MMSE scores (Edison et al., 2008) and binding in the precuneus and 
performance in delayed recall at 30 minutes (as measured by the Rey Auditory Verbal 
Learning Test) (Passamonti et al., 2018) have also been reported. This is  the opposite 
of that reported in DLB in the current study. Hence microglial activation could have 
different roles in these two conditions. It is possible to speculate that extracellular amyloid 
and intraneuronal tau could lead to a different inflammatory pathway compared to 
oligomeric alpha-synuclein and intraneuronal Lewy bodies. 
 A meta-analysis of peripheral inflammatory markers in AD, found elevations in several 
compared to controls, including IL-2, IL-6, high sensitivity CRP, soluble tumour necrosis 
factor receptor 1 and interferon-γ (Lai et al., 2017). In contrast, only IL-2 was raised in 
the current study of DLB, not the others listed. Hence a larger study of inflammatory 
biomarkers in DLB and AD may reveal sufficient differences to allow differentiation of 
these conditions by peripheral inflammatory profile. The current study was able to 
differentiate DLB subjects from controls using a panel of seven inflammatory markers 
and application of a support vector machine, with a sensitivity of 71% and specificity of 
87%, with just 19 DLB participants and 26 controls. Blood tests are less invasive and 
expensive than imaging and CSF analysis and would be a simple and accessible means 
of diagnosis. Attempts to create such a test using metabolites and pathogenic proteins 
in the blood in AD are already underway (Fiandaca et al., 2015; Varma et al., 2018). 
Nevertheless any such test would require careful validation and any potential 
confounders, such as lifestyle differences, concurrent medications and co-existing 
conditions, would need to be considered. 
 
9.2.6 Potential Application to PDD 
This study did not assess inflammation in PDD, because it has been previously studied 
with several reports of early microglial activation (Ouchi et al., 2005; Gerhard et al., 2006; 
Fan et al., 2015). Conversely, only one study has investigated peripheral markers and 
found high sensitivity CRP was elevated in the serum of PDD patients compared to 
controls though tested only one other biomarker – fibrinogen (Song et al., 2013). Hence 
further studies are required to investigate peripheral inflammatory markers. 
Nevertheless, the results of the current study are likely to be relevant to PDD. DLB and 
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PDD are indistinguishable pathologically, hence the inflammatory profile is unlikely to be 
vastly different. Comparison may however reveal the mechanisms behind the differing 
clinical presentations – potentially unravelling why dementia precedes the movement 
disorder in DLB but not PDD, and is also likely to be different to that found in PD subjects, 
hence potentially providing a biomarker for the diagnosis of dementia in PD.  
 
9.3 Strengths and Limitations  
The strengths of the prevalence study survey include the large sample size and its 
clinical relevance as it reported actual diagnostic rates in clinical practice. A potential 
limitation was the inability to verify the diagnoses as it was not feasible to undertake full 
clinical examinations as part of this study on 5000 cases. However, cases were reviewed 
with respect to diagnosis by an expert panel, for the purposes of the subsequent in-depth 
notes study, and a diagnosis of LBD was validated in each case recruited as such.  
The diagnostic and management pathway study used objective information collected 
from medical notes written contemporaneously unlike previous studies of these 
pathways which were dependent on participant recollection of events and subject to 
recall bias. The study is limited however by the small sample size.  
The strengths of the inflammation study include the use of multiple methodologies 
including PET imaging, serum inflammatory profiles and clinical assessments to assess 
the extent and nature of inflammation in DLB subjects. Potential limitations include the 
use of PK11195 imaging, which is accepted to have a high signal to noise ratio and also 
displays non-specific binding (Vivash and OBrien, 2016). It nevertheless provides the 
best means currently available for assessing in vivo central inflammation as other ligands 
for the peripheral benzodiazepine receptor are affected by polymorphisms in the gene 
for the receptor (Owen et al., 2012). In addition, this is a cross-sectional study and did 
not test the evolution of inflammation over time and its impact clinically. The serum 
biomarker study tested a large number of inflammatory markers but was limited by the 
small sample size. 
 
9.4 Applications to Current Practice 
The study showed clinicians in the region tested have high thresholds for diagnosing 
DLB, often requiring two core features or more and that they rarely use dopamine uptake 
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scans. One means of improving diagnosis would be to implement a diagnostic toolkit 
reminding clinicians of the diagnosis criteria and perhaps also the usefulness of 
dopamine uptake scans. Similarly, an assessment toolkit may help clinicians regularly 
reviewing PD patients to be aware of the onset of dementia. In addition, this study 
showed neurologists and geriatricians often referred PD patients to psychiatrists to make 
a formal diagnosis of dementia. Hence, neurologists specialising in movement disorders 
and geriatricians regularly seeing PD patients, may benefit from increased education 
regarding cognition and dementia, to increase their confidence in making a dementia 
diagnosis themselves. Following this study, the Diamond Lewy study team have indeed 
introduced an assessment toolkit for the assessment of LBD. We have also carried out 
teaching sessions for clinicians involved in the study, in the diagnosis of both conditions, 
with the aim of improving diagnosis of both DLB and PDD. 
The study also identified PK11195 binding in the caudate as a potential marker of 
disease severity in DLB. Hence this biomarker could be used as a prognostic marker 
clinically or as a marker of treatment efficacy in clinical trials. However this is limited by 
the short half-life of this ligand of approximately 20 minutes – it is a 11C compound which 
decays relatively quickly. This means only hospitals with an onsite cyclotron that can 
generate PK11195 locally would be able to use this ligand, greatly limiting its application. 
However, if the difficulties associated with the second generation peripheral 
benzodiazepine receptor compounds (namely how to interpret receptor phenotype) can 
be overcome, the ligands which are coupled with 18F and therefore have a much longer 
half-life (of approximately 110 minutes), could be used for these purposes in a much 
larger number of hospitals. 
 
 
9.5 Future Studies 
The next step, and also a key step to validate the results of this cross-sectional study, is 
to undertake a longitudinal study with a large number of (50-60) DLB patients. This 
ideally would be in patients with prodromal DLB (who have core features and cognitive 
impairment, but who do not have dementia) (Donaghy, O’Brien and Thomas, 2015). An 
initial PK11195 scan, MRI head scan, peripheral blood cytokine analysis, cognitive and 
clinical testing as carried out in this study, but also cerebrospinal cytokine analysis, would 
be followed by a repeat of these assessments after three years. Additional cytokine 
analysis in the middle of the intervening period could also be carried out. The longitudinal 
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PET scans would show the trajectory of microglial activation over time and also enable 
an assessment of their impact on clinical markers plus structural imaging of cortical 
thickness. If microglial activation declined in subjects as they progressed from prodromal 
to established disease but remained constant in those that did not decline, this would be 
a good indication that inflammation has a protective effect. If however microglial 
activation increased between prodromal and established dementia, with a concurrent 
decline in clinical and structural markers, this would suggest that inflammation is 
detrimental. The association with peripheral and cerebrospinal cytokines may reveal the 
mechanisms behind either effect. 
There is also a need to investigate the potentially divergent pathways of microglial 
activation in AD and DLB. Similar studies as described above but involving AD and DLB 
subjects are needed to address whether evolution of central inflammation, and its 
correlation with clinical features, is comparable in AD. This will be of crucial importance 
to potential immune modulatory therapies in both disorders. If microglial activation is 
purely beneficial in Lewy body pathology for example, the use of immune suppression 
therapies in patients with AD with concomitant Lewy body pathology, or vice versa, would 
be ineffective at best and catastrophic at worst.  
Larger DLB and AD cohorts should also be assessed for a broad panel of serum 
inflammatory markers to try and distinguish the peripheral inflammatory profiles of these 
disorders and establish a substrate for the use of machine learning tools to enable 
distinction in dementia subjects once it is clear that a patient indeed has dementia. To 
this extent the pooling of resources from centres will be vital to obtain sufficient numbers, 
as DLB subjects are, due to the difficulties in diagnosis already stated, hard to find. This 
could provide a simple bed-side test to differentiate the two conditions. 
Further studies of peripheral inflammation are also required in PDD, in comparison to PD 
subjects as well as controls and could similarly provide an inflammatory biomarker for 
the detection of dementia in PD. Comparison with DLB, in terms of the nature and extent 
of central and peripheral inflammation, is also of importance to understand if similar 
therapeutic strategies can be used in both. 
To study the role of the acquired immune system in Lewy body dementia and also the 
role of macrophage inflammatory protein-3, interleukin-17A and interleukin-2, flow 
cytometry to assess peripheral lymphocyte subsets (as has been carried out in PD (Bas 
et al., 2001), and their relationship to the levels of these three markers, and their 
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trajectory in relation to  clinical features, should be carried out and may confirm a 
pathological role for CD4 T-cells in Lewy body disorders.  
  
9.6 Conclusion 
This study aimed to investigate the rate of Lewy body dementia diagnoses clinically and 
identify if central and peripheral inflammation could provide a biomarker or source for 
disease modifying therapy. 
A survey of a large number of cases, showed a low rate of LBD diagnosis clinically, with 
an in depth notes study of a small sample revealing difficulty in the diagnosis of DLB and 
a delay in the diagnosis of PDD. This study also revealed peripheral inflammation in DLB 
patients as well as an association between microglial activation and mild disease, 
consistent with early central inflammation. This suggests any trials on anti-inflammatory 
approaches in DLB should focus on mild disease. 
Further studies are required to distinguish inflammatory pathways in DLB and AD, as 
well as PDD and PD, to understand the relevant contributions of inflammation between 
these conditions and to identify accessible biomarkers that will assist in the detection of 
LBD. 
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Abstract
Background: The prevalence of dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) in routine
clinical practice is unclear. Prevalence rates observed in clinical and population-based cohorts and neuropathological
studies vary greatly. Small sample sizes and methodological factors in these studies limit generalisability to
clinical practice.
Methods: We investigated prevalence in a case series across nine secondary care services over an 18-month
period, to determine how commonly DLB and PDD cases are diagnosed and reviewed within two regions of
the UK.
Results: Patients with DLB comprised 4.6% (95% CI 4.0–5.2%) of all dementia cases. DLB was represented in a
significantly higher proportion of dementia cases in services in the North East (5.6%) than those in East Anglia
(3.3%; χ2 = 13.6, p < 0.01). DLB prevalence in individual services ranged from 2.4 to 5.9%. PDD comprised 9.7%
(95% CI 8.3–11.1%) of Parkinson’s disease cases. No significant variation in PDD prevalence was observed between regions
or between services.
Conclusions: We found that the frequency of clinical diagnosis of DLB varied between geographical regions in the UK,
and that the prevalence of both DLB and PDD was much lower than would be expected in this case series, suggesting
considerable under-diagnosis of both disorders. The significant variation in DLB diagnostic rates between these two
regions may reflect true differences in disease prevalence, but more likely differences in diagnostic practice.
The systematic introduction of more standardised diagnostic practice could improve the rates of diagnosis of
both conditions.
Keywords: Dementia with Lewy bodies, Dementia in Parkinson’s disease, Epidemiology, Prevalence
Background
Dementia with Lewy bodies (DLB) is a common cause of
dementia in older people, characterised by a tetrad of visual
hallucinations, fluctuations in cognition, spontaneous par-
kinsonism, and REM sleep behaviour disorder. Parkinson’s
disease dementia (PDD) describes dementia arising in the
context of established idiopathic Parkinson’s disease (PD),
and shares both neurobiological and clinical characteristics
with DLB. Together, DLB and PDD comprise Lewy body
dementia (LBD), conceptualised as a spectrum disorder
associated with cortical and subcortical Lewy body path-
ology, with variations in the temporal onset of motor and
cognitive symptoms [1–3].
Validated diagnostic criteria [2] and clinical biomarkers
exist for DLB [4, 5]. However, despite the important impli-
cations of diagnosis for treatment, mortality [6], and carer
well-being [7], previous studies have suggested that only
one in three cases is correctly identified in routine clinical
care [8, 9] and a considerable lack of consensus surrounds
the actual prevalence of DLB.
A recent meta-analysis of epidemiological studies
reported that DLB represented 7.5% of all dementia
cases in clinical populations [10]. These populations
refer to research cohorts in which consecutive referrals
to a service or healthcare organisation were screened for
DLB on the basis of clinical symptoms and
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investigations. The same meta-analysis found that DLB
comprised 4.2% of community-based dementia populations.
However, studies contributing to this meta-analysis ob-
served prevalence rates ranging from 0 to 26% in individual
cohorts [11, 12].
Variation between individual studies’ prevalence
rates could represent true differences in DLB preva-
lence among different regions or countries. However,
the wide range of methodological and sampling prac-
tices adopted in these studies is an alternative cause
for the reported rates.
There is a greater consensus regarding the preva-
lence of PDD. A systematic review in 2005 found the
point prevalence of dementia in PD to be 24.5% [13].
Subsequent studies have reported similar figures of
20–30% [14–16]. Despite the wide variation in the
methodology used, the consistency of the rate found
suggests it is close to the true proportion of dementia
in PD. The systematic review found the prevalence of
PDD as a percentage of all dementia cases to be 3.6%
[13]. The lifetime prevalence of dementia in PD has
also been studied, with 83% of PD patients surviving
20 years developing dementia [17], suggesting that de-
mentia will eventually affect the vast majority of PD
patients.
Neuropathological studies report that DLB com-
prises up to 15–20% of cases of dementia [17, 18], al-
though such cohorts are invariably subject to small
sample sizes and selection bias [19, 20]. Furthermore,
concomitant Alzheimer’s disease (AD) and DLB path-
ology of varying severity has been found in post-
mortem dementia cases, with no clear correlation as
yet found with clinical phenotypes of AD or DLB
[21]. In addition, many studies fail to correlate clin-
ical data with pathological findings, describing DLB
or PDD cases together under the category of LBD.
Nevertheless, the 15–20% described in such studies is
higher than the reported combined prevalence of DLB
(4.2%) and PDD (3.6%) found clinically.
The clinical prevalence of DLB and PDD therefore
remains unclear. We aimed to investigate the preva-
lence in a case series of DLB and dementia in PD
across two distinct geographical sites. By employing
an identical methodology in two comparable popula-
tions, we aimed to identify the rate of diagnosis of
these dementias by clinicians in routine practice and
better understand the variation in reported LBD diag-
nosis rates.
Methods
We investigated prevalence in a case series to determine
the clinical prevalence of DLB and PDD.
For assessing DLB, nine participating psychiatry of old
age/memory clinic services in the UK were identified
across four NHS hospital trusts, spread across two dis-
tinct geographical areas: East Anglia (EA, n = 2 trusts)
and North-East England (NE, n = 2 trusts). Services
were chosen by the research team in order to compile a
cohort generalisable to that seen in routine clinical prac-
tice and included those serving both urban populations
and mixed urban and rural populations. Among these
were multidisciplinary teams serving urban areas (n = 2),
serving rural areas (n = 1), and serving a mixture of both
urban and rural populations (n = 6). One service was a
tertiary memory clinic combining psychiatry and neur-
ology expertise, and another incorporated a tertiary DLB
clinic within a larger secondary care resource. All other
services (n = 7) were secondary care organisations. Two
clinics were closely affiliated with large teaching hospi-
tals, the remaining seven with smaller district hospitals
or community teams. For PDD, five PD or movement
disorder clinics, each from a separate NHS trust (EA,
n = 3 trusts; NE, n = 2 trusts) were sampled. These
consisted of two geriatric medicine services and three
which combined geriatric medicine and neurology
expertise, serving urban (n = 2) and mixed urban and
rural (n = 3) populations. None of these services in-
corporated specialist tertiary clinics.
The research team reviewed the notes of all sub-
jects seen in services to identify patients with a diag-
nosis of dementia (for DLB prevalence), and those
with a diagnosis of PD (for PDD prevalence), over a
fixed 18-month period within a 2-year window from
January 2013 to December 2014. Clinical diagnosis, as
documented by the practitioner reviewing each pa-
tient within respective services, was recorded for each
subject, as were age, gender, cognitive score, and date
of diagnosis. For the DLB/dementia part of the study,
dementia subtype, as determined by the clinician, was
recorded. For the PDD/PD part of the study, the
dates of diagnosis of both PDD (where applicable)
and PD were recorded. Cases were coded as incident
(dementia first diagnosed within the 18-month study
period) or prevalent (dementia diagnosed prior to the
study period, but the subject attended the service
during the 18-month window). Patients who attended
more than one participating service were included
only in the service in which they were first seen. Per-
mission was granted by the UK Confidentiality Advis-
ory Group to collect these limited data from the
clinical notes of all patients attending these services
without the requirement of informed consent. Ethical
approval for the study was also awarded by an NHS
Regional Ethics Committee.
Statistical analysis was performed using SPSS 24.0
for Windows. Confidence intervals for prevalence in a
case series were calculated using the Wilson method.
Mean values and proportions were analysed using
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Student’s t test for independent samples and the χ2
test respectively. The Mantel–Haenszel χ2 test was
used to test for a relationship between stratified age group
and DLB prevalence. Non-parametric Spearman’s rank
correlation was used to test for the correlation between the
age at PD and the time to the onset of dementia, as the lat-
ter showed a non-normal positively skewed distribution.
For each test statistic, p < 0.05 was regarded as statistically
significant.
DLB prevalence in this case series was calculated as
the percentage of DLB cases amongst the total number
of dementia cases identified. PDD prevalence in the case
series was calculated as the number of PD cases diag-
nosed with dementia, divided by the entire PD popula-
tion seen during the screening period.
We approached a subset of patients with DLB and
PDD, as well as cases matched by age (< 3 years) and
gender to patients with non-DLB and PD diagnoses re-
spectively, for consent to access their clinical notes in
greater detail. DLB and non-DLB dementia cases were
also matched by MMSE score (< 5 points). A panel of
three expert clinicians reviewed clinical documentation
and applied consensus criteria to each case. This method
represents the accepted gold standard to post-mortem
diagnosis, and has been validated against autopsy and
imaging measures [22].
Results
DLB in psychiatry of old age services
The research team reviewed the case notes of 9449 indi-
vidual patients, of whom 4504 (47.6%) had a dementia
diagnosis (Fig. 1, Table 1), other diagnoses being mainly
functional psychiatric disorders (such as depression) or
cognitive problems falling short of dementia (such as mild
cognitive impairment). Patients with DLB comprised 4.6%
(95% CI 4.0–5.2%) of all dementia cases. Prevalence in indi-
vidual services ranged from 2.4 to 5.9%, and was
significantly higher among NE services (5.6%; 95% CI 4.8–
6.5%; 70% greater) than in EA services (3.3%; 95% CI 2.6–
4.2%; χ2 = 13.6, p < 0.01). No significant variation in preva-
lence was observed within each region (NE, χ2 = 2.54, p =
0.28; EA, χ2 = 4.88, p = 0.28).
Incident DLB cases made up 4.8% (95% CI 4.0–5.7) of
dementia cases diagnosed within our study window, ran-
ging from 2.7 to 6.4%. Incidence was also higher in NE ser-
vices than in EA services (5.8 vs 3.8; χ2 = 5.9, p < 0.02; 53%
greater).
DLB prevalence was higher in men (χ2 = 24.8, p < 0.01)
(Table 2). In addition, patients with DLB were significantly
younger than their non-DLB counterparts (81.2 vs 82.4;
t(4 502) = −2.1, p = 0.04), although the mean difference
was just over a year, and this age difference was not
seen in newly diagnosed cases. DLB prevalence in the
case series also negatively correlated with stratified age
(Mantel–Haenszel χ2 = 8.2, p < 0.01) (Fig. 2), with simi-
lar findings for incident cases (Table 2) indicating that
DLB was less commonly diagnosed in older people.
Seventy-five (75/207; 36.2%) DLB cases within the
case series consented to a more detailed review of
clinical documentation. The diagnosis made in clinical
services concurred with that reported by expert clin-
ician panel in 99% of cases (74/75). Expert panel also
agreed with clinical diagnosis in 97% (72/74) of cases
with non-DLB dementia.
PDD in geriatric medicine and neurology services
The case notes of 2263 individual patients were examined,
of whom 1563 (69.1%) had an idiopathic Parkinson’s
disease diagnosis. PDD comprised 9.7% (n = 151, 95% CI
8.3–11.1%) of these PD cases. No significant variation was
observed between regions: 8.3% in EA and 10.5% in NE
(χ2 = 1.95, p = 0.16). There was also no significant vari-
ation found between all services, with PDD prevalence
ranging from 4.5 to 11.0% (χ2 = 5.99, p = 0.20).
Fig. 1 DLB prevalence by region and service. DLB dementia with Lewy bodies, EA East Anglia, NE North-East England, A–I services
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There was a male predominance in PD cases but no
significant differences in gender found when comparing
the two regions, in those with PDD, or when considering
the larger cohorts of all PD patients (including PDD)
between the regions (Table 3).
However, both PD and PDD subjects were older in EA
than in NE (PD mean difference of 2.8 years, p < 0.001;
PDD mean difference of 2.7 years, p = 0.03).
Significantly more incident cases of PDD (newly diag-
nosed within our screening period) were found within EA
compared to NE, comprising 59.1% of all PD cases in EA
compared to 40.0% of cases in NE (χ2 = 4.49, p = 0.034;
Fig. 3). In addition, significantly lower Mini-Mental
State Examination (MMSE) scores at the time of PDD
diagnosis were recorded in EA than in NE (Mann–Whitney
U, p = 0.008; Fig. 4).
A highly significant inverse correlation between age at
initial PD diagnosis and time until dementia onset
(Spearman’s correlation, ρ = −0.66, p < 0.001) was also
found in the PDD group as a whole (Fig. 5).
The diagnosis of the expert panel concurred with the
diagnosis documented in the clinical notes in 97% of
PDD cases consented for detailed notes review (37/38)
and in 100% of recruited PD cases (35/35).
Discussion
We found that DLB comprised 4.2% of all dementia
cases in a representative clinical population in NHS sec-
ondary care services. This is a considerably lower figure
than that cited by both neuropathological studies and
previous meta-analyses [10, 18]. We also found dementia
diagnosed in only 9.7% of cases of PD, much lower than
the 20–30% seen in the systematic review [13] and sub-
sequent population and clinic-based studies of PDD
prevalence [14–16].
Our study was deliberately designed to determine the
frequency of diagnoses in routine clinical services, and
reflects current real-life practice for patients being
assessed in specialist services within secondary care.
Services were selected by the research team primarily on
the basis of their generalisability to psychiatry of old age
and neurology/geriatric medicine services, throughout
the UK.
The most likely reason that rates found in our cohorts
are lower than those reported in meta-analysis of other
hospital-referred populations, and indeed nearer to
community-based estimates, is probably to be found in
the methodology employed. Our study was based upon
scrutiny of routine clinical records from services receiv-
ing mainly community-based referrals. This cohort
therefore represents a broader, more generalisable de-
mentia population than those investigated in prevalence
Table 1 DLB prevalence and incidence by region and service
Service Dementia (all subtypes) DLB
Prevalent Incident Prevalent % of prevalent dementia cases (95% CI) Incident % of incident dementia cases (95% CI)
A 1115 548 66 5.9 (4.7–7.5) 35 6.4 (4.6–8.8)
B 1178 637 68 5.8 (4.6–7.3) 36 5.7 (4.1–7.7)
C 282 106 10 3.5 (1.9–6.4) 4 3.8 (1.5–9.3)
North-East England 2575 1291 144 5.6 (4.8–6.5) 75 5.8 (4.7–7.2)
D 355 204 10 2.8 (1.5–5.1) 9 4.4 (2.3–8.2)
E 302 169 10 3.3 (1.8–6.0) 7 4.1 (2.0–8.3)
F 377 186 9 2.4 (1.3–4.5) 5 2.7 (1.2–6.1)
G 361 212 16 4.4 (2.7–7.1) 10 4.7 (2.6–8.5)
H 378 357 10 2.7 (1.4–4.8) 10 2.8 (1.5–5.1)
I 156 150 8 5.1 (2.6–9.8) 7 4.7 (2.3–9.3)
East Anglia 1929 1278 63 3.3 (2.6–4.2) 48 3.8 (2.8–4.9)
Overall 4504 2569 207 4.6 (4.0–5.2) 123 4.8 (4.0–5.7)
CI confidence interval, DLB dementia with Lewy bodies
Table 2 Age and gender of DLB and non-DLB patients
DLB Non-DLB p
Age at screening (± SD)
Prevalent 81.3 (± 7.8) 82.4 (± 7.8) 0.04
Incident 81.8 (± 7.6) 82.1 (± 8.1) 0.59
Gender, male/female (% male)
Prevalent 113/94 (54.6%) 1607/2690 (37.4%) < 0.01
Incident 62/61 (50.4%) 958/1488 (39.2%) 0.01
DLB dementia with Lewy bodies, SD standard deviation
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studies conducted within specialist centres that often
show larger prevalence rates.
Nevertheless, our observed range in prevalence in a
case series likely also reflects a lower rate of disease
detection, rather than true disease prevalence in some
populations. This is supported by the differences in
prevalence of DLB observed between our NE and EA
cohorts, and the wide range in rates observed in
neighbouring services within the same region. This
variation in detection may be related to a number of
factors; the effect on medical education, training, and
service development of Newcastle University’s long
history of LBD research may have contributed to
higher rates in NE. Varying sensitivity to core DLB
features may play a role in detection; Walker et al.
[23] noted that prevalence studies incorporating a
neurological examination reported higher prevalence
rates of DLB. It is also possible that not all practi-
tioners comprising participating services are fully
aware of consensus criteria, but the high level of
agreement between diagnoses made within services
and those made by the expert panel (98%) would sug-
gest that consensus diagnostic guidelines are in rou-
tine use in participating services.
Despite our belief that our findings represent vari-
ation in DLB detection, variation in true disease
prevalence cannot be entirely ruled out. Environmen-
tal factors or a combination of environmental factors
in the pathogenesis of DLB have been proposed [24].
It is not possible to discount the possibility that the
variation in regional diagnostic rates seen within this
study simply reflect the degree of exposure to causa-
tive or precipitating biological factors, but the intra-
regional variation which was also seen would argue
against this.
Contrary to the findings of the meta-analysis,
which reported a positive relationship between age
and DLB prevalence (although this was not statisti-
cally significant), we identified an inverse correlation
between these two factors, and found the mean age
of DLB patients at diagnosis to be lower than that of
non-DLB dementia patients. This may be a reflection
of a more aggressive course and increased mortality
in DLB, or that DLB becomes less common clinically
with advancing age as other pathologies become
more prevalent leading to a mixed pathological and
clinical picture. Our study design and information
systems did not allow us access to accurate mortality
Fig. 2 DLB prevalence and age at dementia diagnosis. DLB dementia with Lewy bodies
Table 3 Group demographics and differences between regions
Demographics North-East England East Anglia Group difference
Gender (PDD), males/females 78/23 35/14 χ2 = 6.0, p = 0.44
Gender (all PD), males/females 587/385 328/260 χ2 = 3.2, p = 0.07
Age (years) at PDD onset, mean (± SD) 75.6 (± 6.7) 78.3 (± 7.3) t = −2.1, p = 0.03
Age (years) at PD onset, mean (± SD) 70.3 (± 9.7) 73.1 (± 8.6) t = 5.8, p < 0.01
Age at midpoint of screening period (all PD), mean (± SD) 76.9 (± 7.2) 78.7 (± 6.9) t = 4.7, p < 0.01
PD Parkinson’s disease, PDD Parkinson’s disease dementia, SD standard deviation
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data, although increased mortality in DLB has been
described [6].
DLB was also more prevalent among men than
women in our cohort, a finding which also conflicts
with the lack of significant association identified in
meta-analysis [10]. A male preponderance has been
observed in neuropathological DLB samples [25] but
population samples have both supported and refuted
this hypothesis [26, 27]. Our very large sample size
and multi-servicing sampling make our data the stron-
gest support for a male preponderance of DLB from
clinical samples to date.
Dementia prevalence in our PD cohorts was much
lower than has been reported previously. A variation
in prevalence of dementia was not identified between
regions, yet higher age and lower MMSE scores at
diagnosis of dementia suggest that dementia is diag-
nosed later on in the disease in EA. However, as the
age at PD diagnosis was also older in EA, once again
the possibility that there may be an environmental fac-
tor driving earlier onset in NE cannot be discounted.
Another reason behind the difference in age may be
the differences in life expectancy between the regions
– the latest figures show this to be 80.4/83.8 years
(male/female) in EA and 78.0/81.7 years in NE [28] –
similar to the age differences we observed between
the two regions in the study. It is, however, possible
that clinicians in the NE region have a lower thresh-
old for making both diagnoses. It should also be
noted that the mean age at the mid-point of our
screening period across both regions was 77.6 years
and was similar to the median of the mean ages in
studies analysed in the systematic review by Aarsland
et al. (74.9 years) [13].
The strong inverse correlation between age at onset
of PD and the time to diagnosis of dementia is con-
sistent with age being a risk factor for PDD [29].
As with DLB, the most likely cause of the lower preva-
lence rate of PDD in our case series is because we have
reported the observed rate of diagnosis of PDD as made
by clinicians in routine practice. Previous studies have
sought to identify dementia specifically in their PD pop-
ulations using standardised diagnostic tools. Although
clinical diagnoses agreed with those made by our inde-
pendent clinician panel in 99% of PDD and PD cases, it
is likely that our findings reflect lower detection rates of
PDD within the PD population.
A lower rate of diagnosis in clinical practice has
important implications for the patients and their carers
who benefit from a diagnosis being made. The develop-
ment of dementia has a profound effect on the patient
and carer, and allows for the provision of support ser-
vices to cater for these. Dementia leads to loss of insight,
poor judgement, poor financial decision-making, increased
carer stress, impaired driving skills, and an increased falls
risk, amongst other difficulties [17]. Healthcare providers
would also need to adapt their services to cater for a higher
population of their patients experiencing the difficulties of
having dementia.
Fig. 3 Percentage of cases of PDD diagnosed within our screening
period compared to cases diagnosed before our screening period.
Confidence interval (CI) calculated using standard
(approximate method)
Fig. 4 Comparison of cognitive scores at the time of PDD diagnosis
between regions. MMSE Mini-Mental State Examination
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Strengths of this study include the very large sam-
ple size compared to previous studies, its multi-site
nature (when previous estimates have usually involved
only single sites), its representativeness, in that access
to all cases within a service was allowed, and, since
we used clinically made diagnoses, its clinical rele-
vance. Potential limitations include the fact that we
could not compare diagnostic rates made by clinicians
with “true” prevalence, which would have required
full clinical examination of all 12,500 cases and would
not have been possible. Another important limitation
of the study is that our methodology permitted inves-
tigation of DLB and PDD prevalence as determined
by primary clinical dementia syndrome alone. We
were therefore unable to determine the contribution
of co-existing AD neuropathology in such cases, al-
though no mechanism currently exists to accurately
determine such cases on the basis of clinical presen-
tation [21].
Conclusion
Our study identified clinical prevalence rates of DLB and
PDD in a case series considerably lower than that reported
by clinical epidemiological cohorts and neuropathological
studies. Importantly, we observed significant differences in
the rates of DLB diagnosis among different regions, and a
preponderance of DLB among males and younger patients.
We found no such regional variations in prevalence
amongst our clinical PDD population, but did find that
PDD cases in EA were older, with a lower MMSE score, at
the point of dementia diagnosis. Although our observation
of regional variation in diagnosis could be attributed to
different patterns of disease prevalence, a more likely
explanation is that varying clinical diagnostic practices
produce differences in DLB and PDD detection, rather
than true disease prevalence.
Since it is important to accurately recognise and diag-
nose both DLB and PDD to optimise clinical care and
management, and service delivery, and to allow more
accurate prognosis, methods by which diagnostic rates
might be improved should be tested. This might include
the introduction of standardised assessments and scales
to facilitate accurate recognition of DLB and PDD,
including widespread use of the new DLB criteria [3], in-
struments such as the Lewy body composite risk score
[30], or the DLB/PDD diagnostic toolkits [31].
Abbreviations
AD: Alzheimer’s disease; DLB: Dementia with Lewy bodies; EA: East Anglia;
LBD: Lewy body dementia; MMSE: Mini-Mental State Examination; NE: North-East
England; NHS: National Health Service (UK); PD: Parkinson’s disease;
PDD: Parkinson’s disease dementia; UK: United Kingdom
Acknowledgements
JPMK and AS are joint first authors. DJB and JTO are joint senior authors. The
authors would like to thank the infrastructure support provided by
Newcastle Biomedical Research Centre hosted by Newcastle upon Tyne
Hospitals NHS Foundation Trust and Newcastle University, and the
Cambridge Biomedical Research Centre hosted by Cambridge University
Hospitals NHS Foundation Trust, Cambridgeshire and Peterborough NHS
Foundation Trust, and the University of Cambridge. They thank their
colleagues at the Dementia and Neurodegenerative Diseases Research
Network (Neil Fullerton, Katrina Holmes, Gloria Calderon, and Julie Philips),
the clinicians within East Anglia and the North East who assisted in the
study, and the study sponsors Northumberland Tyne and Wear NHS
Foundation Trust.
Funding
This article summarises independent research funded by the National
Institute for Health Research (NIHR) under its Programme Grants for Applied
Research Programme (Grant Reference Number DTC-RP-PG-0311-12001). The
views expressed are those of the author(s) and not necessarily those of the
NHS, the NIHR, or the Department of Health.
Fig. 5 Negative correlation between age at initial diagnosis of PD and time before dementia onset. PD Parkinson’s disease, PDD Parkinson’s
disease dementia
Kane et al. Alzheimer's Research & Therapy  (2018) 10:19 Page 7 of 8
201
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request after completion of
the DIAMOND-Lewy programme.
Authors’ contributions
JPMK and AS contributed equally to the article, leading data analysis and
writing of the manuscript. JPMK, AS, AB, and SAHB conducted the data
collection process. JTO and DJB contributed equally to the study approval
and funding process, and supervised data collection and analysis at their
respective sites. All authors contributed to the design of this study and read,
contributed to, and approved the final manuscript.
Ethics approval and consent to participate
Permission was granted by the UK Confidentiality Advisory Group to
collect limited data from the clinical notes of all patients attending
participating services without the requirement of informed consent.
Ethical approval for the study was also awarded by an NHS Regional
Ethics Committee (NRES Committee North East—Newcastle & North
Tyneside 1; Reference 13/NE/0268).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Neuroscience, Biomedical Research Building, Campus for Ageing
and Vitality, Newcastle University, Newcastle upon Tyne NE4 5PL, UK.
2Department of Psychiatry, University of Cambridge School of Clinical
Medicine, Box 189, Level E4 Cambridge Biomedical Campus, Cambridge CB2
0SP, UK. 3Institute of Health and Society, Sir James Spence Institute, Royal
Victoria Infirmary, Newcastle University, Queen Victoria Road, Newcastle upon
Tyne NE1 4LP, UK.
Received: 14 November 2017 Accepted: 29 January 2018
References
1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the
clinical and pathologic diagnosis of dementia with Lewy bodies (DLB):
report of the consortium on DLB international workshop. Neurology.
1996;47:1113–24.
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of
dementia with Lewy bodies: third report of the DLB Consortium. Neurology.
2005;65:1863–72.
3. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of
dementia with Lewy bodies: fourth consensus report of the DLB
Consortium. Neurology. 2017;89:88–100.
4. McKeith IG, O’Brien JT, Walker Z, et al. Sensitivity and specificity of
dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with
Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.
5. Yoshita M, Arai H, Arai H, et al. Diagnostic accuracy of 123I-meta-
iodobenzylguanidine myocardial scintigraphy in dementia with Lewy
bodies: a multicenter study. PLoS One. 2015;10:e01205.
6. Williams MM, Xiong C, Morris JC, et al. Survival and mortality differences
between dementia with Lewy bodies vs Alzheimer disease. Neurology.
2006;67:1935–41.
7. Lee DR, McKeith IG, Mosimann U, et al. Examining carer stress in dementia:
the role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr
Psychiatry. 2013;28:135–41.
8. Galvin JE, Duda JE, Kaufer DI, et al. Lewy body dementia: the caregiver
experience of clinical care. Parkinsonism Relat Disord. 2010;16:388–92.
9. Prince M, Knapp M, Albanese E, et al. Dementia UK: a report into the
prevalence and cost of dementia. London: Alzheimers Society; 2007. https://
www.alzheimers.org.uk/site/scripts/download_info.php?fileID=2. Accessed
12 Feb 2018.
10. Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with
Lewy bodies: a systematic review of population and clinical studies. Psychol
Med. 2014;44:673–83.
11. Arslantas D, Özbabalık D, Metintas S, et al. Prevalence of dementia and
associated risk factors in Middle Anatolia, Turkey. J Clin Neurosci. 2009;
16:1455–9.
12. Bonanni L, Bontempo G, Borrelli I, et al. Ascertainment bias in dementias: a
secondary to tertiary centre analysis in Central Italy and conceptual review.
Aging Clin Exp Res. 2013;25:265–74.
13. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of
dementia in Parkinson’s disease. Mov Disord. 2005;20:1255–63.
14. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in
Parkinson disease: a 12-year population study. Neurology. 2008;70:1017–22.
15. Wang Q, Zhang Z, Li L, et al. Assessment of cognitive impairment in
patients with Parkinson’s disease: prevalence and risk factors. Clin Interv
Aging. 2014;9:275–81.
16. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients
with idiopathic Parkinson’s disease: results from the German Study on
Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol.
2008;255:255–64.
17. Aarsland D, Ballard C, McKeith IG, et al. Comparison of extrapyramidal signs
in dementia with Lewy bodies and Parkinson’s disease. J Neuropsychiatry
Clin Neurosci. 2001;13:374–9.
18. Jellinger KA, Attems J. Prevalence and pathology of dementia with Lewy
bodies in the oldest old: a comparison with other dementing disorders.
Dement Geriatr Cogn Disord. 2011;31:309–16.
19. Zaccai J, Ince P, Brayne C. Population-based neuropathological studies of
dementia: design, methods and areas of investigation—a systematic review.
BMC Neurol. 2006;6:2.
20. Fillenbaum GG, Huber MS, Beekly D, et al. The Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD). Part XIII. Obtaining autopsy in
Alzheimer’s disease. Neurology. 1996;46:142–5.
21. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on
clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;
60:1586–90.
22. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus
criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;
54:1050–8.
23. Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. Lancet. 2015;386:
1683–97.
24. Au R, Seshadri S, Knox K, et al. The Framingham Brain Donation Program:
neuropathology along the cognitive continuum. Curr Alzheimer Res. 2012;9:
673–86.
25. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body
disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s
disease comparison groups. Neurology. 1996;47:1148–52.
26. Yue W, Wang XD, Shi Z, et al. The prevalence of dementia with Lewy
bodies in a rural area of China. Parkinsonism Relat Disord. 2016;29:1–6.
27. Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy
bodies and Parkinson disease dementia. JAMA Neurol. 2013;70:1396–402.
28. Office for National Statistics. Mortality Analysis Team LE and PSD. Life
expectancy at birth and at age 65 by local areas in England and Wales:
2012 to 2014. London: Office for National Statistics; 2015. https://www.ons.
gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/
lifeexpectancies/bulletins/
lifeexpectancyatbirthandatage65bylocalareasinenglandandwales/2015-11-04.
Accessed 12 Feb 2018.
29. Xu Y, Yang J, Shang H. Meta-analysis of risk factors for Parkinson’s disease
dementia. Transl Neurodegener. 2016;5:11.
30. Galvin JE. Improving the clinical detection of Lewy body dementia with the
Lewy body composite risk score. Alzheimer’s Dement Diagnosis Assess Dis
Monit. 2015;1:316–24.
31. Thomas AJ, Taylor JP, McKeith IG, et al. Development of assessment toolkits
for improving the diagnosis of the Lewy body dementias: feasibility study
within the DIAMOND-Lewy study. Int J Geriatr Psychiatry. 2017;32:1280–304.
Kane et al. Alzheimer's Research & Therapy  (2018) 10:19 Page 8 of 8
202
Appendix 2
Published Paper: Neuroinflammation in Lewy 
Body Dementia
203
Editor's Comment: The potential role of neuroinﬂammation in neurodegenerative disease processes has received increasing attention
in recent years. In this timely review, Surendranathan and colleagues provide a masterful summary of what is known about
neuroinﬂammation in Parkinson's disease dementia and dementia with Lewy bodies. They shepherd us through the bewildering array of
factors promoting or inhibiting microglial activation in these two disorders and succinctly review the neuroimaging, neurochemical,
neuropathological, genetic and epidemiologic evidence for neuroinﬂammation in these Lewy body disorders.
Ronald F. Pfeiffer, Editor-in-Chief, Dept. of Neurology, Oregon Health and Science University (OHSU), 3181 SW Sam Jackson Park Rd,
Portland, OR 97201-3098, Oregon, USA.
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a b s t r a c t
Neuroinﬂammation is increasingly recognized as a key factor in the pathogenesis of neurodegenerative
conditions. However, it remains unclear whether it has a protective or damaging role. Studies of Alz-
heimer's disease and Parkinson's disease have provided much of the evidence for inﬂammatory pa-
thology in neurodegeneration. Here we review the evidence for inﬂammation in dementia with Lewy
bodies and Parkinson's disease dementia.
Neuroinﬂammation has been conﬁrmed in vivo using PET imaging, with microglial activation seen in
Parkinson's disease dementia and recently in dementia with Lewy bodies. In Parkinson's disease and
Parkinson's disease dementia, microglial activation suggests a chronic inﬂammatory process, although
there is also evidence of its association with cognitive ability and neuronal function.
Alpha-synuclein in various conformations has also been linked to activation of microglia, with a broad
range of components of the innate and adaptive immune systems associated with this interaction.
Evidence of neuroinﬂammation in Lewy body dementia is further supported by pathological and
biomarker studies. Genetic and epidemiological studies support a role for inﬂammation in Parkinson's
disease, but have yet to provide the same for Lewy body dementia.
This review highlights the need to identify whether the nature and extent of microglial activation in
Lewy body dementia can be linked to structural change, progression of domain speciﬁc cognitive
symptoms and peripheral inﬂammation as a marker of central microglial pathology. Answers to these
questions will enable the evaluation of immunotherapies as potential therapeutic options for prevention
or treatment of dementia with Lewy bodies and Parkinson's disease dementia.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Lewy body dementias (LBDs) include the closely related condi-
tions of dementia with Lewy bodies (DLB) and Parkinson's disease
dementia (PDD). The clinical syndrome of DLB forms at least 4.2% of
all dementia patients and is second only to Alzheimer's disease
(AD) as a cause of degenerative dementia in older people [1]. De-
mentia also develops in over 80% of those with Parkinson's disease
(PD) [2], a disorder where Lewy bodies play a prominent role, with
PDD forming 3.6% of all dementia cases [3]. Autopsy studies of
dementia cases have estimated the combined prevalence rate of
LBDs to be even higher, at around 20% [4,5].
The etiology of LBDs is unclear, but a role for chronic neuro-
inﬂammation has been proposed, analogous to the emerging
* Corresponding author. Box 189, Department of Psychiatry, Cambridge
Biomedical Campus, Cambridge, CB2 0SP, United Kingdom.
E-mail address: as2489@medschl.cam.ac.uk (A. Surendranathan).
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evidence for inﬂammation in the etiology of AD. The evidence to
date for AD includes neuropathological studies with evidence of
brain inﬂammation, Positron Emission Tomography (PET) imaging
displaying microglial activation in vivo, genetic studies implicating
polymorphisms in genes involved in the inﬂammatory response as
risk factors, epidemiological studies indicating a protective effect of
non-steroidal anti-inﬂammatory drugs (NSAIDs) and mouse
models of AD in which NSAIDs reduced neuroinﬂammation and
protein deposition [6e9].
In light of the gathering evidence for neuroinﬂammation in AD,
we asked whether neuroinﬂammation is also involved in the eti-
ology of LBDs. We review the literature for evidence of neuro-
inﬂammation in Parkinson's disease dementia and dementia with
Lewy bodies, across multiple methodologies.
2. Literature search strategy
References were identiﬁed using searches of PubMed with key
words. The following combinations were used in a search of titles
and abstracts in June 2015 (the number of articles yielded is noted
in brackets):
1. ‘Lewy’ and (‘inﬂammation’ OR ‘neuroinﬂammation’) (98
articles)
2. (‘Parkinson's disease dementia’ OR ‘PDD’ OR ‘DLB’ OR (‘De-
mentia AND Parkinson*’)) AND (‘neuroinﬂammation’ OR
‘inﬂammation’) (283 articles)
3. ‘synuclein’ AND ‘microglia’ (185 articles)
4. ‘synuclein’ AND (‘inﬂammation’ OR ‘neuroinﬂammation’) (210
articles)
The abstracts of these articles were screened and full texts of
those potentially relevant articles to the review were obtained. In
order to ensure that all relevant references were sourced, refer-
ences were in turn reviewed for other relevant articles, supple-
mented by articles known to the authors.
3. Microglial function
Neuroinﬂammation describes the response to injury within the
central nervous system (CNS) leading to the activation of microglia
and astrocytes, release of cytokines and chemokines, invasion of
circulating immune cells and complement activation. Microglia are
the resident macrophages of the CNS, originating from progenitors
in the embryonic yolk sac [10]. They provide the innate immune
response to invading pathogens and also initiate the adaptive
response through antigen presentation [11].
Microglia are resting or “inactivated” under physiological con-
ditions with characteristic ramiﬁed morphology and distributed
within brain regions, such that rami are close but not touching,
implying each cell has its own distinctive territory. But even in this
inactive state, they have been shown using two-photonmicroscopy
to be continuously monitoring the extracellular spaces with their
processes and protrusions in adult mice [12]. Activation leads to
morphological change to a more rounded amoeboid shape, with
targeted movement of processes towards sites of injury or stimuli
to initiate phagocytosis [12] and leads to production of chemokines,
that amplify the response by recruiting other microglia, plus cy-
tokines, free radicals and proteases which destroy infectious or-
ganisms and infected neurons.
Microglia appear to have an important part both in MPTP dis-
ease progression and idiopathic PD [13], suggesting a central role
for these glia in nigro-striatal degeneration, irrespective of etiology.
Microglia may be especially susceptible to mechanisms of aging.
Their maintenance is proposed to be dependent on self-renewal
rather than replenishment by peripheral blood precursors [14,15],
which could be highly signiﬁcant in age dependent neurodegen-
erative conditions such as LBD. Systemic infections or disease,
which rise in number with age, could also lead to priming of
microglia, such that their response is exaggerated and damaging to
nearby neurons leading to cognitive decline [16]. It has also been
proposed that an initial stimulus that triggers microglial activation
could persist in neurodegenerative disorders leading to repeated
cyclical chronic neuroinﬂammation causing neuronal dysfunction
and cell death [17,18]. The speciﬁcity of these changes to Lewy body
dementias is unclear.
4. Imaging evidence of neuroinﬂammation and neuronal
dysfunction
Imaging studies have shown an association between neuro-
inﬂammation in vivo and cognitive dysfunction. Microglial activa-
tion as a marker of neuroinﬂammation has been identiﬁed in PD
and PDD [19] (see Table 1) using [11C]-RPK11195 (RPK11195), a PET
ligand that binds to a translocator protein found on microglia in
their activated state. Extensive microglial activation has similarly
been identiﬁed in another a-synucleinopathy: multiple systems
atrophy [20], as well as other degenerative conditions, including AD
[21,22].
An association between microglial activation in the midbrain
and dopaminergic loss in the dorsal putamen has been found in the
early stages of PD (less than 2.5 years), both contralateral to the
clinically affected side, with levels of activation correlating with
severity of motor impairment measured by the Uniﬁed Parkinson's
Disease Rating Scale (UPDRS) [23]. In the later stages of disease
(disease duration range 0.5e21 years), there is extensive microglial
activation, with the basal ganglia, cortex and pons all showing
signiﬁcantly increased levels. The substantia nigra was however
spared. Follow-up scans in eight of these subjects (after 18e28
months) showed no signiﬁcant change inmicroglial activation from
baseline despite a clear deterioration in disability as measured
using the UPDRS. Cognition was however not assessed longitudi-
nally [24]. The authors also noted a clear overlap in the areas of
microglial activation and the regions proposed by Braak et al. [25]
in their study of PD pathology. In PDD subjects, there is increased
cortical microglial activation compared to control subjects, how-
ever levels of activation were also increased in comparison to PD
cases e in the left parietal lobe [26].
In DLB, increased microglial activation in the substantia nigra
and putamen, plus several cortical regions was found in a pilot
imaging study of six cases of less than one year's duration [27]. That
microglial activation occurs in more widespread regions in early
DLB, where there is greater cognitive dysfunction compared to
early PD, strengthens the link between microglial activation and
cognitive decline.
A relationship between microglial activation and cognitive
function was indeed found in PDD, where cortical activation levels
inversely correlated with MMSE in temporo-parietal, occipital, and
frontal cortical regions [19,26]. Fan et al. [19] demonstrated a sig-
niﬁcant negative correlation between whole brain levels of
microglial activation and glucose metabolism. Within the temporo-
parietal cortex there was voxel by voxel signiﬁcant inverse corre-
lation between levels of microglial activation and glucose meta-
bolism in the immediate vicinity suggesting local damage, but the
areas of correlation were small. The authors however suggest
distant microglial activation could be linked to cell dysfunction in
the medial temporal lobe through pre-existing neuronal pathways.
Neither study of PDD assessed whether areas of increased activa-
tion (such as in the hippocampus) were linked to dysfunction in
speciﬁc cognitive domains (such as memory), which may have
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provided a stronger link between inﬂammation and cognitive
dysfunction.
Small clusters of positive correlations were also found between
RPK11195 binding and amyloid load (as determined by [11C] Pitts-
burgh compound B (PIB), a marker of ﬁbrillary amyloid load) in PDD
subjects, but only in the parietal lobe and anterior cingulate, as
opposed to AD subjects in whom there was a stronger correlation
between amyloid load and microglial activation. There was how-
ever little amyloid deposition found in PDD cases overall [19].
Proteins other than amyloid, such as a-synuclein or tau, could be
triggeringmicroglial activation in PDD, however currently there are
no a-synuclein PET ligands available to demonstrate this and tau
ligands have only very recently become available.
Overall small scale studies with in vivo imaging have suggested
that in PD, PDD and in a small preliminary report of DLB, there is
early microglial activation. But, this does not appear to increase
over time. Signiﬁcantly microglial activation also correlates
inversely with cognitive function and to an extent protein deposi-
tion, suggesting microglia may have a crucial role in the patho-
genesis of these conditions.
5. Alpha synuclein and neuroinﬂammation
The evidence for extensive microglial activation in LBDs, in an
immunologically privileged site such as the brain, is highly signiﬁ-
cant. Immune responses are tightly controlled and yet there is
widespread glial cell activation, present chronically during the dis-
ease. The initiation of the innate response occurs through pattern-
recognition receptors (PRRs) expressed on CNS cells (for example
the toll-like receptor (TLR)) through activation by pathogen asso-
ciated molecular patterns or danger associated molecular patterns.
However a-synuclein is the main component of Lewy bodies [28]
which characterize LBDs, and the driving force behind the disease
process, hence the interaction between this protein and microglia
appears tobe critical. Alpha-synuclein inclusions in neurons andglia
are associated with DLB and PDD, as well as PD andmultiple system
atrophy. InDLB and PDD, the inclusions are neuronal and in the form
of Lewy bodies [28]. Lewy neurites are also common in these dis-
orders, consisting of coarse dystrophic neurites immunoreactive for
a-synuclein within affected neurons. With 140 amino acids, a-syn-
uclein's possible intracellular forms include monomeric [29,30] or
relatively stable folded tetramer [31,32].
Alpha-synuclein, has been shown repeatedly to activate
microglia and induce dopamine cell loss [33e35], including
monomeric wild-type and mutant forms as well as extracellular
oligomeric conformations. Indeed, neuron-glia cultures depleted of
microglia have been shown to be resistant to a-synuclein induced
dopaminergic neurotoxicity [33]. More recently the focus has
moved on to possible mechanisms. Models of PD have been used to
study this relationship rather than models of DLB, with over-
expression of a-synuclein in the substantia nigra using viral vec-
tors, the most common. A survey of the literature shows several
possible mechanisms for this interaction (see Table 2).
A number of immunomodulatory proteins and compounds are
implicated in a-synuclein microglial recognition, chemotaxis,
activation and response. TLRs 1 [36], 2 [36,37] and 4 [38] are PRRs
key to the innate response machinery and have been reported as
having a role in recognition of a-synuclein by microglia. Microglia
exposed to higher-ordered oligomers (but not monomers) of a-
synuclein changed to an amoeboid, phagocytic morphology with
increased secretion of Tumor Necrosis Factor a (TNF-a) that was
reduced by inhibition of the TLR 1/2 complex [36]. A separate study
found only b-sheet rich oligomeric conformations of a-synuclein
could activate microglia via TLR 2, but both aggregated and non-
aggregated forms could activate microglia through TLR 4. Further-
more pro-inﬂammatory cytokine/chemokine release was
completely eliminated in TLR 2 knockout mouse microglia exposed
to a-synuclein, but remained unaffected in TLR 4 knockout mouse
microglia [39], suggesting TLR 2 recognition of oligomeric a-syn-
uclein leads to inﬂammation.
Another molecule which could feature in the initiation of
microglia activation is Fractalkine, a membrane bound chemokine
which acts on the CX3CR1 receptor on microglia to suppress pro-
duction of inﬂammatory molecules. A soluble secreted form of
Fractalkine had a protective function in an animal model of a-
synuclein overexpression, suggesting loss of this membrane bound
chemokine could lead to neuronal loss through microglia mediated
cell damage [40].
Table 1
Evidence of in vivo microglial activation in PD, PDD and DLB from RPK11195 PET imaging studies.
Study Participant numbers
(controls)
Participant age (years) Participant MMSE Disease duration (years) Regions with increased microglial
activation compared to controls
Ouchi et al., 2005
[23]
10 PD (10 controls) Range: 43e72;
Mean: 59.6
Range: 26e30; Mean: 28.3 Range: 0.4e2.5;
Mean: 1.4
Midbrain contralateral to the clinically
affected side
Iannaccone et al.,
2013 [27]
6 PD (11 controls) Range: 60e74;
Mean: 70.2
Range: 27e30; Mean: 29 Range: 0.6e1;
Mean: 0.8
Putamen, substantia nigra
Gerhard at al.,
2006 [24]
18 PD (11 controls) Range: 50e69;
Mean: 59.2
Not speciﬁcally stated,
screening tests normal in
PD group
Range: 0.5e21;
Mean: 8.6
Striatum, pallidum, thalamus, cortex
(precentral gyrus, frontal lobe,
anterior cingulate gyrus, posterior
cingulate gyrus) and pons
Edison
et al., 2013 [26]
8 PD (10 controls) Range: 58e75;
Mean: 68.2
Range: 27e30; Mean: 28.8 Mean: 9.2 Cortex (temporal, parietal,
and occipital regions)
Fan et al., 2014 [19] 11 PDD (8 controls) Range: 55e75;
Mean: 68.4
Mean: 22.1 Not stated Anterior cingulate gyrus, posterior
cingulate gyrus, frontal lobe, temporal lobe,
parietal lobe, occipital lobe, medial
temporal lobe, amygdala and hippocampus
Edison
et al., 2013 [26]
11 PDD (10 controls) Range: 56e80;
Mean: 69.3
Range: 16e26; Mean: 21.8 PD duration
mean: 10.6;
Dementia duration
mean: 3.5
Striatum, cortex (frontal, temporal, parietal,
anterior and posterior cingulate gyrus, and
occipital cortical regions)
Iannaccone et al.,
2013 [27]
6 DLB (11 controls) Range: 62e82;
Mean: 72
Range: 19e30; Mean: 24 Range: 0.7e1;
Mean: 0.8
Caudate, putamen, thalamus, substantia nigra,
cortex (frontal lateral, parietal lateral,
temporal lateral, temporal pole, precuneus,
occipital medial, occipital lateral, anterior
cingulate, posterior cingulate) and cerebellum
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Table 2
Potential mechanisms of interaction between a-synuclein and microglia.
Interaction/receptor Proposed mechanism of microglial interaction
with a-synuclein
PD model References
TLR 1&2 complex Oligomeric a-synuclein induces a pro-
inﬂammatory microglial phenotype through
TLR 1/2 complex: microglia exposed to
oligomers of a-synuclein changed to an
amoeboid, phagocytic shape, with increased
secretion of TNF-a and interleukin-1b. TNF-a
secretion was reduced by the addition of a TLR-
1/2 complex inhibitor or by a MyD88 inhibitor.
Primary microglia cultures derived from mouse
cortices were exposed to high-order oligomeric
forms of puriﬁed human wild-type a-synuclein
[36]
Fractalkine receptor (FKN), an immune
regulatory protein
Secreted form of FKN is neuro-protective:
Soluble secreted form of FKN prevents
reduction in tyrosine hydroxylase cell staining
compared to controls and membrane bound
FKNmodels when exposed to overexpression of
a-synuclein, despite increased MHCII
expression on microglia.
Overexpression of human a-synuclein via viral
vector combined with a variety of viral
constructs of FKN
[40]
CD11b receptor Alpha-synuclein binds to CD11b on microglia
to direct microglial migration: neuronal a-
synuclein overexpression led to microglial
migration toward neurons, which was reduced
by antibodies to the CD11b receptor and
diminished in CD11b knockout mice.
Overexpression of human a-synuclein via viral
vector in rat primary neuron-enriched cultures
[41]
Galectin-3 (carbohydrate-binding protein and
inﬂammatory mediator)
Galectin 3 mediates microglial cytokine
release: Release of Interleukin-2 and
Interleukin-12 after exposure to monomeric
and aggregated forms of recombinant a-
synuclein reduced by genetic down regulation
or pharmacological inhibition of galectin-3.
Microglia from wild-type and galectin-3
knockout mice
[46]
Leucine-rich repeat kinase 2 (LRRK2) LRRK2 required for microglial activation and
dopaminergic degeneration: Rats lacking
LRRK2 demonstrated a signiﬁcant reduction in
microglial activation compared to wild type
mice rats, when exposed to lipopolysaccharide
(LPS) and were protected from dopaminergic
neurodegeneration from a-synuclein
overexpression.
Rats exposed to intracranial LPS injection or
overexpression of human a-synuclein via viral
vector
[47]
b1-integrin Migration of microglia to disease affected
regions is via b1-integrin: b1-integrin
inhibition reduced microglial morphological
changes and motility (as shown by reduced
wound healing).
Rat primary microglia exposed to a-synuclein
conditioned medium (aSCM)
[42]
Interleukin-1 (IL-1) IL-1 is required for microglial activation:
behavioral deﬁciencies that occurred in wild-
type mice, following LPS administration did not
occur in IL-1 knockout mice. Tyrosine
Hydroxylase gene expression was similarly
preserved in IL-1 knockout but not wild-type
mice.
Mouse model using intracranial LPS injection
into wild-type and IL-1 (a and b) knockout mice
[44]
MHCII Complex MHCII complex mediates microglial
activation and dopaminergic cell loss:
overexpression of synuclein leads to induction
of MHCII expression on microglia and genetic
knockout of MHCII prevents microglial
activation, IgG deposition and dopaminergic
cell loss in vivo.
Mouse model using overexpression of human
a-synuclein via viral vector in wild-type and
MHCII knockout mice
[50]
TLR 4 TLR 4 mediates microglial phagocytic activity
and cytokine release in the presence of a-
synuclein: Microglial phagocytic activity was
signiﬁcantly reduced in TLR4 knockout
microglia mice after treatment with different
forms of a-synuclein; knockout mice also
showed signiﬁcantly reduced TNF- a production
following treatment with a-synuclein.
Mouse primary microglia from wild type and
TLR4 knockout mice challenged with cloned
human a-synuclein from spinal cord cDNA
[38]
TLR 2 TLR 2 mediates microglial activation by
oligomeric a-synuclein: TLR2 knockout mice
exhibited signiﬁcantly lowered microglial
activation compared with wild type mice when
exposed to a-synuclein overexpression;
cytokine/chemokine gene induction following
exposure to aSCM, was prevented by
antagonizing TLR2 and by depletion of the TLR2
gene; and TLR2 was only activated by
oligomeric alpha synuclein not the dimer or
monomer forms.
Mouse model using overexpression of human
a-synuclein via viral vector in wild-type and
TLR 2 knockout mice; oligomeric human a-
synuclein proteins released from dSY5Y cells
[37]
(continued on next page)
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Аlpha-synuclein, in extracellular aggregated form, has been
shown to be a chemoattractant through CD11b receptors on
microglia [41]. Also, the b1-integrin subunit, which forms trans-
membrane adhesion molecules has been reported as being
required for the morphological changes and migration of microglia
seen in the presence of extracellular a-synuclein [42].
Oncemicroglia are activated, Interleukin-1 (IL-1) appears to be a
key cytokine in promoting an inﬂammatory response. IL-1a and b
knockout mice did not show loss of dopamine neurons or behav-
ioral deﬁcits seen in wild-type mice in a mouse model of PD, uti-
lizing lipopolysaccharide(LPS) injections into the substantia nigra.
LPS injections have been shown to produce microglial activation,
cytokine release and subsequent dopaminergic cell loss in the
substantia nigra [43]. TNF-a knockout mice however showed
similar results to wild-type mice [44], indeed TNF-amay have role
in promoting a-synuclein accumulation [45]. Galectin-3 has also
been shown to be important for the inﬂammatory effect of a-syn-
uclein. Its inhibition signiﬁcantly reduced cytokine release by
microglia in response to aggregated a-synuclein [46].
Leucine-rich repeat kinase 2 (LRRK2) is a protein expressed on
microglia when they are in their inﬂammatory state and has been
shown to have a signiﬁcant role in a-synuclein mediated microglial
activation and subsequent cell loss, with LRRK2 knockout mice
being protected from a-synuclein overexpression [47]. Another
protein involved is NRF2, which is a transcription factor for a
number of cell protection proteins and appears to have a protective
role in the interaction [48].
Several studies suggest the adaptive immune response is
engaged by microglia following their activation. Knockout mice
without Fc gamma receptors (FcgR), which are found on microglia
and involved in facilitating phagocytosis through binding of IgG,
showed reduced pro-inﬂammatory signaling in the presence of
aggregated a-synuclein. Suggesting the latter could be triggering
inﬂammation and antibody mediated cell damage through FcgR
[49]. In addition, a knockout of all four murine MHC II complex
genes prevented a-synuclein induced dopaminergic cell loss in a
mouse model, strongly suggesting that CD4 T lymphocytes are
critical to a-synuclein cell damage. Microglia, as the only resident
cells expressing MHC class II in the CNS, would be candidates for
their recruitment, although inﬁltrating antigen presenting cells
such as macrophages may also be involved [50]. Furthermore, mice
with microglia deﬁcient in Prostaglandin E2, which is thought to
have a role in lymphocyte proliferation, have increased resistance
to MPTP mediated pathology [51].
6. Pathological evidence of inﬂammation
Pathological studies further support a role for inﬂammation.
Large numbers of HLA-DR-positive microglia, indicating reactive
states, have been reported in the substantia nigra of PD and PDD
cases together with Lewy bodies in association with a reduction in
dopaminergic cells. In the PDD cases HLA-DR positive microglia
were also found in the hippocampus, though this was associated
with neuritic plaques and tangles suggestive of AD pathology [52].
Involvement of the transenterohinal, cingulate and temporal
cortices in PD has also been identiﬁed. Activated microglia in these
regions also expressed MHC Class II molecules, HLA-DP, DQ and DR
[53]. The presence of CD4 (as well as CD8) T lymphocyteswithin the
substantia nigra of PD cases at post-mortem has subsequently been
conﬁrmed [54]. In addition, concentrations of interleukin-1b,
interleukin-6 and transforming growth factor-a are higher in the
striatal regions of post-mortem PD brains compared to controls
[55]. Complement proteins are also found with Lewy bodies within
this region in PD [56].
In DLB, both complement proteins andmicroglial interaction are
associated with Lewy body containing degenerated neurons on
autopsy, suggesting microglial involvement [57]. An increase in
activated microglia has also been reported in DLB cases, positively
correlating with the number of Lewy bodies also seen regionally
[58]. However this was not as high as in those cases with
Table 2 (continued )
Interaction/receptor Proposed mechanism of microglial interaction
with a-synuclein
PD model References
Fc gamma receptor (FcgR) FcgR mediates a-synuclein intracellular
localization to autophagosomes and NF-kB
pro-inﬂammatory signaling: microglia
internalized a-synuclein in a dense aggregated
form in wild-type mice but a diffuse manner in
FcgR knockout mice; FcgR knockout mice
treated with a-synuclein also failed to trigger
the enhancement of nuclear NF-kB p65 seen
when wild-type mice are exposed to a-
synuclein.
Primary microglial cultures from wild-type and
FcgR knockout mice, treated with human a-
synuclein
[49]
NRF2 (NF-E2-related factor 2), a transcription
factor
NRF2 protects against a-synuclein mediated
microglial activation and dopaminergic cell
loss: NRF2 knockout mice showed increased
microglial activation and greater nigral
dopaminergic neuronal loss than wild-type
mice when exposed to a-synuclein
overexpression; NRF2 knockout neurons were
characterized by thick dendrites loaded with a-
synuclein, similar in appearance to Lewy
neurites and this was associated with reduced
levels of the beta subunit (PSMB7) of the
catalytic core 20S proteasome compared to
wild-type mice.
Mouse model using overexpression of human
a-synuclein via viral vector in wild-type and
NRF2 knockout mice
[48]
Prostaglandin E2 receptor subtype 2 (PGE2) PGE2 is key to regulation of aggregated a-
synuclein levels: microglia isolated from PGE2
knockout mice exhibited enhanced clearance of
aggregated a-synuclein and showed increased
resistance to MPTP with less aggregated a-
synuclein in the substantia nigra and striatum.
Aggregated a-synuclein from human DLB cases
incubated with wild-type and PGE2 knockout
mice microglia
[51]
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concomitant senile plaques and a second study has shown a lack of
signiﬁcant microglial activation in the absence of tau neuritic pla-
ques in DLB [59]. The link between microglial activation and
pathological protein deposition in both PDD and DLB is therefore
not fully established.
7. Evidence from genetic studies
Genetic studies have identiﬁed polymorphisms in genes coding
IL-1b, TNF-a and Triggering Receptor Expressed on Myeloid cells 2
(TREM2) as risk factors for PD. Up to a doubling of risk has been
reported amongst carriers of a genotype of IL-1b that is associated
with increased gene expression [60,61]. Those carrying the ho-
mozygous variant genotype TNF-a-308, a variant which is thought
to be a stronger transcriptional activator, experience doubled risk
[60]. Overall the results from these two small studies are consistent
with a gene dosing effect for these two powerful cytokines. A rare
variant of the microglial receptor TREM2, that leads to loss of
function, was found to be another risk factor for PD in a study of
1493 cases compared to 1957 controls [62].
Genome wide association studies (GWAS) provide further evi-
dence for inﬂammatory pathology in PD. Polymorphisms in HLA
regions that code segments of the MHC class II molecule present
increased risk. A strong association was found within noncoding
intron 1 of HLA-DRA (in a study of 2000 cases and 1986 controls) by
Hamza and colleagues [63], with subsequent large-scale meta-an-
alyses of single nucleotide polymorphisms(SNP) conﬁrming asso-
ciations amid the HLA-DR locus, with both HLA-DRB5 [64] and
HLA-DQB1 [65] identiﬁed. Wissemann and colleagues [66] found
loci that predisposed to, as well as protected from, PD within the
same 2000 PD and 1986 control GWAS dataset initially analyzed by
Hamza et al. [63], and replicated these in a further 843 cases and
856 controls. The strongest association was again intron 1 of the
HLA-DRA region, which regulates gene expression and linked to
increased risk. This suggests HLA expression levels may play a key
role in determining risk for PD. Indeed subjects homozygous for the
G allele in this SNP, were found to have signiﬁcantly increased MHC
class II expression, compared to subjects who did not have a single
G allele. In addition, exposure to a common insecticide, pyrethroid,
when combined with possession of the GG allele, signiﬁcantly
increased PD risk [67], suggesting a combination of environmental
triggers and inﬂammatory processes may play a part in PD
pathology.
Notwithstanding the accumulated genetic evidence in the
context of PD, the equivalent associations in DLB have not been
established, although methods of investigation may need to be
broadened, as studies have been limited so far [68]. Polymorphisms
in genes associated with inﬂammation are also yet to be identiﬁed
as risk factors for PDD speciﬁcally.
8. Evidence from blood biomarkers
Elevated peripheral inﬂammatory markers both before and after
the onset of PD, suggest inﬂammation is concurrent with the dis-
ease. Increased plasma interleukin-6 (IL-6), measured on average
4.3 years before diagnosis, is associated with increased risk of
developing PD, with higher levels associated with higher risk [69].
After disease onset, levels of IL-6 [70,71], IL-1b [71] and TNF-a [70]
are elevated compared to controls in PD, as is RANTES (regulated on
activation, normal T cell expressed and secreted), a chemokine
which attracts T-cells. RANTES levels also correlated with motor
symptom severity [72]. A change in peripheral blood lymphocyte
subsets further suggests a role for the adaptive immune system. A
decrease in the overall level of T-helper CD4 cells but a rise in the
subset of activated T-helper cells is reported in PD cases compared
to controls [73].
In PDD, high sensitivity CRP is increased compared to controls,
but a signiﬁcant elevation was not found in PDD compared to PD
[74]. Peripheral markers suggestive of inﬂammation are yet to be
found in DLB. Therefore the blood biomarkers evidence for
inﬂammation in LBDs is inconclusive.
9. Evidence from cerebrospinal ﬂuid biomarkers
Attempts to identify a reliable cerebrospinal ﬂuid (CSF)
biomarker for PD or PDD have so far been inconsistent. The main
candidates include total a-synuclein, Ab42, and b-Glucocere-
brosidase [75]. Inﬂammatory cytokines TNF-a [76], IL-6 [77,78] and
IL-1b [71,77] have also been investigated with raised levels seen in
the CSF of PD cases compared to controls. IL-1b levels in the CSF
were associated with raised a-synuclein oligomers also in the CSF,
suggesting a direct link with protein deposition [71].
In a study of 22 cases of PD, IL-6 was found to associate inversely
with disease severity as assessed by the UPDRS [78]. In a larger
study of 62 cases, IL-6 was elevated in cases of PD with cognitive
impairment compared to those without, the levels being negatively
correlated to cognitive function. TNF-a and Interferon g levels were
however reduced in those with cognitive impairment in PD
compared to control subjects [79]. A rise in the fractalkine:Ab42
ratio in CSF is also associated with motor severity of PD (again
measured by UPDRS) but not with disease duration [80]. An in-
crease in this ratio could suggest increased inﬂammatory signaling
and microglial activation. An increase in Leucine rich a2-
glycoprotein (LRG), thought to be a marker of inﬂammation, is re-
ported in the CSF and post-mortem tissue of PDD and DLB cases,
compared to controls [81].
The focus in DLB has been on the variations of Ab peptides and
tau as well as a-synuclein; a combination of biomarkers may be the
best route to increase speciﬁcity and sensitivity [82,83]. The in-
ﬂammatory marker Procalcitonin has been found to be signiﬁcantly
raised in dementia subjects within the CSF, compared to controls,
with the highest median level found in DLB cases [84].
10. Evidence from epidemiological studies
There is limited support for neuroinﬂammation in PD from
epidemiology studies. A meta-analysis of the association of NSAIDs
and the risk of developing PD, showed a 15% reduction in incidence
among users of non-aspirin NSAIDS, with analysis of ibuprofen
alone showing a stronger protective effect. This effect was more
pronounced among regular users [85]. Whether PDD incidence was
lower in those who developed PD despite taking NSAIDS was not
considered.
A further meta-analysis showed conﬂicting results with no
overall protective effect, however there were methodological dif-
ferences including the inclusion of aspirin and studies where NSAID
exposure was entirely within a 1 year of the diagnosis of PD.
Nevertheless a slight protective effect for ibuprofen in lowering the
risk of PD was still conﬁrmed [86]. The evidence from these studies
is however difﬁcult to interpret because of variations in the drugs
investigated, the duration of the drug treatment and the timing of
administration in relation to disease onset.
Whether NSAIDs could reduce the risk of developing DLB or
protect those with PD from developing dementia, has not yet been
established.
11. A role for the adaptive immune system
Despite the evidence of microglial activation and an interaction
between a-synuclein and microglia, the precise mechanism and
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whether it is always detrimental to neurons remains unclear. A
paucity of the relationship between Lewy bodies and antigen pre-
senting activated microglia in post mortem studies was reported by
Imamura et al. [53], indeed there was only a 20% association. This
would suggest that Lewy bodies alone are not sufﬁcient in them-
selves to trigger antigen presentation by microglia. In addition,
increasing neuronal loss in the substantia nigra with lengthening
disease duration was not associated with an increase in microglial
activation, implying a steady rather than escalating inﬂammatory
response [87].
Orr and colleagues [87] also demonstrated that substantia nigra
neurons were immunopositive for IgG in PD, whereas control cases'
substantia nigra neurons as well as the visual cortex of PD cases
showed negative immunoreactivity. Neuronal IgG labelling related
to the degree of neuronal loss and microglial activation, with the
authors suggesting humoral immune system involvement in the
selective destruction of substantia nigra neurons.
Given that the MHC class II complex has also been shown to be
key in dopamine neuronal cell loss in mouse models [50], it may be
that an adaptive immune response is the ﬁnal path to neuronal loss,
following a switch in microglia function from protective to dele-
terious. Consistent with this theory is the genetic risk associated
with HLA class II gene variation previously described, as well as the
alteration in peripheral lymphocyte subsets found in PD cases [73],
and the evidence that B and T lymphocyte inﬁltration of the sub-
stantia nigra is found at post mortem [54] and in a mouse model of
a-synuclein overexpression [35].
It is possible initial protein clearance by microglia could be
switched to a more harmful toxic function involving recruitment of
the adaptive response ultimately leading to neuronal degeneration.
For example due to peripheral inﬂammation or increased vulner-
ability of microglia through ageing. The timing of treatment initi-
ation would be key in such circumstances.
12. Conclusion and future directions
Evidence for the role of neuroinﬂammation in LBDs continues to
accumulate, building on the evidence of neuroinﬂammation in AD
and PD. Imaging studies lead the way in supporting neuro-
inﬂammation as a key part of the pathogen process in LBDs, sup-
ported by pathological and biomarker evidence, though mostly in
PDD. Future studies are required to further establish the presence of
inﬂammation in DLB including imaging, genetic and biomarker
studies.
Involvement of microglia in LBDs is signiﬁed by the presence of
activation years before neuronal death as revealed by in vivo im-
aging, as well as after cell loss in pathology specimens. Microglial
involvement is also supported by evidence of the activation of
microglia by a-synuclein. Levels of activation however appear to
remain relatively stable, which could indicate initiation and prop-
agation of the disease process by microglia or alternatively a pro-
tective function that is eventually overcome. In order to understand
how inﬂammation affects disease progression in Lewy body de-
mentia, studies need to try and link the nature and extent of
microglial activation with important indicators of disease severity
such as structural brain changes, protein deposition and the onset
and progression of key cognitive and non-cognitive symptoms
through longitudinal studies in established disease and in those at
risk.
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r 
no
ty
ou
 a
re
 in
te
re
st
ed
 in
 h
el
pi
ng
 u
s 
w
ith
 th
is
 s
tu
dy
. I
f s
o,
 w
e
w
ill
 
ar
ra
ng
e 
to
 v
is
it 
yo
u,
 e
ith
er
at
 h
om
e
or
 in
 th
e 
cl
in
ic
, w
hi
ch
ev
er
 y
ou
 
pr
ef
er
. D
ur
in
g 
th
is
 v
is
it 
yo
u 
w
ill 
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 th
e 
op
po
rtu
ni
ty
 to
 a
sk
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qu
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tio
ns
 a
bo
ut
 th
e 
st
ud
y 
be
fo
re
 y
ou
 m
ak
e 
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de
ci
si
on
.  
If 
yo
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de
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 ta
ke
 p
ar
t,
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e
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 d
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 c
on
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iv
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r c
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 c
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 d
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 d
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 re
ce
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 c
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 c
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 c
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, p
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 D
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 m
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b
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c
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c
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 p
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t i
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tu
dy
.  
Th
is
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hy
 th
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se
ar
ch
 is
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ng
 d
on
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d 
w
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t t
ak
in
g 
pa
rt 
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ill 
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lv
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fo
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Pl
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 re
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w
in
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in
fo
rm
at
io
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ca
re
fu
lly
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di
sc
us
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it 
w
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 o
th
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ou
 c
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 to
 th
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re
se
ar
ch
er
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be
fo
re
 y
ou
 d
ec
id
e 
w
he
th
er
 to
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o 
ah
ea
d.
  T
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nk
 y
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 fo
r r
ea
di
ng
 th
is
.
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 d
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ra
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 c
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at
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 re
se
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ai
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at
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l R
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 C
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m
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t -
N
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 &
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W
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 o
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d 
pa
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r t
he
 s
tu
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 a
 N
at
io
na
l I
ns
tit
ut
e 
fo
r H
ea
lth
 R
es
ea
rc
h 
(N
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R
) P
ro
gr
am
m
e 
G
ra
nt
 fo
r A
pp
lie
d
R
es
ea
rc
h 
pr
oj
ec
t.
Th
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se
ar
ch
 te
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se
d 
at
 th
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U
ni
ve
rs
iti
es
 o
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ew
ca
st
le
 a
nd
 C
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br
id
ge
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If 
yo
u 
ha
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 a
ny
 c
on
ce
rn
s 
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 c
om
pl
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s 
ab
ou
t t
he
 re
se
ar
ch
, w
e 
w
ill 
do
 
ou
r b
es
t t
o 
re
so
lv
e 
th
em
.  
Pl
ea
se
 c
on
ta
ct
:
Pa
tie
nt
 A
dv
ic
e 
an
d 
Li
ai
so
n 
Se
rv
ic
e 
(P
AL
S)
: 
Te
l:
01
22
3 
72
67
74
 (o
ffi
ce
 h
ou
rs
) o
r f
re
e-
ph
on
e
08
00
 0
52
 1
41
1.
 A
 
co
nf
id
en
tia
l e
-m
ai
l s
er
vi
ce
 is
 a
ls
o 
av
ai
la
bl
e 
at
: p
al
s@
cp
ft.
nh
s.
uk
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DIAMOND-Lewy WP1A Patient consent form Version 1.1, 18 Nov 2013
CONSENT FORM FOR PATIENTS
Diagnosing and managing memory problems: 
a review of current practice 
I ....................................................................................................................................... (name)
of ……………………………………………………………………………………………………………..
      ……………………………………………………………………………………………………(address)
I have read the information sheet giving details of this study, have been given a copy to keep 
and have had the opportunity to ask questions.
I understand that my participation is voluntary and I can withdraw consent at any time without 
giving any reason and without my medical care or legal rights being affected. 
I understand that this consent form and data collected during the study may be looked at by 
responsible individuals from the research Sponsor (Northumberland, Tyne & Wear NHS 
Foundation Trust) or its representatives or from regulatory or ethical authorities where it is relevant 
to my taking part in research. I give permission for these individuals to have access to my records.
I understand that sections of my medical notes, including my GP notes, may be looked at and 
information taken from them used in this research. I give permission for the researchers to have 
such access to my records.
I give permission for information concerning me to be held by Newcastle University.
I understand that records will be confidential and will be stored securely on systems 
within the NHS and University.
I consent to take part in this study.
Signed..................................................................... ………          Date...............................
Consented by .......................................................... …….(signed)      Date...............................
Print Name      .........................................................
Please initial
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 re
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at
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 d
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r r
ea
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ng
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.
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DIAMOND-Lewy WP1B Patient consent form Version 1.1, 18 Nov 2013
CONSENT FORM FOR PATIENTS
Diagnosing and managing memory problems in Parkinson’s disease:
a review of current practice 
I ....................................................................................................................................... (name)
of ……………………………………………………………………………………………………………..
      ……………………………………………………………………………………………………(address)
I have read the information sheet giving details of this study, have been given a copy to keep 
and have had the opportunity to ask questions.
I understand that my participation is voluntary and I can withdraw consent at any time without 
giving any reason and without my medical care or legal rights being affected. 
I understand that this consent form and data collected during the study may be looked at by 
responsible individuals from the research Sponsor (Northumberland, Tyne & Wear NHS 
Foundation Trust) or its representatives or from regulatory or ethical authorities where it is relevant 
to my taking part in research. I give permission for these individuals to have access to my records.
I understand that sections of my medical notes, including my GP notes, may be looked at and 
information taken from them used in this research. I give permission for the researchers to have 
such access to my records.
I give permission for information concerning me to be held by Newcastle University.
I understand that records will be confidential and will be stored securely on systems
within the NHS and University.
I consent to take part in this study.
Signed..................................................................... ………          Date...............................
Consented by .......................................................... …….(signed)      Date...............................
Print Name      ......................................................... ……..
Please initial
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NIMROD (REC No. 13/EE/0104) Information Sheet – Patients CUH V5 11/5/2015 
Information Sheet for Patients and their Informants 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
You are being invited to take part in a research study.  This leaflet explains why the 
research is being done and what taking part will involve.  Please read the following 
information carefully and discuss it with others if you wish.  You can talk to the researchers 
before you decide. 
 If you decide to take part, after reading this information leaflet, please sign the 
consent form. 
If you decide not to take part it will not affect the standard of health care you receive 
in any way. 
What is the purpose of the study? 
There are several different causes of memory problems in later life, including a 
condition called Mild Cognitive Impairment as well as different types of dementia like 
Alzheimer’s disease, Frontotemporal dementia, Lewy body dementia, Progressive 
supranuclear palsy and Vascular dementia. Older people with depression and with Parkinson’s 
disease can also have memory problems.  
While considerable progress has been made over the last decade in understanding 
some of the brain protein and other changes associated with memory problems and dementia, 
a lot is still not known.  For example, why some people with memory problems get worse at a 
faster rate than others is not clear.  It has been established that mild inflammatory changes 
(brain inflammation) are associated with some of these disorders, but the questions whether it 
is present in all of them, and if so precisely where and how it changes with time have received 
little research attention.  This is important as we do not know how much inflammation is the 
result of disease and how much it may be involved as a cause.  If it is a cause, then this is 
extremely important because it may be possible to develop new treatments to help prevent 
memory problems getting worse.  It may also be possible to use measures of inflammation to 
predict groups of individuals who may be more at risk of declining more quickly than others. 
Brain imaging is an important method to investigate brain structure and function. 
Magnetic Resonance Imaging (MRI) can be used to look at brain structure and function in 
great detail.  In addition, Positron Emission Tomography (PET) imaging can be used to help 
visualise some kinds of damaged protein often found in people with memory and other 
problems (amyloid using PIB PET imaging and tau using AV-1451 PET imaging), and also 
can help detect the presence of inflammation in the brain (PK11195 PET).  Further, the 
presence of illnesses, including inflammation, leaves tell-tale changes in the blood and 
cerebro-spinal fluid, the clear fluid that bathes the brain and spinal cord.  In addition there are 
known to be genetic markers found in the blood that are associated with increased or 
decreased risk of dementia. 
This study looks for the presence of damaged protein, genetic markers, inflammation 
and changes in brain structure and function in people with a range of disorders that affect their 
thinking, attention and memory as well as suitable control subjects without such impairments. 
We will compare them to see how they differ on the tests and scans, to understand the causes 
and effects of dementia and related illnesses. 
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Why have I been invited? 
You have been selected because you have either been diagnosed with a 
neurodegenerative disease or with depression or because you have symptoms that are 
suggestive of such a disorder.  
Do I have to take part? 
It is up to you to decide whether to join the study.  If you decide you do not wish to 
take part it would not affect the standard of health care you receive in any way. 
If you agree to take part we will ask you to sign a consent form. 
You are free to withdraw at any time without giving a reason.  This would not affect 
the standard of health care you receive in any way. 
What will I be asked to do? 
The study includes the following types of test, although not everyone will necessarily 
be asked to do all parts of the study: 
1. A clinical assessment, including memory and other cognitive tests. 
2. A blood test.  
3. An MRI brain scan 
4. Either one, two or three PET scans 
5. Some people may also be invited for a lumbar puncture, to examine spinal fluid. 
Participants will have tests of memory, language, vision and attention, which take 
about one and a half hours to complete.    We will ask someone who knows you well to have a 
short interview to answer questions and complete a couple of questionnaires about how you 
are and how you are coping with everyday life.  This would be repeated every year for the 
duration of the study (up to 3 years) and can be carried out either at your home or at 
Addenbrooke’s Hospital, whichever you prefer.  We may use an audio device to record some 
of your answers.  This will only be used as a supplement to written notes to ensure accuracy. 
We would carry out a brief physical examination, which could either be as part of a 
normal clinical attendance or combined with one of the other research visits. This would be 
repeated annually.  We would also take a blood sample (about 80 ml, or 2 eggcups full).  
These take about 10 minutes. 
We propose to undertake up to three PET scans at Addenbrooke’s Hospital in the 
Wolfson Brain Imaging Centre (WBIC) or in the Hospital’s PET/CT Department.  On each 
occasion you will be in the Department for approximately 2 hours, with the scan itself taking 
45 minutes in the case of PIB PET and 90 minutes for the others (PK11195 and AV-1451 
PET).  For each PET scan you will have an injection of about a teaspoon of short lasting 
radioactive liquid.  The radiation dose for each PIB and PK11195 PET scan (2.7 – 3.0 
milliSieverts) is similar to the radiation dose we each experience from radiation in the 
environment during one year living in the East Anglia region, while the radiation dose from 
AV-1451 PET is 9.3 milliSieverts, which is similar to 3½ years’ environmental exposure here.  
The injected radioactivity fades away naturally over a few hours and you can leave the 
Scanning Centre or Department as soon as the scan is finished. 
In all cases our staff would communicate with you throughout the scan to check that 
you stay comfortable.  You could end the scan at any point. 
The MRI brain scan will take around an hour and also takes place at the WBIC. This is 
to look at the size, shape and ‘wiring’ of the brain.  It may be possible to arrange for this to 
take place on the same day as one of the PET scans.  Though MRI scanning is generally very 
safe, there are certain circumstances where it must be avoided.  We will go though a checklist 
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to ask about metal objects attached to or inside your body (e.g. stents, shrapnel, plated 
fractures,) or electronic devices (e.g. heart pace-maker).  Many such items (most modern 
cardiac stents, for instance) are designed to be MRI safe.  Being scanned requires you to lie 
still and relaxed on a bed in the scanner’s ‘tunnel’.  This ‘tunnel’ is quite narrow so please let 
us know if you have experienced claustrophobia in small spaces.  It can be noisy but earplugs 
are supplied and you can also have your own choice of music played over headphones if you 
wish.  As with the PET scans, the technician performing the MRI scan would communicate 
with you throughout the scan to check that you stay comfortable.  It can be stopped at any 
point, but takes up to one hour to complete.  
Some participants would also be invited for a lumbar puncture, on another visit, to 
take a small volume (about 15ml, three teaspoonsful) of the spinal fluid that has bathed the 
brain before travelling down the spine.  It can tell us a lot about what is happening in the 
brain.  A separate information sheet is available on lumbar puncture, as it is not relevant to 
everyone, and is an optional part of the study. 
What are the possible benefits of taking part? 
This is not a trial of any drug or other treatment and there is no direct benefit to you 
from taking part in this study.  However if you do take part you will be making a significant 
contribution to medical knowledge and the challenge of dementia especially.  
Expenses 
If you take part in this study, we would cover all necessary travel expenses and if it 
would help we would arrange transport by taxi for you to come to the hospital and go home. 
Will my taking part in the study be kept confidential? 
If you do take part in the study, all information provided to us and the results of 
studies would be treated confidentially.  It will be stored securely in locked cabinets or on 
password protected computer systems, under the supervision of the Chief investigators. We 
will retain the data for over 10 years.  We will ask for your permission to share your data and 
scans in an anonymised way with collaborators, now and in the future, including researchers 
in the NHS, Medical Research Council, University and National Institute for Health Research.  
The NHS is trying to improve the quality of clinical and research standards.  This is being 
achieved through ‘clinical governance’.  As part of this process, this study may be reviewed 
by a clinical governance team.  Such a team would need to look at our records to make sure 
that the research was carried out in accordance with proper procedures.   
What if there is a problem? 
Although the PET scans are for research purposes only, the MRI scan will be routinely 
reported by a specialist radiologist. Occasionally, brain scanning and other tests reveal a 
medical problem that was not expected. If this happens, we will inform you, and (if you agree) 
we would write to your General Practitioner (GP) and arrange for any necessary NHS follow 
up.  
  We have also arranged insurance, in the unlikely event of any problems, without 
affecting your statutory rights.  If you have any concerns or comments related to your 
participation in this study, you could contact the Chief Investigator (details below) or the 
Patient Advisory and Liaison Service (PALS) at Box 53, Cambridge University Hospitals, 
Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, telephone 01223 216 
756, e-mail pals@addenbrookes.nhs.uk.   
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Who is organising and funding the research? 
The study is primarily funded by the NIHR (National Institute for Health Research) 
Biomedical Research Unit.  The research team are based at the Departments of Psychiatry and 
Clinical Neurosciences at the University of Cambridge and Cambridge University Hospitals 
NHS Foundation Trust (Addenbrooke’s Hospital). 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect the participants’ interests.  This study has been 
reviewed and given a favourable opinion by the East of England – Cambridge Central 
Research Ethics Committee. 
Further information 
If you would like further information please contact Professor John O’Brien, or any 
member of the research team (details below). 
What will happen next? 
The next step will be a telephone call from one of the researchers.  If you are 
interested in helping with the study, they will arrange to visit you at home.  This will give you 
a chance to ask any questions about the study and your taking part before you make a 
decision.  If you do decide to take part, the researcher will discuss a consent form with you 
and ask you to sign it.  It is up to you to decide whether to take part or not.  You do not have 
to give a reason if you decide not to be involved.  If you change your mind you can withdraw 
from the study at any time without giving a reason.  You will be given a copy of this leaflet to 
keep. 
The research team should contact you in the next week or so.  If, at any time, you need 
to get in touch with someone, you can contact us: 
Professor John T O'Brien (Chief Investigator) 
Department of Psychiatry, 
University of Cambridge, 
Level E4, Box 189, 
Addenbrooke's Hospital, 
Hills Road, 
Cambridge, CB2 0SP 
Tel: +44 (0)1223 760682 
 
Dr James B Rowe (co-Chief Investigator) 
Department of Clinical Neurosciences, 
University of Cambridge, 
Herchel Smith Building,  
Forvie Site, Robinson Way, 
Addenbrooke’s Hospital , 
Cambridge, CB2 0SZ 
Telephone: +44 (0) 1223 273 630  
Secretary: +44 (0) 1223 760 696 
Robert Arnold (Research Assistant) 
Herchel Smith Building, 
Forvie Site, Robinson Way, 
Cambridge, CB2 0SZ 
Telephone: 01223 768003 
Email: rja39@medschl.cam.ac.uk 
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 Within this appendix are the specific contributions made by myself for each chapter.  
 
Chapter One:  Lewy Body Dementia Diagnosis - Background 
I carried out all the work in this chapter, including:  
 creation of the concepts for the literature search, and 
 the literature search itself. 
 
Chapter Two: Lewy Body Dementia Diagnosis – Methods 
Chapters two to four were carried out as part of the Diamond Lewy Project, a large study 
based in both East Anglia and the North East which was funded by the NIHR Grant 
Reference Number DTC-RP-PG-0311-12001). These chapters were part of “Diamond Lewy 
Work Package 1” in East Anglia. 
In this chapter, I  
 created the hypotheses for testing,  
 approached and obtained consent from the clinicians for access to their clinic lists for 
the prevalence survey data collection,  
 carried out a third (approximately) of the data collection for the prevalence survey 
(screening of medical records),  
 supervised the remaining data collection for the prevalence survey and checked the 
data for quality, 
 amended the case report form sections to ensure they contained the appropriate 
data to test the hypotheses, 
 assisted with the recruitment of patients for the diagnostic survey (the detailed 
medical notes’ analysis), 
 carried out about a third (approximately) of the data collection for the diagnostic 
survey, 
 supervised the remainder of the data collection for the diagnostic survey, and 
 checked the entire database containing the data from the case report forms (CRFs) 
against each CRF to ensure data transcription was accurate and I made corrections 
as necessary. 
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 Chapter 3: Lewy Body Dementia Diagnosis – Results 
In this chapter, I 
 chose the data to be analysed from the data collection for both the prevalence survey 
and diagnostic survey statistical analyses, 
 chose the appropriate statistical test for the analysis of each dataset, except the 
choice of the Wilson’s test for the prevalence confidence interval which was made 
after discussion with the Diamond Lewy Study statistician, and 
 carried out all the data analysis. 
 
Chapter 4: Lewy Body Dementia Diagnosis – Discussion 
I carried out all the work in this chapter. The published paper (“Clinical Prevalence of Lewy 
Body Dementia”, attached as Appendix 1) where I am joint lead author, was an 
amalgamation of the prevalence survey results in East Anglia (which are in my thesis) and 
the prevalence survey results in the North East (which are not in my thesis). 
 
Chapter 5: Inflammation in Lewy Body Dementia – Background Literature Review 
I carried out all the work in this chapter, including:  
 creation of the concepts for the literature search, and 
 the literature search itself. 
The published paper (“Neuroinflammation in Lewy Body Dementia”, attached as Appendix 
2), where I am lead author and carried out the literature search and wrote the manuscript, 
has been updated in this chapter by a further literature search carried out in March 2018 as 
detailed in the chapter. 
 
Chapter 6: Inflammation in Dementia with Lewy Bodies – Introduction and Methods 
Chapters 6-8 were carried out as part of the NIMROD study (primarily funded by the NIHR 
National Institute for Health Research Cambridge Biomedical Research Centre (grant 
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number RG64473), which is a large multimodal imaging study of different dementia 
subtypes. I was responsible for the dementia with Lewy bodies group within that study. 
In this chapter, I 
 created the hypotheses for testing,  
 obtained the participants’ blood samples and processed them for future analysis, 
 identified the inflammatory markers to be tested from the literature search, 
 collated the relevant blood samples and organised their processing, 
 learned support vector machine methodology, and how to code for it on R 
and for the majority of the DLB participants, I 
 identified and carried out their recruitment, 
 obtained their clinical history, 
 arranged and provided clinical supervision for their MRI and PET scans, and 
 carried out their clinical examinations, including UPDRS. 
 
Chapter 7: Inflammation in Dementia with Lewy Bodies – Results 
In this chapter, I 
 chose the appropriate data to analyse in order to test the hypotheses, 
 identified the most appropriate statistical analysis, 
 carried out the statistical analysis, and 
 carried out the support vector machine analysis. 
The PET modelling was carried out by Young Hong and Tim Fryer. They provided regional 
BPND values from each participant for each PK11195 and Pittsburgh Compound B scan so 
that I could carry out the statistical analysis. The cytokine analysis was carried out by Core 
Biochemical Assay Laboratory, Cambridge University Hospital, who provided the assay 
results for each participant so that I could carry out the statistical analysis. 
 
Chapter 8: Inflammation in Dementia with Lewy Bodies – Discussion 
I carried out all the work in this chapter. 
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I carried out all the work in this chapter. 
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